How many Dapagliflozin clinical trials are there?

552 Dapagliflozin clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 84 are actively recruiting participants. 283 are marked completed.

Are Dapagliflozin clinical trials recruiting in 2026?

Yes — 84 Dapagliflozin trials are actively recruiting in 2026, with 409 U.S. sites across 44 states. See the recruiting trials and the per-state site list further down this page.

What conditions is Dapagliflozin being studied for?

Dapagliflozin is being studied for Type 2 Diabetes, Diabetes Mellitus, Type 2, Type 2 Diabetes Mellitus, Heart Failure, Chronic Kidney Diseases and 409 more. The trials are grouped by indication on this page.

What phase is Dapagliflozin in?

Dapagliflozin clinical trials span 175 Phase 4, 128 Phase 3, 82 Phase 2, 68 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors Dapagliflozin clinical trials?

The lead sponsor across the most Dapagliflozin trials is AstraZeneca, with 268 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Dapagliflozin Clinical Trials (2026): 552 Studies for Type 2 Diabetes & Diabetes Mellitus, Type 2

Creator: Hipa.ai Research
Published: 2026-05-08T19:30:51.200Z

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: June 26, 2026.

552 Dapagliflozin clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 231 indications (including Type 2 Diabetes & Diabetes Mellitus, Type 2) and 1,282,626 total planned enrollment. 128 Phase 3 Dapagliflozin trials and 82 Phase 2, 175 Phase 4 are listed. 115 Dapagliflozin clinical trials are actively recruiting at 409 U.S. sites across 44 states. Most recent activity: NCT05521984 (Jun 2031).

Where to Participate: All Dapagliflozin Trial Sites in the U.S. (409 sites across 44 states)

Every actively recruiting Dapagliflozintrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

State	Facility	City	Trial	Map
AL	Research Site	Alexander City35010	NCT06307652	Map
AL	Research Site	Birmingham35205	NCT06677060	Map
AL	Research Site	Centreville35042	NCT06677060	Map
AL	Research Site	Fairhope36532	NCT06307652	Map
AL	Research Site	Fairhope36532	NCT06677060	Map
AL	Research Site	Fairhope36532	NCT06742723	Map
AL	Research Site	Huntsville35801	NCT06307652	Map
AL	Research Site	Huntsville35801	NCT06677060	Map
AL	Research Site	Mobile36608	NCT06677060	Map
AL	Research Site	Vestavia Hills35216	NCT06677060	Map
AZ	Research Site	Gilbert85296	NCT06677060	Map
AZ	Research Site	Glendale85308	NCT06677060	Map
AZ	Research Site	Phoenix85016	NCT06307652	Map
AZ	Research Site	Phoenix85044	NCT06307652	Map
AZ	Research Site	Surprise85374	NCT06742723	Map
AZ	Research Site	Surprise85374	NCT07222917	Map
AZ	Research Site	Tempe85283	NCT06677060	Map
AZ	Research Site	Tucson85712	NCT06677060	Map
AZ	Research Site	Tucson85710	NCT06742723	Map
AR	Research Site	Little Rock72205	NCT06307652	Map
CA	Research Site	Beverly Hills90211	NCT06307652	Map
CA	Research Site	Beverly Hills90211	NCT06742723	Map
CA	Research Site	Concord94520	NCT06742723	Map
CA	Research Site	Covina91723	NCT06307652	Map
CA	Research Site	Encinitas92024	NCT06307652	Map
CA	Research Site	Fremont94538	NCT06742723	Map
CA	Research Site	Fullerton92835	NCT06742723	Map
CA	Research Site	Huntington Beach92648	NCT06677060	Map
CA	Research Site	Inglewood90301	NCT06677060	Map
CA	Research Site	La Jolla92037	NCT06677060	Map
CA	Research Site	Lincoln95648	NCT06677060	Map
CA	Research Site	Loma Linda92357	NCT06677060	Map
CA	Research Site	Los Alamitos90720	NCT06742723	Map
CA	Research Site	Los Angeles90073	NCT06307652	Map
CA	Research Site	Los Angeles90089	NCT06307652	Map
CA	Research Site	Los Angeles90035	NCT06677060	Map
CA	Research Site	Los Angeles90073	NCT06742723	Map
CA	UCLA / Jonsson Comprehensive Cancer Center	Los Angeles90095	NCT07235280	Map
CA	Research Site	Redding96001	NCT06307652	Map
CA	Research Site	Sacramento95841	NCT06677060	Map
CA	Research Site	San Diego92123	NCT06307652	Map
CA	Research Site	San Diego92120	NCT06677060	Map
CA	Research Site	San Dimas91773	NCT06677060	Map
CA	Research Site	San Francisco94110	NCT06307652	Map
CA	Research Site	San Francisco94121	NCT06307652	Map
CA	Research Site	Santa Maria93454	NCT06677060	Map
CA	Research Site	Tarzana91356	NCT06742723	Map
CA	Research Site	Thousand Oaks91360	NCT06677060	Map
CA	Research Site	Vista92081	NCT06307652	Map
CA	Research Site	West Hills91307	NCT06307652	Map
CO	Research Site	Arvada80002	NCT06742723	Map
CO	Research Site	Aurora80045	NCT06307652	Map
CO	Research Site	Aurora80012	NCT06677060	Map
CO	University of Colorado Anschutz Medical Campus	Aurora80045	NCT06140537	Map
CO	Research Site	Englewood80110	NCT06677060	Map
CT	Research Site	Bridgeport06606	NCT06677060	Map
CT	Research Site	New Britain06051	NCT06742723	Map
CT	Yale Cancer Center Smilow Cancer Hospital	New Haven06520	NCT05989347	Map
CT	Yale New Haven Hospital	New Haven06510	NCT07273838	Map
CT	Yale New Haven Hospital-St. Raphael Campus	New Haven06510	NCT07273838	Map
CT	Research Site	Stamford06905	NCT06677060	Map
CT	Research Site	Waterbury06708	NCT06677060	Map
DC	Research Site	Washington D.C.20037	NCT06742723	Map
FL	Research Site	Boca Raton33486	NCT06307652	Map
FL	Research Site	Boca Raton33487	NCT06742723	Map
FL	Research Site	Boynton Beach33435	NCT06742723	Map
FL	Research Site	Bradenton34209	NCT06307652	Map
FL	Research Site	Crystal River34429	NCT06677060	Map
FL	Research Site	Delray Beach33484	NCT06307652	Map
FL	Research Site	Edgewater32132	NCT06742723	Map
FL	Research Site	Fort Lauderdale33308	NCT06307652	Map
FL	Research Site	Fort Lauderdale33316	NCT06677060	Map
FL	Research Site	Fort Lauderdale33316	NCT06742723	Map
FL	Research Site	Fort Myers33912	NCT06677060	Map
FL	Research Site	Gainesville32610	NCT06307652	Map
FL	Research Site	Hialeah33012	NCT06677060	Map
FL	Research Site	Hollywood33021	NCT06742723	Map
FL	Research Site	Hollywood33021	NCT07222917	Map
FL	Research Site	Jacksonville32209	NCT06307652	Map
FL	Research Site	Jacksonville32216	NCT06677060	Map
FL	Research Site	Jacksonville Beach32250	NCT06742723	Map
FL	Research Site	Lake City32055	NCT06742723	Map
FL	Research Site	Lakeland33813	NCT06677060	Map
FL	Research Site	Lakeland33805	NCT06742723	Map
FL	Research Site	Melbourne32901	NCT06742723	Map
FL	Research Site	Miami33176	NCT06307652	Map
FL	Research Site	Miami Lakes33014	NCT06307652	Map
FL	Research Site	Ocoee34761	NCT06677060	Map
FL	Research Site	Ocoee34761	NCT06742723	Map
FL	Research Site	Orlando32822	NCT06677060	Map
FL	Research Site	Palm Beach Gardens33410	NCT06307652	Map
FL	Research Site	Palmetto Bay33157	NCT06677060	Map
FL	Research Site	Pensacola32503	NCT06307652	Map
FL	Research Site	Port Charlotte33952	NCT06742723	Map
FL	Research Site	Port Charlotte33952	NCT07222917	Map
FL	Research Site	Port Orange32127	NCT06742723	Map
FL	Research Site	Port Orange32127	NCT07222917	Map
FL	Research Site	Riverview33578	NCT06742723	Map
FL	Research Site	Safety Harbor34695	NCT06307652	Map
FL	Research Site	Saint Augustine32086	NCT06307652	Map
FL	Research Site	Saint Augustine32086	NCT06677060	Map
FL	Research Site	St. Petersburg33701	NCT06307652	Map
FL	Research Site	Tampa33617	NCT06307652	Map
GA	Research Site	Albany31707	NCT06677060	Map
GA	Research Site	Atlanta30303	NCT06307652	Map
GA	Research Site	Atlanta30309	NCT06307652	Map
GA	Research Site	Atlanta30303	NCT06677060	Map
GA	Research Site	Atlanta30328	NCT06742723	Map
GA	Research Site	Atlanta30344	NCT06742723	Map
GA	Research Site	Atlanta30344	NCT07222917	Map
GA	Research Site	Brunswick31520	NCT06742723	Map
GA	Research Site	Canton30114	NCT06677060	Map
GA	Research Site	Columbus31904	NCT06677060	Map
GA	Research Site	Conyers30094	NCT06742723	Map
GA	Research Site	Cordele31015	NCT06677060	Map
GA	Research Site	Decatur30030	NCT06742723	Map
GA	Research Site	Lawrenceville30046	NCT06742723	Map
GA	Research Site	Peachtree City30269	NCT06307652	Map
GA	Research Site	Riverdale30274	NCT06742723	Map
GA	Research Site	Suwanee30024	NCT06677060	Map
GA	Research Site	Thomasville31792	NCT06307652	Map
GA	Research Site	Tucker30084	NCT06307652	Map
GA	Research Site	Woodstock30189	NCT06677060	Map
ID	Research Site	Idaho Falls83404	NCT06677060	Map
IL	Research Site	Champaign61822	NCT06677060	Map
IL	Research Site	Champaign61822	NCT06742723	Map
IL	Research Site	Champaign61822	NCT07222917	Map
IL	Northwestern University	Chicago60607	NCT05719714	Map
IL	Research Site	Chicago60637	NCT06307652	Map
IL	Research Site	Chicago60616	NCT06677060	Map
IL	Research Site	Chicago60621	NCT06677060	Map
IL	Research Site	Chicago60631	NCT06677060	Map
IL	Research Site	Glenview60026	NCT06307652	Map
IL	Research Site	Gurnee60031	NCT06677060	Map
IL	Research Site	Hazel Crest60429	NCT06307652	Map
IL	Research Site	Island Lake60042	NCT06677060	Map
IL	Research Site	Maywood60153	NCT06742723	Map
IL	Research Site	Park Ridge60068	NCT06677060	Map
IL	Research Site	Peoria61614	NCT06307652	Map
IL	Research Site	Rockford61107	NCT06742723	Map
IL	Research Site	Winfield60190	NCT06307652	Map
IN	Research Site	Elkhart46514	NCT06307652	Map
IN	Research Site	Evansville47710	NCT06307652	Map
IN	Research Site	Hammond46324	NCT06307652	Map
IN	Research Site	Indianapolis46202	NCT06677060	Map
IN	Research Site	Indianapolis46202	NCT06742723	Map
IN	Research Site	Muncie47303	NCT06307652	Map
IN	Research Site	Munster46321	NCT06307652	Map
IN	Research Site	Munster46321	NCT06677060	Map
IN	Research Site	Richmond47374	NCT06677060	Map
IN	Research Site	South Bend46617	NCT06677060	Map
IA	Research Site	Iowa City52242	NCT06742723	Map
IA	Research Site	Waterloo50701	NCT06307652	Map
IA	Research Site	West Des Moines50266	NCT06742723	Map
KS	Research Site	El Dorado67042	NCT06677060	Map
KS	Research Site	Hutchinson67502	NCT06742723	Map
KS	Research Site	Kansas City66112	NCT06742723	Map
KS	Research Site	Lenexa66219	NCT06677060	Map
KS	Research Site	Newton67114	NCT06677060	Map
KS	Research Site	Wichita67226	NCT06307652	Map
KS	Research Site	Wichita67214	NCT06742723	Map
KS	Research Site	Wichita67214	NCT07222917	Map
KY	Research Site	Lexington40509	NCT06677060	Map
KY	Research Site	Owensboro42301	NCT06677060	Map
KY	Research Site	Paducah42001	NCT06677060	Map
LA	Research Site	Alexandria71303	NCT06677060	Map
LA	Research Site	Metairie70006	NCT06742723	Map
LA	Research Site	Shreveport71101	NCT06677060	Map
LA	Research Site	West Monroe71291	NCT06307652	Map
LA	Research Site	West Monroe71291	NCT06742723	Map
MD	Research Site	Baltimore21229	NCT06677060	Map
MD	Research Site	Beltsville20705	NCT06677060	Map
MD	Research Site	Bethesda20889	NCT06742723	Map
MD	Research Site	Lutherville-Timonium21093	NCT06677060	Map
MD	Research Site	Potomac20854	NCT06677060	Map
MD	Research Site	Rockville20850	NCT06307652	Map
MA	Brigham and Women's Hospital	Boston02115	NCT07323524	Map
MA	Massachusetts General Hospital	Boston02114	NCT07323524	Map
MA	Research Site	Boston02114	NCT06307652	Map
MA	Research Site	Boston02115	NCT06677060	Map
MA	Research Site	Boston02115	NCT06742723	Map
MA	Research Site	New Bedford02740	NCT06677060	Map
MA	Research Site	New Bedford02740	NCT06742723	Map
MA	Research Site	Roslindale02131	NCT06677060	Map
MA	Research Site	Worcester01655	NCT06307652	Map
MA	Research Site	Worcester01608	NCT06742723	Map
MI	Research Site	Ann Arbor48109	NCT06742723	Map
MI	University of Michigan	Ann Arbor48109	NCT06785116	Map
MI	Research Site	Bloomfield Hills48304	NCT06307652	Map
MI	Karmanos Cancer Institute	Detroit48201	NCT06420167	Map
MI	Research Site	Detroit48202	NCT06742723	Map
MI	Research Site	Farmington Hills48334	NCT06307652	Map
MI	Research Site	Farmington Hills48336	NCT06677060	Map
MI	Research Site	Flint48504	NCT06307652	Map
MI	Research Site	Flint48532	NCT06677060	Map
MI	Research Site	Garden City48135	NCT06742723	Map
MI	Research Site	Saint Joseph49085	NCT06742723	Map
MI	Research Site	Troy48098	NCT06677060	Map
MI	Research Site	Ypsilanti48197	NCT06307652	Map
MN	Research Site	Mankato56001	NCT06677060	Map
MN	Research Site	Minneapolis55417	NCT06677060	Map
MN	Mayo Clinic	Rochester55905	NCT06762964	Map
MN	Research Site	Saint Paul55109	NCT06307652	Map
MS	Research Site	Jackson39216	NCT06307652	Map
MO	Research Site	Columbia65201	NCT06307652	Map
MO	Research Site	Columbia65201	NCT06677060	Map
MO	Research Site	Kansas City64111	NCT06307652	Map
MO	Research Site	Kansas City64128	NCT06307652	Map
MO	Research Site	Kansas City64111	NCT06677060	Map
MO	Research Site	Kansas City64151	NCT06677060	Map
MO	Research Site	Kansas City64111	NCT06742723	Map
MO	Research Site	Kansas City64151	NCT06742723	Map
MO	Research Site	St Louis63136	NCT06677060	Map
MO	Research Site	St Louis63136	NCT06742723	Map
MO	Washington University	St Louis63110	NCT07174687	Map
MO	Washington University School of Medicine	St Louis63110	NCT04887935	Map
MO	Washington University School of Medicine/St. Louis Children's Hospital	St Louis63110	NCT05521984	Map
MT	Research Site	Missoula59804	NCT06677060	Map
NE	Research Site	Lincoln68506	NCT06307652	Map
NE	Research Site	Lincoln68510	NCT06307652	Map
NE	Research Site	Norfolk68701	NCT06677060	Map
NE	Research Site	Norfolk68701	NCT06742723	Map
NE	Research Site	Omaha68134	NCT06677060	Map
NV	Research Site	Carson City89706	NCT06677060	Map
NV	Research Site	Henderson89074	NCT06307652	Map
NJ	Research Site	Eatontown07724	NCT06742723	Map
NJ	Research Site	Eatontown07724	NCT07222917	Map
NJ	Research Site	Jersey City07302	NCT06307652	Map
NJ	Research Site	Pennington08534	NCT06677060	Map
NJ	Research Site	Somerset08873	NCT06307652	Map
NJ	Research Site	Somerset08873	NCT06677060	Map
NM	Research Site	Albuquerque87102	NCT06677060	Map
NM	Research Site	Albuquerque87108	NCT06677060	Map
NY	Research Site	Albany12208	NCT06677060	Map
NY	Research Site	Albany12205	NCT06742723	Map
NY	Research Site	Brooklyn11220	NCT06307652	Map
NY	Research Site	Brooklyn11201	NCT06677060	Map
NY	Research Site	Brooklyn11220	NCT06677060	Map
NY	Research Site	Buffalo14203	NCT06742723	Map
NY	Research Site	Massapequa11758	NCT06677060	Map
NY	Research Site	New York10029	NCT06307652	Map
NY	Research Site	New York10016	NCT06742723	Map
NY	Research Site	Queens Village11428	NCT06677060	Map
NY	Research Site	Staten Island10310	NCT06307652	Map
NY	Research Site	The Bronx10451	NCT06307652	Map
NY	Research Site	The Bronx10455	NCT06307652	Map
NC	Research Site	Asheville28801	NCT06307652	Map
NC	Research Site	Chapel Hill27517	NCT06307652	Map
NC	Research Site	Charlotte28204	NCT06307652	Map
NC	Research Site	Charlotte28287	NCT06677060	Map
NC	Research Site	Durham27710	NCT06307652	Map
NC	Research Site	Durham27701	NCT06677060	Map
NC	Research Site	Fayetteville28304	NCT06677060	Map
NC	Research Site	Greenville27834	NCT06742723	Map
NC	Research Site	Greenville27834	NCT07222917	Map
NC	Research Site	Hickory28601	NCT06742723	Map
NC	Research Site	Jacksonville28546	NCT06742723	Map
NC	Research Site	Jacksonville28546	NCT07222917	Map
NC	Research Site	Kinston28504	NCT06742723	Map
NC	Research Site	Monroe28112	NCT06677060	Map
NC	Research Site	Morehead City28557	NCT06742723	Map
NC	Research Site	New Bern28562	NCT06677060	Map
NC	Research Site	New Bern28562	NCT06742723	Map
NC	Research Site	New Bern28562	NCT07222917	Map
NC	Research Site	Pinehurst28374	NCT06307652	Map
NC	Research Site	Raleigh27607	NCT06677060	Map
NC	Research Site	Raleigh27609	NCT06742723	Map
NC	Research Site	Rocky Mount27804	NCT06677060	Map
NC	Research Site	Rocky Mount27804	NCT06742723	Map
NC	Research Site	Sanford27330	NCT06742723	Map
NC	Research Site	Statesville28625	NCT06307652	Map
NC	Research Site	Statesville28625	NCT06742723	Map
NC	Research Site	Wilmington28401	NCT06307652	Map
NC	Research Site	Wilmington28401	NCT06742723	Map
NC	Research Site	Wilmington28412	NCT06742723	Map
NC	Research Site	Winston-Salem27103	NCT06742723	Map
ND	Research Site	Fargo58104	NCT06677060	Map
OH	Research Site	Beavercreek45431	NCT06677060	Map
OH	Research Site	Canton44718	NCT06677060	Map
OH	Research Site	Canton44718	NCT06742723	Map
OH	Research Site	Cincinnati45219	NCT06307652	Map
OH	Research Site	Cincinnati45267	NCT06307652	Map
OH	Research Site	Cincinnati45219	NCT06677060	Map
OH	Research Site	Cincinnati45220	NCT06677060	Map
OH	Research Site	Cincinnati45212	NCT06742723	Map
OH	Research Site	Cincinnati45219	NCT06742723	Map
OH	Research Site	Columbus43215	NCT06677060	Map
OH	Research Site	Columbus43210	NCT06742723	Map
OH	Research Site	Columbus43213	NCT06742723	Map
OH	Research Site	Columbus43215	NCT06742723	Map
OH	Research Site	Columbus43215	NCT07222917	Map
OH	Research Site	Dayton45414	NCT06307652	Map
OH	Research Site	Maumee43537	NCT06677060	Map
OH	Research Site	Springfield45504	NCT06307652	Map
OK	Research Site	Oklahoma City73111	NCT06677060	Map
OK	Research Site	Oklahoma City73120	NCT06677060	Map
OK	University of Oklahoma Health Sciences Center	Oklahoma City73104	NCT05174052	Map
OR	Research Site	Portland97225	NCT06307652	Map
PA	Research Site	Abington19001	NCT06307652	Map
PA	Research Site	Bridgeville15017	NCT06742723	Map
PA	Research Site	Butler16001	NCT06742723	Map
PA	Research Site	Camp Hill17011	NCT06307652	Map
PA	Research Site	Camp Hill17011	NCT06677060	Map
PA	Research Site	Exton19341	NCT06742723	Map
PA	Research Site	Hershey17033	NCT06307652	Map
PA	Research Site	Horsham19044	NCT06677060	Map
PA	Research Site	Media19063	NCT06742723	Map
PA	Research Site	Media19063	NCT07222917	Map
PA	Research Site	Philadelphia19104	NCT06307652	Map
PA	Research Site	Philadelphia19114	NCT06677060	Map
PA	Research Site	Scottdale15683	NCT06677060	Map
PA	Research Site	Smithfield15478	NCT06677060	Map
RI	Research Site	East Providence02914	NCT06742723	Map
RI	Research Site	East Providence02915	NCT06742723	Map
RI	Research Site	East Providence02914	NCT07222917	Map
RI	Research Site	Providence02908	NCT06307652	Map
SC	Research Site	Charleston29401	NCT06307652	Map
SC	Research Site	Charleston29425	NCT06307652	Map
SC	Research Site	Charleston29414	NCT06742723	Map
SC	Research Site	Columbia29203	NCT06742723	Map
SC	Research Site	Fort Mill29715	NCT06677060	Map
SC	Research Site	Lancaster29720	NCT06307652	Map
SC	Research Site	Mt. Pleasant29464	NCT06677060	Map
SC	Research Site	North Charleston29405	NCT06677060	Map
SC	Research Site	Spartanburg29301	NCT06677060	Map
SD	Research Site	Rapid City57701	NCT06307652	Map
TN	Research Site	Chattanooga37421	NCT06742723	Map
TN	Research Site	Cleveland37312	NCT06677060	Map
TN	Research Site	Jackson38305	NCT06307652	Map
TN	Research Site	Knoxville37916	NCT06307652	Map
TN	Research Site	Knoxville37912	NCT06742723	Map
TN	Research Site	Knoxville37938	NCT06742723	Map
TN	Research Site	Memphis38120	NCT06307652	Map
TN	Research Site	Morristown37813	NCT06677060	Map
TN	Research Site	Nashville37212	NCT06307652	Map
TN	Research Site	Nashville37203	NCT06677060	Map
TN	Research Site	Nashville37232	NCT06742723	Map
TN	Research Site	Tullahoma37388	NCT06307652	Map
TX	Research Site	Allen75013	NCT06307652	Map
TX	Research Site	Amarillo79106	NCT06307652	Map
TX	Research Site	Amarillo79121	NCT06307652	Map
TX	Research Site	Arlington76015	NCT06742723	Map
TX	Research Site	Arlington76015	NCT07222917	Map
TX	Research Site	Austin78704	NCT06677060	Map
TX	Research Site	Austin78726	NCT06742723	Map
TX	Research Site	Austin78735	NCT06742723	Map
TX	Research Site	Austin78751	NCT06742723	Map
TX	Research Site	Beaumont77702	NCT06677060	Map
TX	Research Site	Cypress77429	NCT06307652	Map
TX	Research Site	Dallas75204	NCT06307652	Map
TX	Research Site	Dallas75216	NCT06307652	Map
TX	Research Site	Dallas75390	NCT06307652	Map
TX	Research Site	Dallas75390-9015	NCT06677060	Map
TX	Research Site	Dallas75234	NCT06742723	Map
TX	Research Site	Dallas75246	NCT06742723	Map
TX	Research Site	Duncanville75137	NCT06677060	Map
TX	Research Site	El Paso79905	NCT06307652	Map
TX	Research Site	Houston77025	NCT06307652	Map
TX	Research Site	Houston77084	NCT06677060	Map
TX	Research Site	Houston77089	NCT06677060	Map
TX	Research Site	Houston77004	NCT06742723	Map
TX	Research Site	Houston77099	NCT06742723	Map
TX	Research Site	Humble77346	NCT06742723	Map
TX	Research Site	McAllen78501	NCT06677060	Map
TX	Research Site	McAllen78503	NCT06677060	Map
TX	Research Site	McKinney75069	NCT06307652	Map
TX	Research Site	McKinney75071	NCT06307652	Map
TX	Research Site	Mesquite75149	NCT06677060	Map
TX	Research Site	Odessa79761	NCT06307652	Map
TX	Research Site	Paris75462	NCT06677060	Map
TX	Research Site	Pasadena77504	NCT06742723	Map
TX	Research Site	Pasadena77504	NCT07222917	Map
TX	Research Site	San Antonio78229	NCT06307652	Map
TX	Research Site	San Antonio78257	NCT06677060	Map
TX	Research Site	San Antonio78212	NCT06742723	Map
TX	Research Site	San Antonio78212	NCT07222917	Map
TX	The University of Texas Health Science Center at San Antonio	San Antonio78229	NCT02969798	Map
TX	Research Site	Stephenville76401	NCT06677060	Map
TX	Research Site	Sugar Land77479	NCT06677060	Map
TX	Research Site	Temple76508	NCT06307652	Map
TX	Research Site	Tomball77375	NCT06677060	Map
TX	Research Site	Tyler75701	NCT06307652	Map
TX	Research Site	Tyler75702	NCT06307652	Map
TX	Research Site	Weslaco78596	NCT06677060	Map
TX	Research Site	Woodway76712	NCT06677060	Map
UT	Research Site	Clearfield84015	NCT06677060	Map
UT	Research Site	Ogden84405	NCT06677060	Map
UT	Research Site	Salt Lake City84148	NCT06307652	Map
UT	Research Site	South Salt Lake84115	NCT06742723	Map
VT	Research Site	Burlington05401	NCT06742723	Map
VA	Research Site	Arlington22205	NCT06742723	Map
VA	Research Site	Burke22015	NCT06677060	Map
VA	Research Site	Charlottesville22911	NCT06677060	Map
VA	University of Virginia	Charlottesville22908	NCT05762952	Map
VA	Research Site	Falls Church22042	NCT06307652	Map
VA	Research Site	Falls Church22042	NCT06677060	Map
VA	Research Site	Manassas20110	NCT06742723	Map
VA	Research Site	Midlothian23112	NCT06677060	Map
VA	Research Site	Newport News23606	NCT06307652	Map
VA	Research Site	Newport News23606	NCT06742723	Map
VA	Research Site	Norfolk23502	NCT06677060	Map
VA	Research Site	Salem24153	NCT06677060	Map
VA	Research Site	Woodbridge22192	NCT06742723	Map
VA	Research Site	Woodbridge22192	NCT07222917	Map
WA	Research Site	Redmond98052	NCT06677060	Map
WA	Research Site	Renton98057	NCT06677060	Map
WA	Research Site	Seattle98195	NCT06742723	Map
WV	Research Site	Kingwood26537	NCT06677060	Map
WV	Research Site	Morgantown26505	NCT06677060	Map

Dapagliflozin clinical trials at a glance: phase × recruitment status

Phase	recruiting	active not recruiting	enrolling by invitation	completed	terminated	withdrawn	suspended	not yet recruiting	unknown	Total
Early P1	1			1				1	3	6
P1	6	1		49	4			3	5	68
P1/P2	2	1		3					1	7
P2	17	4	1	32	6	5		5	12	82
P2/P3	4	3		10		1		1	3	22
P3	24	8	1	69	3		1	6	16	128
P4	19	6	2	89	9	4	1	9	36	175
N/A	7	7		30				6	14	64

Recruiting Dapagliflozin clinical trials (115)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT ID	Title	Phase	Indication	Enrollment	Started
NCT05521984	Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)	P1	Pediatric Brain Tumor	20	Apr 2023
NCT06364930	SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes Mellitus	P4	Chronic Hepatitis B	412	Mar 2024
NCT06642623	ENVELOPA Prospective Trial of Enavogliflozin to Evaluate Cardio-renal Outcome in Type 2 Diabetes Mellitus Patients	P4	Diabetes Mellitus, Type 2	2,862	Jan 2024
NCT07310433	NHADapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prostate Cancer	P2	Prostate Cancer	60	Jun 2026
NCT07108985	Effect of Add-on SGLT2i, TZD, or Combination Therapy in Type 2 Diabetes Patients on DPP4 Inhibitors	P4	Diabetes Mellitus, Type 2	100	Sep 2025
NCT07280585	STOP-PKDSTOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease	P3	Polycystic Kidney, Autosomal Dominant	420	Dec 2025
NCT07539259	RELIEF-ASTo Establish Whether Dapagliflozin and Spironolactone in Patients With Severe Aortic Stenosis Undergoing Aortic Valve Replacement, Result in Better Left Ventricular Mass Regression, Myocardial Health and Patient Reported Outcomes	P2	Aortic Stenosis	445	Dec 2026
NCT07323524	Dapa-Active LNDapagliflozin in Active Lupus Nephritis	P4	Lupus Nephritis (LN)	33	May 2026
NCT06742723	BaxDuo-PacificA Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure	P3	Chronic Kidney Disease and Hypertension	5,000	Mar 2025
NCT06677060	Prevent-HFPhase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin	P3	Heart Failure	11,300	Mar 2025
NCT07273838	Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome	P2	Heart Failure	130	Mar 2026
NCT07516847	DAPA-MDS1Dapagliflozin for Anemia in Lower-Risk Myelodysplastic Syndromes	P2	Myelodysplastic Syndromes (MDS)	37	Sep 2026
NCT07254572	CASCADESAnti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes	P4	Coronary Artery Disease	300	Jul 2025
NCT06907251	DALCODapagliflozin for Long COVID Syndrome	P3	COVID - 19	192	Apr 2026
NCT07235280	Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung Adenocarcinoma	Early P1	Lung Adenocarcinoma	48	Dec 2025
NCT07245069	AlpacaUse of Dapagliflozin in Primary Prevention of Cardiotoxicity of Anthracycline Chemotherapy in Breast Cancer Patients	P2	Heart Failure	100	Feb 2025
NCT07025629	DAPA-ICUDapagliflozin for Cardio-renal Protection After ICU Discharge	P3	Heart Failure and Chronic Kidney Disease Post-ICU	600	Dec 2025
NCT07342764	Dapagliflozin Versus Metformin for the Management of Antipsychotic-Induced Weight Gain: A Pragmatic Pilot Randomized Controlled Trial	P4	Antipsychotic-induced Weight Gain (AIWG)	110	Sep 2026
NCT07403955	The Effect of Dapagliflozin on Myocardial Strain in Patients With Acute Heart Failure	N/A	Congestive Heart Failure Acute	188	Feb 2026
NCT06072326	ASPIRE-1dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation	P2	Type 1 Diabetes Mellitus With Diabetic Nephropathy	36	Jan 2026
NCT06642272	APPLE TREEA Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health Record	P4	Diabetes Mellitus, Type 2	17,200	Oct 2024
NCT06140537	Efficacy and Mechanisms of Dapagliflozin in Promoting Kidney Function and Cardiovascular Health in Kidney Transplant Recipients	P4	Kidney Transplant; Complications	80	Feb 2024
NCT06759909	Dapagliflozin on Outcomes of Rhythm Control Strategy (Pharmacological ± Interventional) in Patient with Atrial Fibrillation	P1	Dapagliflozin (Forxiga)	100	Jan 2025
NCT05852704	STENOTYPESGLT2 Inhibitor TrEatment iN Patients Awaiting cOronary arTery bYpass Surgery to Reduce Post-opErative AF	P3	Chronic Coronary Syndrome	800	Apr 2024
NCT06785116	DAPA-HPA Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP)	P4	Gestational Hypertension	200	Mar 2025
NCT07491718	TAKO MEMRIManganese-enhanced Magnetic Resonance Imaging in Takotsubo Cardiomyopathy	N/A	Takotsubo Cardiomyopathy	100	Aug 2025
NCT04591639	DAPA-MEMRIThe DAPA-MEMRI Trial	N/A	Heart Failure	160	Aug 2020
NCT05986136	Activation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel Disease	P2/P3	Inflammatory Bowel Diseases	50	Aug 2023
NCT07469722	POINTER-HFPOcus INTERvention for Tailoring Diuretic Strategy in Acute Decompensated Heart Failure	P2/P3	Acute Heart Failure (AHF)	128	Mar 2026
NCT07174687	SGLT2 Inhibitors in Geographic Atrophy	P2	Retinal Degeneration	70	Dec 2025
NCT07239570	CKD-bioMatchA Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease	P4	Chronic Kidney Disease(CKD)	125	Jun 2025
NCT05788276	DEAKTransplantCan Dapagliflozin Preserve Structure and Function in Transplanted Kidneys?	P4	Kidney Transplant; Complications	330	May 2023
NCT05321706	DAPARHTDAPAgliflozin for Renal Protection in Heart Transplant Recipients	P3	Heart Transplant Failure	430	Jun 2022
NCT07482943	The Effect of Dapagliflozin on Exercise and Cardiac Functional Status of Patients After Fontan Procedure	P4	Fontan	30	Apr 2026
NCT05938712	HALLMARKThe Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients	P2	Kidney Transplant Recipients	20	Oct 2023
NCT07392788	GlifloFastEREarly Gliflozin for Elderly Patients With Acute Decompensated Heart Failure in the Emergency Department	N/A	Acute Heart Failure (AHF)	144	Apr 2026
NCT07187570	RECUR-AFRECURrence of Atrial Fibrillation After Cardioversion of Patients Randomized to Dapagliflozin or Usual Care	P3	Atrial Fibrillation (AF)	1,600	Jun 2025
NCT06174753	DAPA STEMIDapagliflozin in STEMI	P3	ST Elevation Myocardial Infarction	256	Jan 2025
NCT06562582	STAMI-BASSTunning in Acute Myocardial Infarction - BAS	P4	Myocardial Infarct	120	Jan 2025
NCT06528405	ESS-AKDThe Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease	P2	Acute Kidney Injury	264	Nov 2024
NCT05989347	Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy	P1	Breast Cancer	20	Oct 2024
NCT06304857	PROTECTAACardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL	P3	Breast Cancer	188	Apr 2024
NCT06572215	DYNAMODYNAMic Renal Assessment: NOvel Methods to Assess KIDNEY Functional Reserve	—	Chronic Kidney Diseases	44	Dec 2023
NCT05174052	DAPA-AFDapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)	P3	Diabetes Mellitus	28	Jun 2022
NCT07436663	SGLT2i/DPPiComparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC	P4	Breast Cancer	150	Feb 2026
NCT07405216	IECA-MEXEfficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Early Stages of Chronic Kidney Disease	P4	Chronic Kidney Disease (Mild to Moderate)	200	Apr 2026
NCT06054035	SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes	P4	Type2diabetes	170	Oct 2023
NCT05374291	The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD	P3	Kidney Disease, Chronic	1,750	Nov 2022
NCT02969798	IFGPre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)	N/A	Diabetes Mellitus, Type 2	700	Jan 2014
NCT06668753	Effect of SGLT2 Inhibitors on NAFLD in Type 2 Diabetic Patients with Diabetic Nephropathy	—	Effect of SGLT2 Inhibitors NAFLD in Type 2 Diabetic Patients with Diabetic Nephropathy	114	Nov 2024
NCT06887062	DERAIL-LVVDapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV)	P2	Large Vessel Vasculitis	60	Mar 2025
NCT07056699	SGLT2i, Pioglitazone, and Ketone Production in T1D	P3	Type1diabetes	24	Jul 2026
NCT06307652	BalanceD-HFStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function	P3	Heart Failure and Impaired Kidney Function	4,800	Apr 2024
NCT06954090	SIGNALUrinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study	P4	Type 2 DM	50	Nov 2025
NCT07222917	BaxDuo-BalticA Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.	P2	Chronic Kidney Disease and Hypertension	218	Dec 2025
NCT07082114	A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus	P3	Type 2 Diabetes	800	Jul 2025
NCT06820567	Effects Dapagliflozin on Inflammatory Markers Erythropoiesis and Iron Metabolism in Patients With Type 2 Diabetes and CKD	P3	Chronic Kidney Diseases	210	Mar 2025
NCT06420167	FLORALDapagliFLOzin in Renal AL Amyloidosis (FLORAL)	P2	Renal AL Amyloidosis	20	Jul 2024
NCT07297589	EPIC-CTEpicardial Cardiac Fat-CT (EPIC-CT)	P3	STEMI - ST Elevation Myocardial Infarction	136	Dec 2025
NCT06890143	The Efficacy and Safety of Dapagliflozin in the Treatment of Hereditary Kidney Disease With Proteinuria in Children	P3	Pediatric Hereditary Kidney Diseases	44	Mar 2025
NCT06762964	CAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation	P2	Fontan Circulation	27	May 2025
NCT06772168	Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia	P3	Dyslipidemia	240	Apr 2024
NCT07491042	Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients.	N/A	End Stage Chronic Renal Failure	38	Apr 2026
NCT05886088	DÁLIAEfficacy and Safety of LID104 in the Treatment of Type II Diabetes Mellitus	P3	Type 2 Diabetes Mellitus	597	Feb 2024
NCT06922656	Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration?	P4	Type 1 Diabetes	60	Sep 2025
NCT07331727	EAT-DARE-AFEpicardial Adipose Tissue-Targeted DApagliflozin for Reducing Electrical Remodeling in Atrial Fibrillation	N/A	Atrial Fibrillation (AF)	280	Jan 2026
NCT07311551	BMIA Comparison of Effectiveness, Safety, and Cost-effectiveness of Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes Mellitus and High Body Mass Index (BMI)	P4	Type 2 Diabetes	112	Dec 2025
NCT06668389	STEPSSodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary Status Trial	P4	Congenital Heart Disease	106	May 2025
NCT06626737	DAPALAG-01Dapagliflozin in Allo-HCT for aGVHD	P2	Graft-versus-host Disease (GVHD)	72	Apr 2025
NCT05944016	DOUBLE_PROTECTPhase 3 Clinical Trial with Dapagliflozin in Chronic Kidney Disease in Adolescents and Young Adult Patients	P3	Chronic Kidney Failure in Children and Young Adults	102	Mar 2024
NCT06398977	Dapagliflozin Delays the Loss of Renal Function in Peritoneal Dialysis Patients	N/A	Peritoneal Dialysis Complication	70	Mar 2024
NCT06560801	Dapagliflozin on Renal Morphology and Renal Perfusion in Patients One Year After Kidney Transplantation	P4	Chronic Kidney Diseases	48	Jul 2023
NCT06155604	SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease	P2	Lupus Nephritis	150	Jan 2023
NCT07351643	DAPA-PCATCCTA Evaluation of SGLT2i-related Pericoronary Fat Changes in Non-diabetic ACS Patients Without HF	P4	ACS (Acute Coronary Syndrome)	110	Feb 2026
NCT07239011	Dapagliflozin in Depression	P1/P2	Depression	60	Nov 2025
NCT06750458	Dapagliflozin Versus Dexamethasone Role in Pre-operative Management of Non- Diabetic Brain Tumor Patients	P3	Glioma	75	Aug 2025
NCT06434025	COMBINED-HFIV Iron and SGLT2 Inhibitor on Ventricular Function and Myocardial Iron Content in Heart Failure With Iron Deficiency	P3	Heart Failure, Systolic	99	May 2024
NCT06982079	Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Kidney Function in Advanced Chronic Kidney Disease	P3	Chronic Kidney Disease Stage 5	60	May 2025
NCT07018622	DAPA-ARMORProtecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity	P2	Solid Tumors	46	May 2025
NCT07515391	Dapagliflozin Effect on Glucose Variability in Patients Post Bariatric Surgery	P2	Bariatric Surgery Candidate	30	Oct 2019
NCT05764057	DAPAPROTECTORDAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction	P3	AMI	450	Jun 2023
NCT06612086	Dapagliflozin in Mangement of Pulmonary Hypertension Patients	P1	Pulmonary Hypertension	70	Oct 2024
NCT06972732	TELOSA Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes	P4	Type 2 Diabetes	204	Jun 2025
NCT06427226	Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity	P2	Doxorubicin Induced Cardiomyopathy	46	Oct 2024
NCT07295223	GALACTUSEffect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)	P3	Acute Myocardial Infarction With ST Elevation	44	Dec 2025
NCT05719714	Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease	P1/P2	Chronic Kidney Diseases	60	Jan 2024
NCT07214818	SGLT2-NSSGLT2 Inhibitors in Adult Primary Nephrotic Syndrome	P2/P3	Nephrotic Syndrome	75	Nov 2025
NCT06845163	DAPA-DMERandomized Clinical Trial to Evaluate the Effect of Dapagliflozin in Patients With Diabetic Macular Edema	P2	Diabetic Macular Edema	56	Feb 2025
NCT04887935	Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer	P1	Prostate Cancer	24	Jun 2024
NCT06009874	Clinical Investigation of the Cardioprotective Effect of Early Administration of SGLT2 in Patients Presented With AMI	N/A	Myocardial Infarction	80	Oct 2023
NCT06711185	DAPA-MYOCANCEREffect of DAPAglifozin on MYOcardial Remodeling of Breast CANCER Patients Treated with Anthracycline Based Chemotherapy	P3	Breast Cancer	80	Jan 2024
NCT07396844	The Food Effect on Pharmacokinetics of Fixed Dose Combination of Gemigliptin/Dapagliflozin/Metformin in Healthy Volunteers	P1	Healthy	28	Jul 2026
NCT07351864	FIN-SGLT2-HFFinerenone Plus SGLT2 Inhibitors in Heart Failure	P4	Heart Failure	60	Jan 2026
NCT06942910	ZODIACA Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria	P2	Chronic Kidney Disease With High Proteinuria	224	May 2025
NCT06589765	A Study of HRS-7535 Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Metformin	P3	Type 2 Diabetes	800	Sep 2024
NCT07083401	A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fed)	P1	Diabete Mellitus	40	Jul 2025
NCT07083388	A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fasting)	P1	Diabetes Mellitus	52	Jul 2025
NCT06491680	Cardiotoxicity in Breast Cancer Patients	P4	Breast Cancer	40	Sep 2024
NCT05741658	FonDapThe Fontan Dapagliflozin Pilot Study	P4	Heart Failure	29	Nov 2023
NCT05345327	STARTSGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes	P3	Type 2 Diabetes	994	Jan 2023
NCT07076615	DapagliflozinThe Effect of Dapagliflozin on Patients With Cardiomyopathy	P4	Acute Decompensated Heart Failure (ADHF)	100	Aug 2025
NCT06740786	Efficacy and Safety of Dapagliflozin in Preventing Atrial Fibrillation Recurrence After Catheter Ablation	N/A	Atrial Fibrillation (AF)	250	Dec 2024
NCT05762952	SMILEEffect of Dapagliflozin on Microvascular Function in Women With Symptoms of Coronary Artery Disease	P1	Myocardial Ischemia	40	Jun 2023
NCT06442280	DAPA-TONICSGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HF	P4	Heart Failure Acute	544	Jun 2024
NCT04707261	ADIDASAssociation Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients (ADIDAS)	P4	Anemia	1,990	Aug 2021
NCT06578520	Effect of the Use of Dapagliflozin in Patients With Refractory Heart Failure	P4	Heart Failure	31	Jul 2024
NCT06897605	Impact of Dapagliflozin in Anemic Chronic Kidney Disease Patients	P2	Chronic Kidney Disease(CKD)	80	Apr 2025
NCT06510270	Dapagliflozin in Reducing Epicardial Adipose Tissue in Heart Failure with Preserved Ejection Fraction	N/A	Heart Failure with Preserved Ejection Fraction	70	Aug 2024
NCT06919523	Clinical Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patients With Refractory Cirrhotic Ascites	P2	Refractory Ascites	70	Apr 2025
NCT06535529	Acetazolamide Versus Dapagliflozin in Acute Decompensated Heart Failure Patients	P3	Acute Decompensated Heart Failure	60	Aug 2024
NCT06783166	Assessing the Clinical Outcomes of Dapagliflozin Versus Acetazolamide in Patients With Acute Heart Failure	P2/P3	Acute Heart Failure	100	Aug 2024
NCT06373523	SHIELDMASLD in Primary Hypothyroidism and Efficacy of Dapaglifozin	Early P1	Hepatic Steato-Fibrosis	60	Sep 2024
NCT06286878	Pleiotropic Effects of Dapagliflozin in Patients With Acute Coronary Syndromes	P2/P3	Myocardial Infarction	80	Dec 2021
NCT05359263	DECODE-CKDEffects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with CKD	P2	Chronic Kidney Diseases	222	Jun 2022
NCT06576375	Efficacy of Dapagliflozin Versus Metformin in Polycystic Ovary Syndrome	P3	Polycystic Ovary Syndrome	70	Sep 2024

Dapagliflozin clinical trials by indication

Type 2 Diabetes (54)

NCT	Acronym	Phase	Status	Title
NCT07082114	—	P3	recruiting	A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
NCT07311551	BMI	P4	not yet recruiting	A Comparison of Effectiveness, Safety, and Cost-effectiveness of Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes Mellitus and High Body Mass Index (BMI)
NCT07033585	GD-T2D	P2/P3	active not recruiting	Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers
NCT07026968	—	P3	active not recruiting	A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes
NCT06972732	TELOS	P4	recruiting	A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes
NCT06589765	—	P3	recruiting	A Study of HRS-7535 Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Metformin
NCT05345327	START	P3	recruiting	SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes
NCT07120828	CYP8B1-SGLT2-T	P4	completed	The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity
+ 46 more, see All trials below.

Type 2 Diabetes Mellitus (50)

NCT	Acronym	Phase	Status	Title
NCT05886088	DÁLIA	P3	not yet recruiting	Efficacy and Safety of LID104 in the Treatment of Type II Diabetes Mellitus
NCT02616666	DECIDE	P4	completed	A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients
NCT03919656	—	P4	completed	SGLT-2 Inhibition, Metabolomics and Cardiovascular/Kidney Disease
NCT04445714	—	P4	completed	To Assess Safety of Fixed Dose Combination of Dapagliflozin and Saxagliptin in Type 2 Diabetes Mellitus Patients
NCT03782259	—	P4	completed	Effects of SGLT-2 Inhibition on Myocardial Fibrosis and Inflammation as Assessed by Cardiac MRI in Patients With DM2
NCT03871621	ELUCIDATE	P4	completed	Left Ventricular Functional Changes of Uncontrolled Diabetes by Dapagliflozin Treatment Trial
NCT03961659	—	N/A	unknown	Effects of Liraglutid, Dapagliflozin and Acarbose on the Cognitive Function, Olfactory Function, and Odor-induced Brain Activation in Overweight/Obese T2DM Patients Controlled Inadequately With Metformin Monotherapy.
NCT04195243	—	P3	unknown	Dapagliflozin vs Empagliflozin on Flow Mediated Dilation in Type 2 Diabetes Mellitus
+ 42 more, see All trials below.

Diabetes Mellitus, Type 2 (45)

NCT	Acronym	Phase	Status	Title
NCT06642623	ENVELOP	P4	recruiting	A Prospective Trial of Enavogliflozin to Evaluate Cardio-renal Outcome in Type 2 Diabetes Mellitus Patients
NCT07108985	—	P4	not yet recruiting	Effect of Add-on SGLT2i, TZD, or Combination Therapy in Type 2 Diabetes Patients on DPP4 Inhibitors
NCT06642272	APPLE TREE	P4	recruiting	A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health Record
NCT02969798	IFG	N/A	recruiting	Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)
NCT05621551	—	P4	completed	Dapagliflozin Therapy In Cardiac Surgery
NCT05139914	SFRNDM2	P4	terminated	Assessment of Dapagliflozin on Vascular Health in Patients With Type 2 Diabetes
NCT03499704	EPIDOTE	P4	completed	A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy
NCT03199053	T2DM	P3	completed	Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old
+ 37 more, see All trials below.

Heart Failure (21)

NCT	Acronym	Phase	Status	Title
NCT06677060	Prevent-HF	P3	recruiting	Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT07273838	—	P2	recruiting	Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome
NCT07245069	Alpaca	P2	recruiting	Use of Dapagliflozin in Primary Prevention of Cardiotoxicity of Anthracycline Chemotherapy in Breast Cancer Patients
NCT04591639	DAPA-MEMRI	N/A	recruiting	The DAPA-MEMRI Trial
NCT07303556	ICDDTKZ26	N/A	active not recruiting	Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs
NCT07351864	FIN-SGLT2-HF	P4	not yet recruiting	Finerenone Plus SGLT2 Inhibitors in Heart Failure
NCT05741658	FonDap	P4	enrolling by invitation	The Fontan Dapagliflozin Pilot Study
NCT06578520	—	P4	recruiting	Effect of the Use of Dapagliflozin in Patients With Refractory Heart Failure
+ 13 more, see All trials below.

Chronic Kidney Diseases (13)

NCT	Acronym	Phase	Status	Title
NCT06572215	DYNAMO	N/A	recruiting	DYNAMic Renal Assessment: NOvel Methods to Assess KIDNEY Functional Reserve
NCT06820567	—	P3	not yet recruiting	Effects Dapagliflozin on Inflammatory Markers Erythropoiesis and Iron Metabolism in Patients With Type 2 Diabetes and CKD
NCT06560801	—	P4	recruiting	Dapagliflozin on Renal Morphology and Renal Perfusion in Patients One Year After Kidney Transplantation
NCT05719714	—	P1/P2	recruiting	Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease
NCT05965440	DAPA-GUT	N/A	completed	Impact of Dapagliflozin on Intestinal Microbiota Composition and on the Metabolites Derived From the Intestinal Microbiota in Non-diabetic Chronic Renal Failure Patients
NCT06421870	—	P3	unknown	Renoprotective Effects of Dapagliflozin Versus Pentoxiphylline in Chronic Kidney Disease Patients
NCT06281899	PRODAPA-CKD	P4	unknown	Effect of Low Protein Diet on Top of Dapagliflozin on Chronic Kidney Disease in Patients With Type 2 Diabetes Mellitus
NCT05570305	ZODIAC	P2	completed	Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria
+ 5 more, see All trials below.

Diabetes Mellitus (12)

NCT	Acronym	Phase	Status	Title
NCT05174052	DAPA-AF	P3	recruiting	Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)
NCT07083388	—	P1	recruiting	A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fasting)
NCT05042505	Dapa-LiT	N/A	completed	Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver Transplantation
NCT07020377	NAFLD	P1/P2	active not recruiting	Dapagliflozin in Nonalcoholic Fatty Liver Disease (NAFLD) and Type 2 Diabetes Mellitus Patients (T2DM).
NCT06915870	—	N/A	completed	Comparison of Empagliflozin and Dapagliflozin in Patients With Heart Failure Taking Standard Treatment
NCT05505994	—	P3	unknown	The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin
NCT06241638	—	N/A	completed	Improving HbA1c Levels by Methylcobalamin Vitamin in Diabetic Volunteers
NCT04080518	DAPA-Shuttle1	P4	completed	Hepato-renal Regulation of Water Conservation in Heart Failure Patients With SGLT-2 Inhibitor Treatment
+ 4 more, see All trials below.

Type2 Diabetes (11)

NCT	Acronym	Phase	Status	Title
NCT04451837	—	P2	active not recruiting	Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology
NCT05194592	—	P4	unknown	Comparison of the Effects of Dapagliflozin and Gemigliptin on Ketone Metabolism and Cardiac Remodeling in Type 2 Diabetes
NCT05262257	—	Early P1	unknown	Evaluation and Intervention of Cognitive Function in Patients With Diabetes Mellitus.
NCT04885712	—	P3	completed	A Study to Evaluate the Efficacy and Safety of Pioglitazone 15mg or 30mg Add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin
NCT03748810	—	N/A	completed	Head-to-head Comparison of Empagliflozin and Dapagliflozin
NCT04170998	—	P3	completed	Efficacy and Safety of Evogliptin When Added to Ongoing Metformin and Dapagliflozin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
NCT04200586	SGLTi	P4	unknown	The Effects of SGLTi on Diabetic Cardiomyopathy
NCT03887416	—	P4	unknown	Effect of Dapagliflozin on Nighttime Blood Pressure in Type 2 Diabetes
+ 3 more, see All trials below.

Chronic Kidney Disease (9)

NCT	Acronym	Phase	Status	Title
NCT06610526	—	P4	active not recruiting	A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease
NCT06350123	MIRO-CKD	P2	completed	Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease
NCT05998837	GLUTREPRO	P2/P3	completed	GLUcose Transport and REnalPROtection in Chronic Kidney Disease
NCT07344922	—	P3	completed	SGLT2 Inhibitors in Non-Diabetic CKD: Effects on Vascular Calcification and Anemia
NCT04724837	ZENITH-CKD	P2	completed	Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial)
NCT04492722	—	P2	terminated	A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease
NCT04991571	—	P1	completed	Study to Collect Samples for MIST Analysis of Zibotentan and Bioavailability of Zibotentan and Dapagliflozin in Heatlhy Participants
NCT04882813	—	N/A	completed	Replication of the DAPA-CKD (Chronic Kidney Disease) Trial in Healthcare Claims Data
+ 1 more, see All trials below.

Breast Cancer (7)

NCT	Acronym	Phase	Status	Title
NCT05989347	—	P1	recruiting	Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy
NCT06304857	PROTECTAA	P3	recruiting	CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL
NCT07436663	SGLT2i/DPPi	P4	not yet recruiting	Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC
NCT06711185	DAPA-MYOCANCER	P3	recruiting	Effect of DAPAglifozin on MYOcardial Remodeling of Breast CANCER Patients Treated with Anthracycline Based Chemotherapy
NCT06491680	—	P4	recruiting	Cardiotoxicity in Breast Cancer Patients
NCT06341842	PROTECT	P2	unknown	Potential Protective Role of SGLT-2 Inhibitors for Chemotherapy-induced Cardiotoxicity
NCT04899349	EPIK-B4	P2	terminated	Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant

Diabetes (7)

NCT	Acronym	Phase	Status	Title
NCT05440591	DMVascular	P4	unknown	Effects of Dapagliflozin and Metformin on Vascular Function in Newly-Diagnosed Treatment-Naive Type 2 Diabetes
NCT04956263	—	P2	completed	A Comparison of Postprandial Glucose After a MMTT, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study in Subjects With Type 1 Diabetes
NCT04215523	—	N/A	completed	Replication of the DECLARE Diabetes Trial in Healthcare Claims
NCT02419612	—	P3	completed	A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone
NCT02610088	—	P4	completed	Effect of Dapagliflozin on Vascular Functions in Patients With Type 2 Diabetes Compared to Gliclazide
NCT02798757	—	P4	completed	Evaluation of the Tubular Effects of Dapagliflozin Using 1HNMR Spectroscopy
NCT02096705	—	P3	completed	Phase III Insulin Add-On Asia Regional Program - ST

Type 1 Diabetes Mellitus (7)

NCT	Acronym	Phase	Status	Title
NCT03899402	—	P2/P3	active not recruiting	Triple Therapy in T1DM
NCT02460978	DEPICT 2	P3	completed	Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes
NCT02268214	DEPICT 1	P3	completed	Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes
NCT02582814	—	P3	completed	The Safety and Efficacy of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM
NCT02582840	—	P1	completed	The PK and PD of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM
NCT02518945	—	P3	completed	Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes
NCT01498185	PK	P2	completed	BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes

Healthy (6)

NCT	Acronym	Phase	Status	Title
NCT07396844	—	P1	not yet recruiting	The Food Effect on Pharmacokinetics of Fixed Dose Combination of Gemigliptin/Dapagliflozin/Metformin in Healthy Volunteers
NCT06127212	—	N/A	completed	Bioequivalence Study of Dapagliflozin 10 mg Film-coated Tablets
NCT03364985	—	P1	completed	Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP16001 After Oral Administration in Healthy Male Volunteers
NCT01877889	—	P1	completed	A Study to Compare the Pharmacodynamics of Canagliflozin and Dapagliflozin in Healthy Volunteers
NCT01156246	—	P1	completed	Study to Assess the Effect of Food on Combination Dapagliflozin/Metformin Tablet in Healthy Volunteers
NCT00688493	—	P1	completed	Effects of Single Oral Dose Dapagliflozin QT Study

Type 1 Diabetes (6)

NCT	Acronym	Phase	Status	Title
NCT06922656	—	P4	not yet recruiting	Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration?
NCT05390307	OTID	N/A	completed	Obesity Treatment to Improve Diabetes
NCT04545411	—	P1/P2	completed	Combination GRA and SGLT-2i Treatment in Type 1 Diabetes
NCT04234867	Dapa-Stress	P1	terminated	Study to Explore the Effect of Dapagliflozin and Stress in Adolescent and Adult Subjects With Type 1 Diabetes (T1D)
NCT02777073	1974	N/A	completed	Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes
NCT02325206	DAPA-IIT1	P1	completed	Phase 1 Study to Explore the Safety and Pharmacokinetics of DAPAglifozin in Adolescents and Adults With Type 1 Diabetes

Diabetes Mellitus Type 2 (6)

NCT	Acronym	Phase	Status	Title
NCT02879409	—	N/A	active not recruiting	HbA1c Variability in Type II Diabetes
NCT06851962	EPHIC-DIA2	P4	active not recruiting	Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.
NCT03387683	DAPACARD	P4	completed	A Clinical Study to Investigate the Effects of Dapagliflozin on Heart Work, Heart Nutrient Uptake, and Heart Muscle Efficiency in Type 2 Diabetes Patients
NCT02719132	FLORA	P4	withdrawn	Effect of DapagliFLOzin on Quality of Life in Patients With Type 2 Diabetes in a Real Clinical PrActice
NCT02372955	—	P4	unknown	Mechanistic Study of the Systolic Blood Pressure Lowering Effect of Dapagliflozin in Type 2 Diabetes
NCT02383238	Dapa	P3	completed	Effect of Dapagliflozin on Microvascular and Macrovascular Circulation and Total Body Sodium Content

Healthy Volunteers (5)

NCT	Acronym	Phase	Status	Title
NCT07399470	—	P1	active not recruiting	A Clinical Study in Healthy Adults to See How the Body Processes and How Safe a Tablet That Combines Gemigliptin, Dapagliflozin, and Metformin is, Compared With Taking Zemiglo and Xigduo XR Together While Fasting.
NCT05429593	—	P1	completed	A Research Study Investigating How Semaglutide and Dapagliflozin Act in Your Body When Dosed in One Tablet
NCT05105698	—	P1	unknown	Food-effect Bioavailability of Gemigliptin and Dapagliflozin 50/10 mg
NCT01072578	—	P1	completed	A Study to to Assess the Effect of Dapagliflozin When Administered Once a Day Versus Twice a Day on Blood Glucose
NCT01055691	—	P1	completed	A Study Comparing the Amount of Metformin and After Taking a Combination Tablet vs. Separate Tablets

Obesity (5)

NCT	Acronym	Phase	Status	Title
NCT06000462	DAPA-ANDO	P4	active not recruiting	The Effect of Dapagliflozin on Weight Loss in Obese Adults Without Diabetes
NCT06344247	—	N/A	unknown	Comparison of the Efficacy and Safety of SGLT2i and GLP-1 Receptor Agonists in Obese Patients With Kidney Disease
NCT03710460	—	P4	unknown	Effect of Dapagliflozin/Metformin XR vs Monotherapies on Anthropometric Indicators in Obesity
NCT03419624	—	P3	terminated	The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients
NCT02313220	Dapalost	P2	completed	Exploratory Study to Investigate the Effect of Dapagliflozin and Exenatide Combined on Body Weight

Myocardial Infarction (5)

NCT	Acronym	Phase	Status	Title
NCT06009874	—	N/A	recruiting	Clinical Investigation of the Cardioprotective Effect of Early Administration of SGLT2 in Patients Presented With AMI
NCT06286878	—	P2/P3	recruiting	Pleiotropic Effects of Dapagliflozin in Patients With Acute Coronary Syndromes
NCT04783870	—	P4	unknown	Effect of Dapagliflozin on LV Remodeling Post AMI
NCT05050500	—	P4	completed	Effects of Dapagliflozin on Inflammatory Factorslevel and Prognosis in Type 2 Diabetes With Acute Myocardial Infarction
NCT05335629	—	N/A	completed	Evaluation of the Effect of SGLT-2 Inhibitors on Cardiac Remodeling in Post Myocardial Infarction Patients

Type 2 Diabetes Mellitus (T2DM) (4)

NCT	Acronym	Phase	Status	Title
NCT06327815	—	P4	completed	Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM
NCT06719661	—	N/A	completed	The Impact of Clinical Pharmacist Intervention and Dapagliflozin as Add-On Therapy in the Management of Type 2 Diabetes Mellitus.
NCT03423355	—	P4	withdrawn	Dapagliflozin Effect on Erythropoiesis and Physical Fitness
NCT01002807	FDC	P1	completed	Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State

Acute Kidney Injury (4)

NCT	Acronym	Phase	Status	Title
NCT06528405	ESS-AKD	P2	recruiting	The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease
NCT05468203	PREVENTS-AKI	P3	terminated	PREVENTion With Sglt-2 Inhibition of Acute Kidney Injury in Intensive Care
NCT05590143	MERCURI-2	P4	active not recruiting	proMoting Effective Renoprotection in Cardiac sURgery Patients by Inhibition of SGLT-2
NCT05435235	DAPA-PCI-AKI	P4	suspended	Dapagliflozin in the Prevention of Post-Coronary Angioplasty Acute Kidney Injury

Acute Heart Failure (4)

NCT	Acronym	Phase	Status	Title
NCT06783166	—	P2/P3	recruiting	Assessing the Clinical Outcomes of Dapagliflozin Versus Acetazolamide in Patients With Acute Heart Failure
NCT04363697	—	P4	completed	Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)
NCT06012279	—	P4	completed	Clinical Outcomes of Dapagliflozin in Acute Heart Failure With Reduced Ejection Fraction (CODA-HFrEF)
NCT05406505	DAPA-RESPONSE-AHF	P2/P3	completed	Effect of Dapagliflozin in Patients With Acute Heart Failure (DAPA-RESPONSE-AHF)

Healthy Subjects (4)

NCT	Acronym	Phase	Status	Title
NCT06233045	DAP-030-23	P1	unknown	Dapagliflozin Tablet 10 mg Relative to Forxiga® Tablets 10 mg
NCT05236998	—	P1	completed	A Pharmacokinetic Study of SID1903 (FDC of Dapagliflozin and Sitagliptin) in Healthy Adult Volunteers
NCT04880993	—	P1	completed	Bioequivalence of Dapagliflozin 10 mg Tablets Under Fasting Conditions
NCT04881006	—	P1	completed	Bioequivalence of Dapagliflozin 10 mg Tablets Under Fed Conditions

Atrial Fibrillation (AF) (3)

NCT	Acronym	Phase	Status	Title
NCT07187570	RECUR-AF	P3	recruiting	RECURrence of Atrial Fibrillation After Cardioversion of Patients Randomized to Dapagliflozin or Usual Care
NCT07331727	EAT-DARE-AF	N/A	not yet recruiting	Epicardial Adipose Tissue-Targeted DApagliflozin for Reducing Electrical Remodeling in Atrial Fibrillation
NCT06740786	—	N/A	not yet recruiting	Efficacy and Safety of Dapagliflozin in Preventing Atrial Fibrillation Recurrence After Catheter Ablation

Chronic Kidney Disease and Hypertension (3)

NCT	Acronym	Phase	Status	Title
NCT06742723	BaxDuo-Pacific	P3	recruiting	A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
NCT06268873	—	P3	active not recruiting	A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
NCT07222917	BaxDuo-Baltic	P2	recruiting	A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.

Nephrotic Syndrome (3)

NCT	Acronym	Phase	Status	Title
NCT07214818	SGLT2-NS	P2/P3	recruiting	SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome
NCT05966818	—	P4	unknown	Effect of Dapagliflozin in Non-Diabetic Patients With Nephrotic Syndrome.
NCT06026787	—	P4	completed	Clinical Value of Adding Dapagliflozin in Patients With Nephrotic Syndrome

Polycystic Ovary Syndrome (3)

NCT	Acronym	Phase	Status	Title
NCT06576375	—	P3	recruiting	Efficacy of Dapagliflozin Versus Metformin in Polycystic Ovary Syndrome
NCT04213677	DEAP	P3	completed	Dapagliflozin Efficacy and Action in PCOS
NCT02635386	PCOS	P3	completed	EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)

Diabetic Kidney Disease (3)

NCT	Acronym	Phase	Status	Title
NCT06532682	—	P4	active not recruiting	Efficacy of Dapagliflozin in Early Diabetic Nephropathy in Type 1 Diabetes
NCT06187493	—	N/A	unknown	Treatment of Patients With Diabetic Kidney Disease
NCT04170543	—	P2	completed	A Phase 2b Diabetic Kidney Disease Study

Prediabetic State (3)

NCT	Acronym	Phase	Status	Title
NCT05914857	—	P2	unknown	Evaluation of the Safety and Efficacy of SGLT2 Inhibitors in Pre-diabetic Patients
NCT03721874	MaasFlex	P4	completed	Effects of 2 Weeks Treatment With Dapagliflozin in Subjects With an Impaired Glucose Homeostasis on Nocturnal Substrate Oxidation
NCT02695810	—	P2	completed	The PRE-D Trial: Effect of Dapagliflozin, Metformin and Physical Activity in Pre-diabetes

Type2diabetes (3)

NCT	Acronym	Phase	Status	Title
NCT06054035	—	P4	recruiting	SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes
NCT05591235	—	P3	unknown	Effect of Metformin, Dapagliflozin, Combination of Metformin and Pioglitazone in Patients With Type 2 Diabetes
NCT05457933	—	P4	completed	Efficacy and Safety of Dapagliflozin for the Hospital Management of Patients With Type 2 Diabetes

Hypertension (3)

NCT	Acronym	Phase	Status	Title
NCT06063109	—	P1	completed	A Clinical Trial to Evaluate the Safety and the Pharmacokinetic Interaction of Telmisartan and Dapagliflozin.
NCT03592667	—	P4	unknown	Dapagliflozin on Blood Pressure Variability and Ambulatory Arterial Stiffness Index in Hypertension
NCT03089333	—	P4	completed	Effects of SGLT2 Inhibitor on Hemodynamic Parameters in Resistant Hypertensive Subjects

Heart Failure With Preserved Ejection Fraction (3)

NCT	Acronym	Phase	Status	Title
NCT05676684	SOGALDI-PEF	P2/P3	completed	Dapagliflozin With or Without Spironolactone for HFpEF
NCT04730947	DAPA	P2	completed	Dapagliflozin (DAPA) Effects in HFpEF
NCT03619213	DELIVER	P3	completed	Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.

Diabetes Mellitus, Type 1 (3)

NCT	Acronym	Phase	Status	Title
NCT04333823	ATTEMPT	P3	active not recruiting	Adolescent Type 1 Diabetes Treatment With SGLT2i for hyperglycEMia & hyPerfilTration Trial
NCT03537131	DEPTH	P2	terminated	Dapagliflozin During Exercise for the PrevenTion of Hypoglycaemia
NCT03556033	—	P2	completed	Effect of Dapagliflozin on IAH in T1DM

Type2 Diabetes Mellitus (3)

NCT	Acronym	Phase	Status	Title
NCT03313752	DapaHeart	P3	completed	Effects of SGLT2 Inhibition on Myocardial Insulin Sensitivity
NCT03714594	—	P2	completed	Effects of Dapagliflozin+Saxagliptin in Addition to Metformin v/s Saxagliptin or Dapagliflozin in Patients With DM2.
NCT04287387	—	P4	unknown	Response of Gut Microbiota in Type 2 Diabetes to Hypoglycemic Agents

PreDiabetes (3)

NCT	Acronym	Phase	Status	Title
NCT03968224	—	P2/P3	completed	Effectiveness of Dapagliflozin for Weight Loss
NCT03658031	—	P3	unknown	Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction
NCT03006471	—	P4	completed	Effect of Dapagliflozin on Blood Pressure Variability in Prediabetes and Prehypertension

Aortic Stenosis (2)

NCT	Acronym	Phase	Status	Title
NCT07539259	RELIEF-AS	P2	not yet recruiting	To Establish Whether Dapagliflozin and Spironolactone in Patients With Severe Aortic Stenosis Undergoing Aortic Valve Replacement, Result in Better Left Ventricular Mass Regression, Myocardial Health and Patient Reported Outcomes
NCT04696185	DapaTAVI	P4	completed	Dapagliflozin After Transcatheter Aortic Valve Implantation

Type1diabetes (2)

NCT	Acronym	Phase	Status	Title
NCT07056699	—	P3	not yet recruiting	SGLT2i, Pioglitazone, and Ketone Production in T1D
NCT02987738	DapaDream	P1	completed	Pilot Study to Explore the Efficacy of DAPAglifozin as add-on to Closed-loop Control in Patients With Type 1 Diabetes

Prostate Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT07310433	NHA	P2	not yet recruiting	Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prostate Cancer
NCT04887935	—	P1	recruiting	Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer

Acute Heart Failure (AHF) (2)

NCT	Acronym	Phase	Status	Title
NCT07469722	POINTER-HF	P2/P3	not yet recruiting	POcus INTERvention for Tailoring Diuretic Strategy in Acute Decompensated Heart Failure
NCT07392788	GlifloFastER	N/A	not yet recruiting	Early Gliflozin for Elderly Patients With Acute Decompensated Heart Failure in the Emergency Department

Healthy Participants (2)

NCT	Acronym	Phase	Status	Title
NCT07404137	—	P1	completed	A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food
NCT06979388	—	P1	completed	A Study to Investigate the Effect of Food on Balcinrenone/Dapagliflozin Pharmacokinetics in Fed and Fasted State and Pharmacokinetics of Balcinrenone When Dosed With a P-gp Inhibitor in Healthy Participants.

STEMI - ST Elevation Myocardial Infarction (2)

NCT	Acronym	Phase	Status	Title
NCT07297589	EPIC-CT	P3	recruiting	Epicardial Cardiac Fat-CT (EPIC-CT)
NCT05045274	—	N/A	unknown	The Effect of Early Administration of Dapagliflozin in STEMI Patients With LV Systolic Dysfunction

Coronary Artery Disease (2)

NCT	Acronym	Phase	Status	Title
NCT07254572	CASCADES	P4	recruiting	Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes
NCT04330079	—	P4	terminated	Effects of dapaglifloziN Therapy on Myocardial Perfusion Reserve in Prediabetic Patients With Stable coronarY Artery Disease

Chronic Kidney Disease(CKD) (2)

NCT	Acronym	Phase	Status	Title
NCT07239570	CKD-bioMatch	P4	recruiting	A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease
NCT06897605	—	P2	recruiting	Impact of Dapagliflozin in Anemic Chronic Kidney Disease Patients

Chronic Kidney Disease With High Proteinuria (2)

NCT	Acronym	Phase	Status	Title
NCT06087835	—	P3	active not recruiting	Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
NCT06942910	ZODIAC	P2	recruiting	A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria

Dapagliflozin (Forxiga) (2)

NCT	Acronym	Phase	Status	Title
NCT06759909	—	P1	not yet recruiting	Dapagliflozin on Outcomes of Rhythm Control Strategy (Pharmacological ± Interventional) in Patient with Atrial Fibrillation
NCT06748105	DAPACOID	P2	active not recruiting	Dapagliflozin as Prophylaxis for Glucocorticoid-Induced Hyperglycemia

Healthy Volunteer (2)

NCT	Acronym	Phase	Status	Title
NCT06651021	—	P1	completed	A Phase I PK Study of Balcinrenone/Dapagliflozin in Healthy Chinese Participants
NCT04856007	—	P1	completed	A Study to Assess the Bioequivalence of Fixed Dose Combination of Dapagliflozin/Metformin XR Relative to Co-administration of the Individual Components in Healthy Chinese Subjects.

Acute Decompensated Heart Failure (2)

NCT	Acronym	Phase	Status	Title
NCT05776043	EMPATHY	P3	unknown	Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart Failure
NCT06535529	—	P3	recruiting	Acetazolamide Versus Dapagliflozin in Acute Decompensated Heart Failure Patients

Atrial Fibrillation (2)

NCT	Acronym	Phase	Status	Title
NCT06433479	DARE-AF	N/A	completed	Efficacy of Dapagliflozin on Recurrence After Catheter Ablation for Atrial Fibrillation
NCT04792190	DAPA-AF	P4	completed	Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation

T2DM (Type 2 Diabetes Mellitus) (2)

NCT	Acronym	Phase	Status	Title
NCT06415773	HARMONY	P3	completed	Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin
NCT04634500	ENHANCE-M	P3	completed	The Efficacy and Safety of DWP16001 in Combination With Metformin in Patients With Type 2 Diabetes.

Heart Failure, Systolic (2)

NCT	Acronym	Phase	Status	Title
NCT06434025	COMBINED-HF	P3	not yet recruiting	IV Iron and SGLT2 Inhibitor on Ventricular Function and Myocardial Iron Content in Heart Failure With Iron Deficiency
NCT04570865	DAPA-MEMS	P4	unknown	Dapagliflozin And Pulmonary Artery Hemodynamics in Heart Failure With Reduced Ejection Fraction Patients With CardioMEMS®

Peritoneal Dialysis Complication (2)

NCT	Acronym	Phase	Status	Title
NCT06398977	—	N/A	recruiting	Dapagliflozin Delays the Loss of Renal Function in Peritoneal Dialysis Patients
NCT04923295	—	N/A	completed	The Effect of Dapagliflozin on Ultrafiltration Among Peritoneal Dialysis Patients

Alport Syndrome (2)

NCT	Acronym	Phase	Status	Title
NCT06226896	—	N/A	active not recruiting	Effects of Dapagliflozin on Progression of Alport Syndrome
NCT06499948	COMBINE-ALPORT	P4	completed	Albuminuria Lowering Effect of Dapagliflozin, Spironolactone and Their Combination in Adult Patients With Alport Syndrome (COMBINE-ALPORT)

Liver Cirrhosis (2)

NCT	Acronym	Phase	Status	Title
NCT05516498	ZEAL	P2	terminated	Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)
NCT06269484	ZEAL UNLOCK	P2	completed	A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK

Kidney Transplant; Complications (2)

NCT	Acronym	Phase	Status	Title
NCT06140537	—	P4	recruiting	Efficacy and Mechanisms of Dapagliflozin in Promoting Kidney Function and Cardiovascular Health in Kidney Transplant Recipients
NCT05788276	DEAKTransplant	P4	recruiting	Can Dapagliflozin Preserve Structure and Function in Transplanted Kidneys?

Lupus Nephritis (2)

NCT	Acronym	Phase	Status	Title
NCT06155604	—	P2	recruiting	SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease
NCT06113900	—	P1/P2	unknown	Assessment of Safety and Efficacy of SGLT2is Among LN Patients

Atrial Fibrillation Recurrent (2)

NCT	Acronym	Phase	Status	Title
NCT06111443	—	P2/P3	active not recruiting	Effect of Dapagliflozin on the Recurrence of Atrial Tachyarrhythmia in Patients Undergoing Catheter Ablation of Atrial Fibrillation
NCT04780438	—	Early P1	unknown	Dapagliflozin to Prevent Atrial Fibrillation Recurrence After Transcatheter Pulmonary Venous Isolation.

Kidney Transplant Recipients (2)

NCT	Acronym	Phase	Status	Title
NCT05938712	HALLMARK	P2	recruiting	The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients
NCT04965935	INFINITI2019	P3	completed	Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients

Cystinuria (2)

NCT	Acronym	Phase	Status	Title
NCT05058859	SGLT-2	P2	withdrawn	Long Term Clinical Efficacy of Sodium-glucose Cotransporter-2 (SGLT-2) Inhibitor in Cystinurics
NCT04818034	SGLT	P2	completed	The Effect of Sodium-glucose Cotransporter (SGLT) 2 Inhibitors on Cystine Stone Formation: A Preliminary Study

Diabete Type 2 (2)

NCT	Acronym	Phase	Status	Title
NCT07338331	AS-NAFLD	N/A	completed	Comparative Effects of Aspirin and SGLT2 Inhibitors on Liver Enzymes, Lipid Profile, and FibroScan Findings in Non-Alcoholic Fatty Liver Disease
NCT05998525	—	P3	completed	Dapagliflozin Effects on Coronary Calcium and Epicardial Fat Assessed by Cardiotomography

Functional Mitral Regurgitation (2)

NCT	Acronym	Phase	Status	Title
NCT05848102	DEFORM	P4	unknown	Dapagliflozin Effect on FunctiOnal Mitral Regurgitation and Myocardial Fibrosis (DEFORM)
NCT05606718	DEFORM	P4	unknown	Dapagliflozin Effect on FunctiOnal Mitral Regurgitation and Myocardial Remodeling

Renal Insufficiency, Chronic (2)

NCT	Acronym	Phase	Status	Title
NCT04930549	DAPAVASC	P2	completed	Vascular Impact of Dapagliflozin in CKD Patients (DAPAVASC)
NCT05225077	—	P4	unknown	Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients

Anemia (2)

NCT	Acronym	Phase	Status	Title
NCT04707261	ADIDAS	P4	recruiting	Association Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients (ADIDAS)
NCT06813222	—	N/A	active not recruiting	Anemia-Related Outcomes in Patients With CKD Treated With Dapagliflozin

T2DM (2)

NCT	Acronym	Phase	Status	Title
NCT05159882	—	P3	unknown	Safety and Efficacy of THR-1442 Compared to Dapagliflozin as Add-on Therapy to Metformin in T2DM
NCT04544319	—	P1	unknown	Clinical Trial to Compare the PK of the Fixed-dose Combinations and Each Component of Gemigliptin/Dapagliflozin 50/10 mg

Acute Myocardial Infarction (2)

NCT	Acronym	Phase	Status	Title
NCT04564742	DAPA-MI	P3	completed	Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack.
NCT04717986	DAPA-AMI	N/A	completed	Dapagliflozin Effects on Mayor Adverse Cardiovascular Events in Patients With Acute Myocardial Infarction (DAPA-AMI)

Proteinuria (2)

NCT	Acronym	Phase	Status	Title
NCT04531397	—	P4	withdrawn	Efficacy and Safety of Dapagliflozin in Children With Proteinuric Chronic Kidney Disease
NCT04534270	—	P4	completed	Efficacy and Safety of Dapagliflozin in Children With Proteinuria

COVID-19 (2)

NCT	Acronym	Phase	Status	Title
NCT04393246	—	P2/P3	completed	mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms
NCT04350593	DARE-19	P3	completed	Dapagliflozin in Respiratory Failure in Patients With COVID-19

Heart Failure With Reduced Ejection Fraction (HFrEF) (2)

NCT	Acronym	Phase	Status	Title
NCT04304560	—	P2	unknown	Value of SGLT2 Inhibitor (Dapagliflozin) as an Added Therapy in Diabetic Patients With Heart Failure With Reduced Ejection Fraction; Randomized Controlled Clinical Trial
NCT03877237	—	P3	completed	DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction

Weight Loss (2)

NCT	Acronym	Phase	Status	Title
NCT03180489	—	P2	completed	Does Dapagliflozin Provide Additional Health Benefits To Dietary Counseling For Weight Loss?
NCT02520518	—	P2	terminated	Does Dapagliflozin Promote Favorable Health Benefits That Are Independent Of Weight Loss?

Myelodysplastic Syndromes (MDS) (1)

NCT	Acronym	Phase	Status	Title
NCT07516847	DAPA-MDS1	P2	not yet recruiting	Dapagliflozin for Anemia in Lower-Risk Myelodysplastic Syndromes

Lupus Nephritis (LN) (1)

NCT	Acronym	Phase	Status	Title
NCT07323524	Dapa-Active LN	P4	recruiting	Dapagliflozin in Active Lupus Nephritis

Fontan (1)

NCT	Acronym	Phase	Status	Title
NCT07482943	—	P4	not yet recruiting	The Effect of Dapagliflozin on Exercise and Cardiac Functional Status of Patients After Fontan Procedure

Antipsychotic-induced Weight Gain (AIWG) (1)

NCT	Acronym	Phase	Status	Title
NCT07342764	—	P4	not yet recruiting	Dapagliflozin Versus Metformin for the Management of Antipsychotic-Induced Weight Gain: A Pragmatic Pilot Randomized Controlled Trial

Chronic Kidney Disease (Mild to Moderate) (1)

NCT	Acronym	Phase	Status	Title
NCT07405216	IECA-MEX	P4	recruiting	Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Early Stages of Chronic Kidney Disease

COVID - 19 (1)

NCT	Acronym	Phase	Status	Title
NCT06907251	DALCO	P3	not yet recruiting	Dapagliflozin for Long COVID Syndrome

End Stage Chronic Renal Failure (1)

NCT	Acronym	Phase	Status	Title
NCT07491042	—	N/A	recruiting	Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients.

Congestive Heart Failure Acute (1)

NCT	Acronym	Phase	Status	Title
NCT07403955	—	N/A	not yet recruiting	The Effect of Dapagliflozin on Myocardial Strain in Patients With Acute Heart Failure

ACS (Acute Coronary Syndrome) (1)

NCT	Acronym	Phase	Status	Title
NCT07351643	DAPA-PCAT	P4	not yet recruiting	CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes in Non-diabetic ACS Patients Without HF

Type 1 Diabetes Mellitus With Diabetic Nephropathy (1)

NCT	Acronym	Phase	Status	Title
NCT06072326	ASPIRE-1	P2	not yet recruiting	dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation

Acute Myocardial Infarction With ST Elevation (1)

NCT	Acronym	Phase	Status	Title
NCT07295223	GALACTUS	P3	recruiting	Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)

Polycystic Kidney, Autosomal Dominant (1)

NCT	Acronym	Phase	Status	Title
NCT07280585	STOP-PKD	P3	recruiting	STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease

Heart Failure and Chronic Kidney Disease Post-ICU (1)

NCT	Acronym	Phase	Status	Title
NCT07025629	DAPA-ICU	P3	recruiting	Dapagliflozin for Cardio-renal Protection After ICU Discharge

Retinal Degeneration (1)

NCT	Acronym	Phase	Status	Title
NCT07174687	—	P2	recruiting	SGLT2 Inhibitors in Geographic Atrophy

Lung Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT07235280	—	Early P1	recruiting	Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung Adenocarcinoma

Type 2 DM (1)

NCT	Acronym	Phase	Status	Title
NCT06954090	SIGNAL	P4	enrolling by invitation	Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study

Depression (1)

NCT	Acronym	Phase	Status	Title
NCT07239011	—	P1/P2	recruiting	Dapagliflozin in Depression

Fed Conditions (1)

NCT	Acronym	Phase	Status	Title
NCT07333742	—	P1	completed	A Clinical Study to See How the Body Handles and How Safe a Combination Tablet of Gemigliptin, Dapagliflozin, and Metformin 50/10/1000mg is Compared to Taking Gemigliptin 50mg Separately With Dapagliflozin/Metformin 10/1000mg in Healthy Adults After a Meal

Acute Decompensated Heart Failure (ADHF) (1)

NCT	Acronym	Phase	Status	Title
NCT07076615	Dapagliflozin	P4	recruiting	The Effect of Dapagliflozin on Patients With Cardiomyopathy

Glioma (1)

NCT	Acronym	Phase	Status	Title
NCT06750458	—	P3	not yet recruiting	Dapagliflozin Versus Dexamethasone Role in Pre-operative Management of Non- Diabetic Brain Tumor Patients

SGLT 2 Inhibitors (1)

NCT	Acronym	Phase	Status	Title
NCT07204743	—	N/A	active not recruiting	Efficacy and Safety of Dapagliflozin in Children With Proteinuria

Takotsubo Cardiomyopathy (1)

NCT	Acronym	Phase	Status	Title
NCT07491718	TAKO MEMRI	N/A	recruiting	Manganese-enhanced Magnetic Resonance Imaging in Takotsubo Cardiomyopathy

Diabete Mellitus (1)

NCT	Acronym	Phase	Status	Title
NCT07083401	—	P1	recruiting	A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fed)

Fontan Circulation (1)

NCT	Acronym	Phase	Status	Title
NCT06762964	—	P2	recruiting	CAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation

Congenital Heart Disease (1)

NCT	Acronym	Phase	Status	Title
NCT06668389	STEPS	P4	recruiting	Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary Status Trial

Solid Tumors (1)

NCT	Acronym	Phase	Status	Title
NCT07018622	DAPA-ARMOR	P2	recruiting	Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity

Chronic Kidney Disease Stage 5 (1)

NCT	Acronym	Phase	Status	Title
NCT06982079	—	P3	recruiting	Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Kidney Function in Advanced Chronic Kidney Disease

Graft-versus-host Disease (GVHD) (1)

NCT	Acronym	Phase	Status	Title
NCT06626737	DAPALAG-01	P2	recruiting	Dapagliflozin in Allo-HCT for aGVHD

Refractory Ascites (1)

NCT	Acronym	Phase	Status	Title
NCT06919523	—	P2	not yet recruiting	Clinical Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patients With Refractory Cirrhotic Ascites

Pediatric Hereditary Kidney Diseases (1)

NCT	Acronym	Phase	Status	Title
NCT06890143	—	P3	recruiting	The Efficacy and Safety of Dapagliflozin in the Treatment of Hereditary Kidney Disease With Proteinuria in Children

Large Vessel Vasculitis (1)

NCT	Acronym	Phase	Status	Title
NCT06887062	DERAIL-LVV	P2	recruiting	Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV)

Gestational Hypertension (1)

NCT	Acronym	Phase	Status	Title
NCT06785116	DAPA-HP	P4	recruiting	A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP)

Diabetic Macular Edema (1)

NCT	Acronym	Phase	Status	Title
NCT06845163	DAPA-DME	P2	recruiting	Randomized Clinical Trial to Evaluate the Effect of Dapagliflozin in Patients With Diabetic Macular Edema

ST Elevation Myocardial Infarction (1)

NCT	Acronym	Phase	Status	Title
NCT06174753	DAPA STEMI	P3	recruiting	Dapagliflozin in STEMI

Heart Failure NYHA Class II (1)

NCT	Acronym	Phase	Status	Title
NCT06778330	—	N/A	completed	The Effect of Combination of Dapagliflozin and Sildenafil in Treatment of Heart Failure Patients With Secondary Pulmonary Hypertension

Myocardial Infarct (1)

NCT	Acronym	Phase	Status	Title
NCT06562582	STAMI-BAS	P4	recruiting	STunning in Acute Myocardial Infarction - BAS

Kidney Diseases (1)

NCT	Acronym	Phase	Status	Title
NCT06759077	—	P3	active not recruiting	Cardio Protective Effect of SGL2I in Hemodialysis Patients and Its Impact on Patient Quality of Life

HIV Infections (1)

NCT	Acronym	Phase	Status	Title
NCT06317051	OPTIMAR	P3	active not recruiting	Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART)

Effect of SGLT2 Inhibitors NAFLD in Type 2 Diabetic Patients with Diabetic Nephropathy (1)

NCT	Acronym	Phase	Status	Title
NCT06668753	—	N/A	not yet recruiting	Effect of SGLT2 Inhibitors on NAFLD in Type 2 Diabetic Patients with Diabetic Nephropathy

Doxorubicin Induced Cardiomyopathy (1)

NCT	Acronym	Phase	Status	Title
NCT06427226	—	P2	recruiting	Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity

Diabetic (1)

NCT	Acronym	Phase	Status	Title
NCT07083232	—	P4	completed	The Effect of Sitagliptin, Pioglitazone and Dapagliflozine on Myocardial Infarction in Diabetic Rats

Pulmonary Hypertension (1)

NCT	Acronym	Phase	Status	Title
NCT06612086	—	P1	not yet recruiting	Dapagliflozin in Mangement of Pulmonary Hypertension Patients

Polycystic Ovary (1)

NCT	Acronym	Phase	Status	Title
NCT06405178	—	P3	completed	Adjuvant Therapy With Letrozole in Induction of Ovulation With Polycystic Ovarian Syndrome

Renal Impairment (1)

NCT	Acronym	Phase	Status	Title
NCT06639087	AURORA	P1	terminated	A Phase Ib Study of AZD5462 on Top of Dapagliflozin in Participants With Heart Failure and Moderate Renal Impairment

Kidney Transplant (1)

NCT	Acronym	Phase	Status	Title
NCT07555106	DAPA-GRAFT	P2	active not recruiting	Dapagliflozin in Living-Donor Kidney Transplant Recipients

Anthracyclines-Induced Cardiotoxicity (1)

NCT	Acronym	Phase	Status	Title
NCT06888505	DAPA-AIC	P2	completed	Dapagliflozin to Prevent Anthracycline-Induced Cardiotoxicity

Hepatic Steato-Fibrosis (1)

NCT	Acronym	Phase	Status	Title
NCT06373523	SHIELD	Early P1	not yet recruiting	MASLD in Primary Hypothyroidism and Efficacy of Dapaglifozin

Heart Failure with Preserved Ejection Fraction (1)

NCT	Acronym	Phase	Status	Title
NCT06510270	—	N/A	not yet recruiting	Dapagliflozin in Reducing Epicardial Adipose Tissue in Heart Failure with Preserved Ejection Fraction

Renal AL Amyloidosis (1)

NCT	Acronym	Phase	Status	Title
NCT06420167	FLORAL	P2	recruiting	DapagliFLOzin in Renal AL Amyloidosis (FLORAL)

Heart Failure Acute (1)

NCT	Acronym	Phase	Status	Title
NCT06442280	DAPA-TONIC	P4	not yet recruiting	SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HF

Cardiorenal Syndrome (1)

NCT	Acronym	Phase	Status	Title
NCT06111768	SGLT2i in CRS	P2	active not recruiting	Sodium-Glucose Cotransporter-2 Inhibitor for Acute Cardiorenal Syndrome: A Feasibility Study

Inflammation (1)

NCT	Acronym	Phase	Status	Title
NCT06812429	EFSII	Early P1	completed	Effects of Sodium-Glucose Co-transporter 2 Inhibitors on Inflammation

Lewy Body Dementia (1)

NCT	Acronym	Phase	Status	Title
NCT06263673	—	P4	completed	Anti-Diabetic Medications to Fight PD and LBD

Dyslipidemia (1)

NCT	Acronym	Phase	Status	Title
NCT06772168	—	P3	recruiting	Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia

Heart Failure and Impaired Kidney Function (1)

NCT	Acronym	Phase	Status	Title
NCT06307652	BalanceD-HF	P3	recruiting	Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

Chronic Coronary Syndrome (1)

NCT	Acronym	Phase	Status	Title
NCT05852704	STENOTYPE	P3	recruiting	SGLT2 Inhibitor TrEatment iN Patients Awaiting cOronary arTery bYpass Surgery to Reduce Post-opErative AF

Chronic Hepatitis B (1)

NCT	Acronym	Phase	Status	Title
NCT06364930	—	P4	recruiting	SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes Mellitus

Chronic Kidney Failure in Children and Young Adults (1)

NCT	Acronym	Phase	Status	Title
NCT05944016	DOUBLE_PROTECT	P3	recruiting	Phase 3 Clinical Trial with Dapagliflozin in Chronic Kidney Disease in Adolescents and Young Adult Patients

M-protein Related Cardiac Disease (1)

NCT	Acronym	Phase	Status	Title
NCT06297681	—	N/A	unknown	Combination of Daratumumab and BD Regimen and Dapagliflozin in the Treatment of M-protein Related Cardiac Disease

Urolithiasis (1)

NCT	Acronym	Phase	Status	Title
NCT05443932	—	P4	unknown	Dapagliflozin and Hydrochlorothiazide in Recurring Kidney Stone Patients

The Efficacy and Safety of Dapagliflozin in Improving Heart Failure in Dialysis Patients (1)

NCT	Acronym	Phase	Status	Title
NCT06365541	—	P4	unknown	The Efficacy and Safety of Dapagliflozin in Improving Heart Failure in Dialysis Patients

Genetic Polymorphisms (1)

NCT	Acronym	Phase	Status	Title
NCT06201000	—	N/A	unknown	Effect of Genetic Polymorphisms on the Clinical Response to SGLT2 Inhibitors in Heart Failure Patients

Compensated Cirrhosis (1)

NCT	Acronym	Phase	Status	Title
NCT06147518	—	N/A	unknown	To Compare the Safety and Efficacy of Dapagliflozin Plus Metformin Versus Sitagliptin Plus Metformin for Treatment of Diabetes in Patients With Compensated and Stable Decompensated Cirrhosis

Heart Failure - NYHA II - IV (1)

NCT	Acronym	Phase	Status	Title
NCT06901609	—	N/A	active not recruiting	Effect of Genetic Polymorphism on the Clinical Outcome to SGLT2 Inhibitors in Heart Failure Patients

Atrial Fibrillation Recurrence (1)

NCT	Acronym	Phase	Status	Title
NCT05816733	DETAIL-CMIV	P4	unknown	Dapagliflozin Evaluation on Atrial Fibrillation Patients Followed Cox Maze IV Procedure

Fabry Disease (1)

NCT	Acronym	Phase	Status	Title
NCT05710367	—	P2	unknown	Effects Of Sodium Glucose Cotranspoter 2 Inhibitors On Heart And Kidneys In Fabry Disease Patients

Inflammatory Bowel Diseases (1)

NCT	Acronym	Phase	Status	Title
NCT05986136	—	P2/P3	recruiting	Activation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel Disease

Chronic Renal Failure (1)

NCT	Acronym	Phase	Status	Title
NCT05884866	DapaBalci-Leap	P2	completed	A Study to Investigate the Mechanistic Effects of Dapagliflozin Alone or in Combination With Balcinrenone, Compared to Balcinrenone and Placebo on Body Fluid and Electrolyte Handling and Energy Metabolism in Participants Over 50 Years of Age With Chronic Kidney Disease.

AMI (1)

NCT	Acronym	Phase	Status	Title
NCT05764057	DAPAPROTECTOR	P3	recruiting	DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction

Depressive Disorder (1)

NCT	Acronym	Phase	Status	Title
NCT05792540	—	P2	completed	Clinical Study to Evaluate the Possible Efficacy of Dapagliflozin and Atorvastatin in Patients With Major Depressive Disorders

Myocardial Ischemia (1)

NCT	Acronym	Phase	Status	Title
NCT05762952	SMILE	P1	recruiting	Effect of Dapagliflozin on Microvascular Function in Women With Symptoms of Coronary Artery Disease

NAFLD Cirrhosis (1)

NCT	Acronym	Phase	Status	Title
NCT05849220	—	N/A	unknown	Dapagliflozin in Non Alcoholic Fatty Liver Disease Associated Cirrhosis and Its Role in Preventing Development of Chronic Kidney Disease.

NAFLD (Nonalcoholic Fatty Liver Disease) (1)

NCT	Acronym	Phase	Status	Title
NCT07363707	(Dapa)& (Empa)	P4	completed	A Study Between Dapagliflozin and Empagliflozin Effect on NAFLD in Patients With Type 2 Diabetes.

Dilated Cardiomyopathy (1)

NCT	Acronym	Phase	Status	Title
NCT05849766	—	P3	completed	Effect of Dapagliflozin on Cardiac Structure, Function and Secondary Mitral Regurgitation in Patients with Left Ventricle Dysfunction

Pediatric Brain Tumor (1)

NCT	Acronym	Phase	Status	Title
NCT05521984	—	P1	recruiting	Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)

Metabolic Associated Fatty Liver Disease (1)

NCT	Acronym	Phase	Status	Title
NCT05782972	—	P4	active not recruiting	Therapeutic Response of Sodium-glucose Co-transporter Type-2 Inhibitor in Non-diabetic MAFLD Patients: a Pilot Study

Insulin Pump，Continuous Glucose Monitoring Technology (1)

NCT	Acronym	Phase	Status	Title
NCT06127433	—	P4	unknown	The Effect of Short-term Insulin Intensive Therapy Based on the Application of Insulin Pump and Real-time Dynamic Glucose Monitoring Technology on Reversing the Newly Diagnosed Type 2 Diabetes

End-stage Kidney Disease (1)

NCT	Acronym	Phase	Status	Title
NCT05685394	Dare-Esrd	P4	unknown	DApagliflozin Cardiovascular Effects on Patients at End-stage REnal Disease

Arrhythmias, Cardiac (1)

NCT	Acronym	Phase	Status	Title
NCT06721442	DAPA-ECG	P4	completed	Effect of Dapagliflozin on Electrocardiographic Parameters in Type 2 Diabetes Patients: DAPA - ECG Study

Pulmonary Arterial Hypertension (1)

NCT	Acronym	Phase	Status	Title
NCT05179356	DAPAH	P2	completed	Dapagliflozin in Pulmonary Arterial Hypertension

AKI - Acute Kidney Injury (1)

NCT	Acronym	Phase	Status	Title
NCT05713851	DAKI-CKD	P2/P3	unknown	Dapaglifozin to Avoid Acute Kindey Injury (AKI) to Chronic Kidney Disease (CKD) Transition: DAKI-CKD Study

Rheumatic Heart Disease (1)

NCT	Acronym	Phase	Status	Title
NCT05618223	Dapa-Rhemis	P3	unknown	Dapagliflozin Effect on Rheumatic Mitral Stenosis

Kidney Disease, Chronic (1)

NCT	Acronym	Phase	Status	Title
NCT05374291	—	P3	enrolling by invitation	The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD

Critical Illness (1)

NCT	Acronym	Phase	Status	Title
NCT05558098	DEFENDER	P3	completed	Dapagliflozin in Patients With Critical Illness

SGLT2 INHIBITORS (1)

NCT	Acronym	Phase	Status	Title
NCT05704088	—	P4	completed	SGLT2 Inhibitors Between Reno Protective Effects and Impact on Bone and Mineral Disease Among Lupus Nephritis Patients

SLE (1)

NCT	Acronym	Phase	Status	Title
NCT05748925	—	P4	completed	Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients

Kidney Failure (1)

NCT	Acronym	Phase	Status	Title
NCT05179668	DAPA-HD	P2	completed	SGLT2 Inhibition in Hemodialysis

End-stage Heart Failure (1)

NCT	Acronym	Phase	Status	Title
NCT04782245	ARCADIA-HF	P2	withdrawn	Acute Reno-Cardiac Action of Dapagliflozin In Advanced Heart Failure Patients on Heart Transplant Waiting List

Non-alcoholic Steatohepatitis (1)

NCT	Acronym	Phase	Status	Title
NCT05254626	—	P2	completed	Efficacy and Safety of Dapagliflozin in Patients with Non-alcoholic Steatohepatitis

Dapagliflozin Adverse Reaction (1)

NCT	Acronym	Phase	Status	Title
NCT05717257	DAPA-SERVE	P4	unknown	Dapagliflozin in Systemic Right Ventricle (DAPA-SERVE)

Myocardial Dysfunction (1)

NCT	Acronym	Phase	Status	Title
NCT05330013	—	P2	withdrawn	The Effect of Inflammation in Heart Failure

Obstructive Sleep Apnea (1)

NCT	Acronym	Phase	Status	Title
NCT06690723	D3DOSA	P3	completed	Vitamin D and SGLT-2 Inhibitor in CPAP-naive Obstructive Sleep Apnea

Heart Transplant Failure (1)

NCT	Acronym	Phase	Status	Title
NCT05321706	DAPARHT	P3	recruiting	DAPAgliflozin for Renal Protection in Heart Transplant Recipients

Diabetic Retinopathy (1)

NCT	Acronym	Phase	Status	Title
NCT05310916	—	P3	unknown	Effect of SGLT2i on Diabetic Retinopathy in Type 2 Diabetes Mellitus Patients

Heart Failure With Reduced Ejection Fraction (1)

NCT	Acronym	Phase	Status	Title
NCT05795400	—	N/A	completed	Administration of the SGLT-2 Inhibitor Dapagliflozin in the Patients With Amyloid Cardiomyopathy

Diabetic Nephropathy Type 2 (1)

NCT	Acronym	Phase	Status	Title
NCT06326034	—	P4	completed	Impact of Dapagliflozin as Add-on Therapy on Glycemic Status and Quality of Life in Type 2 Diabetic Patients

Nonalcoholic Fatty Liver Disease (1)

NCT	Acronym	Phase	Status	Title
NCT05459701	T2DM	P4	completed	Dapagliflozin in Type 2 Diabetes Mellitus Patients (T2DM) With Nonalcoholic Fatty Liver Disease (NAFLD)

Diabetic Peripheral Neuropathy (1)

NCT	Acronym	Phase	Status	Title
NCT05162690	DINE	P2/P3	unknown	Efficacy of Dapagliflozin in Diabetes Associated Peripheral Neuropathy

End-stage Renal Disease (1)

NCT	Acronym	Phase	Status	Title
NCT05343078	DARE-ESKD 1	P4	completed	Pharmacokinetics and Dialyzability of Dapagliflozin in Dialysis Patients

Heart Failure, Reduced Ejection Fraction (1)

NCT	Acronym	Phase	Status	Title
NCT05250011	EVOLUTION-HF	N/A	completed	Observation of Italian Patients With Heart Failure Being Treated With Dapagliflozin in Clinical Practice

STEMI (1)

NCT	Acronym	Phase	Status	Title
NCT05957887	—	P3	unknown	Short and Intermediate Term Effect of Dapagliflozin on Left Ventricular Remodeling in Anterior STEMI Patients

Tricuspid Regurgitation (1)

NCT	Acronym	Phase	Status	Title
NCT05686616	Reduction-TR	N/A	unknown	SGLT2 Inhibitor for Severe Tricuspid Regurgitation

Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus) (1)

NCT	Acronym	Phase	Status	Title
NCT05266404	—	P1	completed	Phase 1 Bioequivalence Study of Dapagliflozin/Sitagliptin FDC vs Loose Combination of Single Components

Reperfusion Injury (1)

NCT	Acronym	Phase	Status	Title
NCT05217654	—	P1	unknown	Trial to Investigate the Effect of Dapagliflozin on Ischemia Reperfusion Induced Endothelial Dysfunction

Albuminuria (1)

NCT	Acronym	Phase	Status	Title
NCT05268926	TIMOTHY	P2	terminated	TreatIng Microalbuminuria Over 24 Weeks in Subjects With or Without Type 2 Diabetes or HYpertension

Diabetic Nephropathies (1)

NCT	Acronym	Phase	Status	Title
NCT05418465	—	N/A	unknown	Huangqi Guizhi Wuwu Decoction in CKD Stage 2-4 Diabetic Nephropathy

PCO (1)

NCT	Acronym	Phase	Status	Title
NCT05601336	—	P3	unknown	of Sodium Glucose Cotransporter-2 Inhibitors on Metabolic, Hormonal and Clinical Parameters in PCO

Hemodialysis Complication (1)

NCT	Acronym	Phase	Status	Title
NCT05141552	SDHF	N/A	unknown	The Safety of Dapagliflozin in Hemodialysis Patients With Heart Failure

Diabetes Type 2 (1)

NCT	Acronym	Phase	Status	Title
NCT05915949	Location-F	P4	unknown	Comparison of Dapagliflozin, Lobeglitazone, and Its Combination in Efficacy and Safety

End Stage Renal Disease (1)

NCT	Acronym	Phase	Status	Title
NCT05250752	PRESERVE	P2	unknown	Reduction of Peritoneal Glucose Uptake With Use of SGLT2 in Humans Undergoing Peritoneal Dialysis Treatment

Overweight (1)

NCT	Acronym	Phase	Status	Title
NCT06383832	—	P4	completed	Effect of Dapagliflozin on Body Weight in Overweight Women Consuming Different Proportions of Carbohydrate Diet.

HFrEF (1)

NCT	Acronym	Phase	Status	Title
NCT04956809	—	P2	completed	Effect of Dapagliflozin on Submaximal Exercise Tolerance in Heart Failure

Anterior MI (1)

NCT	Acronym	Phase	Status	Title
NCT05424315	DACAMI	P2/P3	completed	Impact of DApagliflozin on Cardiac Function Following Anterior Myocardial Infarction in Non-Diabetic Patients

Cirrhosis (1)

NCT	Acronym	Phase	Status	Title
NCT05014594	SGLT-2	P2	unknown	Sodium-glucose Linked Transporter 2 (SGLT-2) Inhibitors in Recurrent Ascites: a Pilot RCT

Metastatic Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT05025735	—	P2	unknown	Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer

Kidney Transplantation (1)

NCT	Acronym	Phase	Status	Title
NCT04743453	—	P4	completed	EFFECT OF ADDING DAPAGLIFLOZIN TO ALLOGRAFT DYSFUNCTION OF RENAL TRANSPLANTED PATIENTS.

Pancreatic Lipomatosis (1)

NCT	Acronym	Phase	Status	Title
NCT05797935	—	P4	completed	Evaluation of Changes in Pancreatic Fat Content Using Advanced MR Sequences in Diabetics on Dapagliflozin Therapy

Cardiovascular Diseases (1)

NCT	Acronym	Phase	Status	Title
NCT04764097	DECODED	P2/P3	withdrawn	Dapagliflozin Effect on Cardiovascular Outcomes in Haemodialysis for End Stage Renal Disease

Fatty Liver (1)

NCT	Acronym	Phase	Status	Title
NCT05308160	—	P3	unknown	A Single Center, Randomized, Open Label, Parallel Group, Phase 3 Study to Evaluate the Efficacy of Dapagliflozin in Subjects With Nonalcoholic Fatty Liver Disease

ST-segment Elevation Myocardial Infarction (STEMI) (1)

NCT	Acronym	Phase	Status	Title
NCT06619600	DAPA-STEMI	P3	active not recruiting	Effect of Dapagliflozin in Myocardial Fibrosis and Ventricular Function in Patients With a ST-segment Elevation Myocardial Infarction

Left Cardiac Catheterization (1)

NCT	Acronym	Phase	Status	Title
NCT04806633	—	Early P1	unknown	Dapagliflozin to Prevent the Incidence of Contrast Induced Nephropathy After Heart Catheterization and Percutaneous Coronary Intervention

Healthy Adult Volunteers (1)

NCT	Acronym	Phase	Status	Title
NCT04856969	—	P1	completed	Clinical Trial to Evaluate Pharmacokinetic Interaction of ATB-1011 and ATB-1012 in Healthy Adult Volunteers

Pancreas Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT04542291	SGLT2	P1	completed	Targeting Pancreatic Cancer With Sodium Glucose Transporter 2 (SGLT2) Inhibition

Heart Failure，Congestive (1)

NCT	Acronym	Phase	Status	Title
NCT04869124	DAPA-VOLVO	P4	completed	Dapagliflozin on Volume Vascular Outcomes.

Bone Diseases, Metabolic (1)

NCT	Acronym	Phase	Status	Title
NCT04706637	EVOMETA	P4	unknown	A Clinical Trial to Evaluate the Bone Metabolism and the Blood Sugar of Evogliptin and Dapagliflozin

Congestive Heart Failure (1)

NCT	Acronym	Phase	Status	Title
NCT04778787	—	P4	completed	Sodium-glucose Cotransporter Type 2 Inhibitors for Acute Cardiorenal Syndrome Prevention

Stroke, Ischemic (1)

NCT	Acronym	Phase	Status	Title
NCT05565976	DECIST	P2/P3	unknown	Dapagliflozin Effect in Cognitive Impairment in Stroke Trial

Heart Failure, Diastolic (1)

NCT	Acronym	Phase	Status	Title
NCT04475042	STADIA-HFpEF	P2	unknown	Stratified Treatment to Ameliorate Diastolic Left Ventricular Stiffness in Heart Failure With Preserved Ejection Fraction

Aging (1)

NCT	Acronym	Phase	Status	Title
NCT04401904	SGLT2i	P1/P2	completed	SGLT2 Inhibition in Older Obese Adults With Pre-diabetes

Hypotension (1)

NCT	Acronym	Phase	Status	Title
NCT04575675	—	P4	completed	Dapagliflozin on Hypotensive Heart Failure Patients After Sacubitril/Valsartan Therapy

Diabetes Mellitus Type 2 Without Complication (1)

NCT	Acronym	Phase	Status	Title
NCT05109949	—	P3	unknown	Acute Effect of Empagliflozin vs Dapagliflozin Over Pulse Wave Velocity in Type Two Diabetes

Cardiovascular Risk Factor (1)

NCT	Acronym	Phase	Status	Title
NCT04258371	DAPA-SWEET	P2	unknown	DAPAgliflozin Sodium Water glucosE EffecTs in Patients at High Cardiovascular Risk

Bariatric Surgery Candidate (1)

NCT	Acronym	Phase	Status	Title
NCT07515391	—	P2	enrolling by invitation	Dapagliflozin Effect on Glucose Variability in Patients Post Bariatric Surgery

Renal Function Disorder (1)

NCT	Acronym	Phase	Status	Title
NCT04242758	PURITY	P4	unknown	Phthalates Exposure in Type 2 Diabetic Patients and Diuretic Therapy

Heart Failure With Preserved Ejection Fraction (HFpEF) (1)

NCT	Acronym	Phase	Status	Title
NCT03877224	—	P3	completed	DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction

Nonalcoholic Steatohepatitis (1)

NCT	Acronym	Phase	Status	Title
NCT03723252	DEAN	P3	completed	Dapagliflozin Efficacy and Action in NASH

Alzheimer Disease (1)

NCT	Acronym	Phase	Status	Title
NCT03801642	—	P1/P2	completed	Dapagliflozin In Alzheimer's Disease

Immunoglobulin A Nephropathy (1)

NCT	Acronym	Phase	Status	Title
NCT03762850	PROTECT	P3	active not recruiting	A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy

Type1 Diabetes Mellitus (1)

NCT	Acronym	Phase	Status	Title
NCT03704818	—	P1	completed	Dapagliflozin Effects on Hypoglycemia

Coronary Disease With Diabetes Mellitus (1)

NCT	Acronym	Phase	Status	Title
NCT03398577	—	P4	unknown	Effects of SGLT2 Inhibitor in Diabetic Patients With Coronary Artery Disease

Type-2 Diabetes (1)

NCT	Acronym	Phase	Status	Title
NCT03269058	Cinétique DAPA	P4	completed	Evaluate the Effects of Dapagliflozin in Patients With Type 2 Diabetes

Asymptomatic Hyperuricemia (1)

NCT	Acronym	Phase	Status	Title
NCT03316131	UA	P2	completed	A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA

Healthy Subjects in Fasted and Fed State (1)

NCT	Acronym	Phase	Status	Title
NCT03216278	—	P1	completed	The Purpose of the Study is to Compare Two Fixed Dose Combination Tablets of Dapagliflozin/Metformin XR in Healthy Subjects Under Fasting and Fed Conditions

Type II; Diabetes (1)

NCT	Acronym	Phase	Status	Title
NCT02984644	AZ11040	P3	completed	Paradoxical Stimulation of Hepatic Glucose Production With Dapagliflozin

Steatosis, Liver (1)

NCT	Acronym	Phase	Status	Title
NCT03007329	EXENDA	P4	completed	Effects of Combined Dapagliflozin and Exenatide Versus Dapagliflozin and Placebo on Ectopic Lipids in Patients With Uncontrolled Type 2 Diabetes Mellitus.

Chronic Heart Failure With Preserved Systolic Function (1)

NCT	Acronym	Phase	Status	Title
NCT03030235	PRESERVED-HF	P4	completed	Dapagliflozin in PRESERVED Ejection Fraction Heart Failure

Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (1)

NCT	Acronym	Phase	Status	Title
NCT03036124	DAPA-HF	P3	completed	Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure

Evaluate Ketogenic Stress (1)

NCT	Acronym	Phase	Status	Title
NCT02962492	—	N/A	completed	An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes

Prediabetes (1)

NCT	Acronym	Phase	Status	Title
NCT02700334	—	P4	completed	Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes

Chronic Heart Failure With Reduced Systolic Function (1)

NCT	Acronym	Phase	Status	Title
NCT02653482	DEFINE-HF	P4	completed	Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure

Bioequivalence (1)

NCT	Acronym	Phase	Status	Title
NCT02637037	—	P1	completed	A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects

Type II Diabetes Mellitus (1)

NCT	Acronym	Phase	Status	Title
NCT02592421	—	P3	completed	SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2

Focal Segmental Glomerulosclerosis (1)

NCT	Acronym	Phase	Status	Title
NCT02585804	TRANSLATE	P4	completed	Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects

Type 2 Diabetes Mellitus, CKD and Albuminuria (1)

NCT	Acronym	Phase	Status	Title
NCT02547935	—	P2/P3	completed	A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD

Physical Activity (1)

NCT	Acronym	Phase	Status	Title
NCT02371187	—	P2	completed	Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?

Hyperglycemia Steroid-induced (1)

NCT	Acronym	Phase	Status	Title
NCT02253121	GluCon-COPD	P4	completed	Glucose Control During Glucocorticoid Therapy in Acute Exacerbation of Chronic Obstructive Pulmonary Disease

T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin) (1)

NCT	Acronym	Phase	Status	Title
NCT02279407	EFFECTII	P2	completed	A Study to Investigate Effects of Omega-3 Carboxylic Acids and Dapagliflozin on Liver Fat Content in Diabetic Patients

Endothelial Function (1)

NCT	Acronym	Phase	Status	Title
NCT02501616	—	P4	unknown	Effect of Dapagliflozine on Systemic and Renal Endothelial Function

Acute Myocardial Infarction (AMI) (1)

NCT	Acronym	Phase	Status	Title
NCT07198191	SGLT2i-AMI	N/A	active not recruiting	SGLT2 Inhibitor Use After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Nationwide Cohort Study

Fasting Glucose (1)

NCT	Acronym	Phase	Status	Title
NCT02211742	DapaT1DM	P4	completed	Dapagliflozin in Type 1 Diabetes

Metabolic Syndrome X (1)

NCT	Acronym	Phase	Status	Title
NCT02113241	—	P2/P3	completed	Effect of Dapagliflozin Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion

Diabetes Mellitus, Non-Insulin-Dependent (1)

NCT	Acronym	Phase	Status	Title
NCT01730534	DECLARE-TIMI58	P3	completed	Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events

Insulin Sensitivity (1)

NCT	Acronym	Phase	Status	Title
NCT01439854	DAPA MITO	N/A	completed	Study of Dapagliflozin on Mitochondrial Dysfunction and Impaired Insulin Signaling/Action

Diabetes, NOS (1)

NCT	Acronym	Phase	Status	Title
NCT00726505	MOA	P1	terminated	Renal Mechanism of Action/Splay vs. TmG

Healthy Male and Female Subjects (1)

NCT	Acronym	Phase	Status	Title
NCT00546741	—	P1	completed	Drug Interaction With Metformin

Dapagliflozin pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

Acronym	NCT	Phase	Status	Indication	Enrollment	PubMed
ENVELOP	NCT06642623	P4	recruiting	Diabetes Mellitus, Type 2	2,862	—
Dapa-Active LN	NCT07323524	P4	recruiting	Lupus Nephritis (LN)	33	—
CASCADES	NCT07254572	P4	recruiting	Coronary Artery Disease	300	—
APPLE TREE	NCT06642272	P4	recruiting	Diabetes Mellitus, Type 2	17,200	—
DAPA-HP	NCT06785116	P4	recruiting	Gestational Hypertension	200	—
CKD-bioMatch	NCT07239570	P4	recruiting	Chronic Kidney Disease(CKD)	125	—
DEAKTransplant	NCT05788276	P4	recruiting	Kidney Transplant; Complications	330	—
STAMI-BAS	NCT06562582	P4	recruiting	Myocardial Infarct	120	—
SGLT2i/DPPi	NCT07436663	P4	not yet recruiting	Breast Cancer	150	—
IECA-MEX	NCT07405216	P4	recruiting	Chronic Kidney Disease (Mild to Moderate)	200	—
SIGNAL	NCT06954090	P4	enrolling by invitation	Type 2 DM	50	—
BMI	NCT07311551	P4	not yet recruiting	Type 2 Diabetes	112	—
STEPS	NCT06668389	P4	recruiting	Congenital Heart Disease	106	PMID 36171554
DAPA-PCAT	NCT07351643	P4	not yet recruiting	ACS (Acute Coronary Syndrome)	110	—
TELOS	NCT06972732	P4	recruiting	Type 2 Diabetes	204	—
FIN-SGLT2-HF	NCT07351864	P4	not yet recruiting	Heart Failure	60	PMID 38692445
EPHIC-DIA2	NCT06851962	P4	active not recruiting	Diabetes Mellitus Type 2	504	—
FonDap	NCT05741658	P4	enrolling by invitation	Heart Failure	29	PMID 33189798
Dapagliflozin	NCT07076615	P4	recruiting	Acute Decompensated Heart Failure (ADHF)	100	—
COMBINE-ALPORT	NCT06499948	P4	completed	Alport Syndrome	12	—
DAPA-TONIC	NCT06442280	P4	not yet recruiting	Heart Failure Acute	544	PMID 36607775
CYP8B1-SGLT2-T	NCT07120828	P4	completed	Type 2 Diabetes	260	PMID 32855502
SMARTEST	NCT03982381	P4	completed	Type 2 Diabetes	2,067	PMID 34389234
ADIDAS	NCT04707261	P4	recruiting	Anemia	1,990	PMID 33779938
DAPA-ANDO	NCT06000462	P4	active not recruiting	Obesity	150	PMID 26641646
DECIDE	NCT02616666	P4	completed	Type 2 Diabetes Mellitus	632	—
MERCURI-2	NCT05590143	P4	active not recruiting	Acute Kidney Injury	784	PMID 40153894
DAPA-PCI-AKI	NCT05435235	P4	suspended	Acute Kidney Injury	250	—
DEFORM	NCT05848102	P4	unknown	Functional Mitral Regurgitation	166	—
PRODAPA-CKD	NCT06281899	P4	unknown	Chronic Kidney Diseases	200	—
SFRNDM2	NCT05139914	P4	terminated	Diabetes Mellitus, Type 2	4	—
DapaTAVI	NCT04696185	P4	completed	Aortic Stenosis	1,257	PMID 34693613
Dare-Esrd	NCT05685394	P4	unknown	End-stage Kidney Disease	80	—
DAPA-VOLVO	NCT04869124	P4	completed	Heart Failure，Congestive	80	PMID 40601599
DAPA-SERVE	NCT05717257	P4	unknown	Dapagliflozin Adverse Reaction	50	—
DETAIL-CMIV	NCT05816733	P4	unknown	Atrial Fibrillation Recurrence	348	—
T2DM	NCT05459701	P4	completed	Nonalcoholic Fatty Liver Disease	50	PMID 23707905
DAPA-ECG	NCT06721442	P4	completed	Arrhythmias, Cardiac	174	PMID 40230406
(Dapa)& (Empa)	NCT07363707	P4	completed	NAFLD (Nonalcoholic Fatty Liver Disease)	108	—
EPIDOTE	NCT03499704	P4	completed	Diabetes Mellitus, Type 2	133	—
Location-F	NCT05915949	P4	unknown	Diabetes Type 2	99	—
GOLDEN-AGE	NCT04796428	P4	unknown	Diabetes Mellitus, Type 2	1,167	—
DEFORM	NCT05606718	P4	unknown	Functional Mitral Regurgitation	98	—
DAPAMICRO	NCT05392959	P4	terminated	Diabetes Mellitus, Type 2	4	PMID 26400825
Hyper	NCT02911792	P4	completed	Diabetes Mellitus, Type 2	72	PMID 3011862
DAPA-AF	NCT04792190	P4	completed	Atrial Fibrillation	25	PMID 22249528
DMVascular	NCT05440591	P4	unknown	Diabetes	150	—
EVOMETA	NCT04706637	P4	unknown	Bone Diseases, Metabolic	120	—
READ	NCT04004793	P4	completed	Type 2 Diabetes	328	PMID 39843169
CARDIA-STIFF	NCT04739215	P4	unknown	Diabetes Mellitus, Type 2	62	PMID 28402411
DARE-ESKD 1	NCT05343078	P4	completed	End-stage Renal Disease	5	—
@HOME	NCT06374043	P4	completed	Diabetes Mellitus, Type 2	20	—
ELUCIDATE	NCT03871621	P4	completed	Type 2 Diabetes Mellitus	76	PMID 38639353
DAPA-MEMS	NCT04570865	P4	unknown	Heart Failure, Systolic	100	—
DAPA-Shuttle1	NCT04080518	P4	completed	Diabetes Mellitus	40	PMID 38599715
SGLTi	NCT04200586	P4	unknown	Type2 Diabetes	30	—
PRESERVED-HF	NCT03030235	P4	completed	Chronic Heart Failure With Preserved Systolic Function	324	PMID 34711976
MaasFlex	NCT03721874	P4	completed	Prediabetic State	16	PMID 36592688
Cinétique DAPA	NCT03269058	P4	completed	Type-2 Diabetes	28	—
PURITY	NCT04242758	P4	unknown	Renal Function Disorder	30	PMID 28756396
DECREASE	NCT03361098	P4	completed	Type 2 Diabetes Mellitus	65	PMID 35134184
DAPASALT	NCT03152084	P4	terminated	Diabetes Mellitus, Type 2	24	PMID 33318125
DapaSaxaBBIT	NCT02965443	P4	terminated	Type 2 Diabetes	4	—
EXENDA	NCT03007329	P4	completed	Steatosis, Liver	34	PMID 33464703
DAPAMAAST	NCT03338855	P4	completed	Diabetes Mellitus, Type 2	26	PMID 36280113
T2D	NCT02973477	P4	completed	Type2 Diabetes	45	PMID 34024686
DEFINE-HF	NCT02653482	P4	completed	Chronic Heart Failure With Reduced Systolic Function	263	PMID 39421941
PROTOCOL 3	NCT03168295	P4	completed	Diabetes Mellitus, Type 2	34	PMID 32144165
DAPA-LVH	NCT02956811	P4	completed	Type 2 Diabetes	66	PMID 38997620
ADDENDA	NCT02919345	P4	completed	Diabetes Mellitus, Type 2	98	PMID 41888924
DAPACARD	NCT03387683	P4	completed	Diabetes Mellitus Type 2	53	—
EFFORT	NCT02925559	P4	completed	Diabetes Mellitus, Type 2	135	PMID 19644119
Dexlar	NCT02811484	P4	withdrawn	Diabetes Mellitus, Type 2	0	—
RED	NCT02682563	P4	completed	Diabetes Mellitus, Type 2	44	PMID 32516291
DAPHNIS	NCT02577159	P4	unknown	Diabetes Mellitus, Type 2	50	PMID 24882621
DICE	NCT03074630	P4	completed	Diabetes Mellitus, Type 2	12	—
BEYOND	NCT02564926	P4	completed	Diabetes Mellitus, Type 2	125	—
FLORA	NCT02719132	P4	withdrawn	Diabetes Mellitus Type 2	0	—
REFORM	NCT02397421	P4	completed	Heart Failure	56	PMID 32245746
DapKid	NCT02914691	P4	completed	Type 2 Diabetes	40	PMID 37171199
DIVE	NCT02459353	P4	completed	Type 2 Diabetes Mellitus	86	—
GluCon-COPD	NCT02253121	P4	completed	Hyperglycemia Steroid-induced	46	—
TRANSLATE	NCT02585804	P4	completed	Focal Segmental Glomerulosclerosis	10	—
DapaT1DM	NCT02211742	P4	completed	Fasting Glucose	12	PMID 23170914
DAPA-HDL	NCT02327039	P4	completed	Type 2 Diabetes	33	PMID 28376855
DERISC	NCT02426541	P4	completed	Type 2 Diabetes Mellitus	55	PMID 30885955
STOP-PKD	NCT07280585	P3	recruiting	Polycystic Kidney, Autosomal Dominant	420	PMID 40199734
BaxDuo-Pacific	NCT06742723	P3	recruiting	Chronic Kidney Disease and Hypertension	5,000	—
Prevent-HF	NCT06677060	P3	recruiting	Heart Failure	11,300	PMID 40913594
DALCO	NCT06907251	P3	not yet recruiting	COVID - 19	192	—
DAPA-ICU	NCT07025629	P3	recruiting	Heart Failure and Chronic Kidney Disease Post-ICU	600	PMID 41991273
STENOTYPE	NCT05852704	P3	recruiting	Chronic Coronary Syndrome	800	—
DAPARHT	NCT05321706	P3	recruiting	Heart Transplant Failure	430	PMID 40840822
RECUR-AF	NCT07187570	P3	recruiting	Atrial Fibrillation (AF)	1,600	—
DAPA STEMI	NCT06174753	P3	recruiting	ST Elevation Myocardial Infarction	256	—
PROTECTAA	NCT06304857	P3	recruiting	Breast Cancer	188	—
DAPA-AF	NCT05174052	P3	recruiting	Diabetes Mellitus	28	—
BalanceD-HF	NCT06307652	P3	recruiting	Heart Failure and Impaired Kidney Function	4,800	—
EPIC-CT	NCT07297589	P3	recruiting	STEMI - ST Elevation Myocardial Infarction	136	—
DÁLIA	NCT05886088	P3	not yet recruiting	Type 2 Diabetes Mellitus	597	—
OPTIMAR	NCT06317051	P3	active not recruiting	HIV Infections	300	PMID 42050587
DOUBLE_PROTECT	NCT05944016	P3	recruiting	Chronic Kidney Failure in Children and Young Adults	102	PMID 38308509
COMBINED-HF	NCT06434025	P3	not yet recruiting	Heart Failure, Systolic	99	—
DAPAPROTECTOR	NCT05764057	P3	recruiting	AMI	450	—
GALACTUS	NCT07295223	P3	recruiting	Acute Myocardial Infarction With ST Elevation	44	—
DAPA-MYOCANCER	NCT06711185	P3	recruiting	Breast Cancer	80	—
PROTECT	NCT03762850	P3	active not recruiting	Immunoglobulin A Nephropathy	406	PMID 38299639
START	NCT05345327	P3	recruiting	Type 2 Diabetes	994	—
EMPATHY	NCT05776043	P3	unknown	Acute Decompensated Heart Failure	1,364	—
PREVENTS-AKI	NCT05468203	P3	terminated	Acute Kidney Injury	51	—
ACHIEVE-2	NCT06192108	P3	completed	Type 2 Diabetes	962	—
HARMONY	NCT06415773	P3	completed	T2DM (Type 2 Diabetes Mellitus)	367	—
DAPA-STEMI	NCT06619600	P3	active not recruiting	ST-segment Elevation Myocardial Infarction (STEMI)	54	PMID 40558655
D3DOSA	NCT06690723	P3	completed	Obstructive Sleep Apnea	160	PMID 40055713
DAPA-advKD	NCT05196347	P3	completed	Chronic Kidney Diseases	180	—
INFINITI2019	NCT04965935	P3	completed	Kidney Transplant Recipients	52	PMID 41385300
ATTEMPT	NCT04333823	P3	active not recruiting	Diabetes Mellitus, Type 1	100	PMID 40481206
DEAN	NCT03723252	P3	completed	Nonalcoholic Steatohepatitis	154	PMID 40467095
T2DM	NCT03199053	P3	completed	Diabetes Mellitus, Type 2	256	PMID 38320500
DEFENDER	NCT05558098	P3	completed	Critical Illness	507	PMID 38873723
DAPA-MI	NCT04564742	P3	completed	Acute Myocardial Infarction	4,017	PMID 38320489
Dapa-Rhemis	NCT05618223	P3	unknown	Rheumatic Heart Disease	36	PMID 28447181
DICTATE-AHF	NCT04298229	P3	completed	Heart Failure	240	PMID 38569758
DAPARESIST	NCT04860011	P3	unknown	Heart Failure	61	PMID 37210742
MODA	NCT04707352	P3	completed	Heart Failure	162	PMID 37211950
DEAP	NCT04213677	P3	completed	Polycystic Ovary Syndrome	165	—
DapaHeart	NCT03313752	P3	completed	Type2 Diabetes Mellitus	25	PMID 34037951
DELIVER	NCT03619213	P3	completed	Heart Failure With Preserved Ejection Fraction	6,263	PMID 39909641
ENHANCE-M	NCT04634500	P3	completed	T2DM (Type 2 Diabetes Mellitus)	200	PMID 36756676
DARE-19	NCT04350593	P3	completed	COVID-19	1,250	PMID 34302745
PCOS	NCT02635386	P3	completed	Polycystic Ovary Syndrome	119	PMID 34097062
Dapa-CKD	NCT03036150	P3	completed	Chronic Kidney Disease	4,304	PMID 38580424
AZ11040	NCT02984644	P3	completed	Type II; Diabetes	30	—
DAPA-HF	NCT03036124	P3	completed	Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)	4,744	PMID 35483792
DECLARE-TIMI58	NCT01730534	P3	completed	Diabetes Mellitus, Non-Insulin-Dependent	17,190	PMID 36857035
DEPICT 2	NCT02460978	P3	completed	Type 1 Diabetes Mellitus	815	PMID 30756462
DERIVE	NCT02413398	P3	completed	Type 2 Diabetes Mellitus	321	PMID 29888547
T2DM	NCT02532855	P3	completed	Type 2 Diabetes Mellitus	614	PMID 30019498
DEPICT 1	NCT02268214	P3	completed	Type 1 Diabetes Mellitus	833	PMID 32691513
Dapa	NCT02383238	P3	completed	Diabetes Mellitus Type 2	59	PMID 29301520
TZD	NCT00683878	P3	completed	Type 2 Diabetes	972	PMID 22446170
NHA	NCT07310433	P2	not yet recruiting	Prostate Cancer	60	—
RELIEF-AS	NCT07539259	P2	not yet recruiting	Aortic Stenosis	445	—
DAPA-MDS1	NCT07516847	P2	not yet recruiting	Myelodysplastic Syndromes (MDS)	37	PMID 31707794
Alpaca	NCT07245069	P2	recruiting	Heart Failure	100	—
ASPIRE-1	NCT06072326	P2	not yet recruiting	Type 1 Diabetes Mellitus With Diabetic Nephropathy	36	—
HALLMARK	NCT05938712	P2	recruiting	Kidney Transplant Recipients	20	—
ESS-AKD	NCT06528405	P2	recruiting	Acute Kidney Injury	264	—
DERAIL-LVV	NCT06887062	P2	recruiting	Large Vessel Vasculitis	60	—
BaxDuo-Baltic	NCT07222917	P2	recruiting	Chronic Kidney Disease and Hypertension	218	—
FLORAL	NCT06420167	P2	recruiting	Renal AL Amyloidosis	20	—
DAPALAG-01	NCT06626737	P2	recruiting	Graft-versus-host Disease (GVHD)	72	PMID 36574342
DAPA-ARMOR	NCT07018622	P2	recruiting	Solid Tumors	46	—
DAPA-GRAFT	NCT07555106	P2	active not recruiting	Kidney Transplant	54	PMID 33855198
DAPA-DME	NCT06845163	P2	recruiting	Diabetic Macular Edema	56	—
ZODIAC	NCT06942910	P2	recruiting	Chronic Kidney Disease With High Proteinuria	224	—
SGLT2i in CRS	NCT06111768	P2	active not recruiting	Cardiorenal Syndrome	30	—
DAPA-HD	NCT05179668	P2	completed	Kidney Failure	220	—
DapaBalci-Leap	NCT05884866	P2	completed	Chronic Renal Failure	103	PMID 33590724
DAPAH	NCT05179356	P2	completed	Pulmonary Arterial Hypertension	52	—
DAPACOID	NCT06748105	P2	active not recruiting	Dapagliflozin (Forxiga)	38	—
SGLT-2	NCT05058859	P2	withdrawn	Cystinuria	0	—
PiVOT	NCT05833958	P2	withdrawn	Type 2 Diabetes	0	—
DAPA-AIC	NCT06888505	P2	completed	Anthracyclines-Induced Cardiotoxicity	94	—
ZEAL	NCT05516498	P2	terminated	Liver Cirrhosis	205	—
MIRO-CKD	NCT06350123	P2	completed	Chronic Kidney Disease	324	PMID 40623005
PROTECT	NCT06341842	P2	unknown	Breast Cancer	316	PMID 40890873
ZODIAC	NCT05570305	P2	completed	Chronic Kidney Diseases	42	PMID 41805697
DECODE-CKD	NCT05359263	P2	recruiting	Chronic Kidney Diseases	222	PMID 41147829
ZEAL UNLOCK	NCT06269484	P2	completed	Liver Cirrhosis	73	—
DAPAVASC	NCT04930549	P2	completed	Renal Insufficiency, Chronic	32	—
ICARD	NCT05420285	P2	unknown	Heart Failure	40	—
ADAPT	NCT04794517	P2	completed	Chronic Kidney Diseases	32	—
ARCADIA-HF	NCT04782245	P2	withdrawn	End-stage Heart Failure	0	—
DAPA-SWEET	NCT04258371	P2	unknown	Cardiovascular Risk Factor	50	PMID 41347301
MIRACLE	NCT04595370	P2	completed	Heart Failure	153	—
ZENITH-CKD	NCT04724837	P2	completed	Chronic Kidney Disease	542	PMID 33990507
EPIK-B4	NCT04899349	P2	terminated	Breast Cancer	2	—
TIMOTHY	NCT05268926	P2	terminated	Albuminuria	9	—
PRESERVE	NCT05250752	P2	unknown	End Stage Renal Disease	10	—
DAPA	NCT04730947	P2	completed	Heart Failure With Preserved Ejection Fraction	38	PMID 39101201
STADIA-HFpEF	NCT04475042	P2	unknown	Heart Failure, Diastolic	26	—
SGLT-2	NCT05014594	P2	unknown	Cirrhosis	44	PMID 39384712
SGLT	NCT04818034	P2	completed	Cystinuria	10	—
DEPTH	NCT03537131	P2	terminated	Diabetes Mellitus, Type 1	9	—
DIAMOND	NCT03190694	P2	completed	Chronic Kidney Diseases	53	PMID 33587286
UA	NCT03316131	P2	completed	Asymptomatic Hyperuricemia	36	PMID 33075806
Dapalost	NCT02313220	P2	completed	Obesity	50	—
EFFECTII	NCT02279407	P2	completed	T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin)	223	PMID 29971527
PK	NCT01498185	P2	completed	Type 1 Diabetes Mellitus	171	PMID 35403243

Terminated and withdrawn Dapagliflozin trials (34)

Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.

NCT04764097withdrawnDapagliflozin Effect on Cardiovascular Outcomes in Haemodialysis for End Stage Renal Disease
NCT05468203terminatedPREVENTion With Sglt-2 Inhibition of Acute Kidney Injury in Intensive Care
NCT05058859withdrawnLong Term Clinical Efficacy of Sodium-glucose Cotransporter-2 (SGLT-2) Inhibitor in Cystinurics
NCT05833958withdrawnPolypill Versus Metformin in New Onset Type 2 Diabetes
NCT04640493withdrawnSGLT2-Inhibitors for Sleep Apnea in Heart Failure
NCT05516498terminatedZibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)
NCT05435235suspendedDapagliflozin in the Prevention of Post-Coronary Angioplasty Acute Kidney Injury
NCT06639087terminatedA Phase Ib Study of AZD5462 on Top of Dapagliflozin in Participants With Heart Failure and Moderate Renal Impairment
NCT05139914terminatedAssessment of Dapagliflozin on Vascular Health in Patients With Type 2 Diabetes
NCT04782245withdrawnAcute Reno-Cardiac Action of Dapagliflozin In Advanced Heart Failure Patients on Heart Transplant Waiting List
NCT03423355withdrawnDapagliflozin Effect on Erythropoiesis and Physical Fitness
NCT05392959terminatedEffect of the Antidiabetic Drug Dapagliflozin on the Coronary Macrovascular and Microvascular Function in Type 2 Diabetic Patients
NCT04899349terminatedStudy of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant
NCT05268926terminatedTreatIng Microalbuminuria Over 24 Weeks in Subjects With or Without Type 2 Diabetes or HYpertension
NCT04531397withdrawnEfficacy and Safety of Dapagliflozin in Children With Proteinuric Chronic Kidney Disease
NCT04492722terminatedA Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease
NCT04234867terminatedStudy to Explore the Effect of Dapagliflozin and Stress in Adolescent and Adult Subjects With Type 1 Diabetes (T1D)
NCT05330013withdrawnThe Effect of Inflammation in Heart Failure
NCT03660683terminatedEffect of Saxagliptin and Dapagliflozin on Endothelial Progenitor Cell in Patients With Type 2 Diabetes Mellitus
NCT03537131terminatedDapagliflozin During Exercise for the PrevenTion of Hypoglycaemia
NCT04330079terminatedEffects of dapaglifloziN Therapy on Myocardial Perfusion Reserve in Prediabetic Patients With Stable coronarY Artery Disease
NCT03608358terminatedSafety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin
NCT03152084terminatedThe Study Will Evaluate Average 24-hr Sodium Excretion During Dapagliflozin Treatment in Patients With Type 2 Diabetes Mellitus With Preserved or Impaired Renal Function or Non-diabetics With Impaired Renal Function.
NCT02965443terminatedDapagliflozin + Saxagliptin in a Basal-bolus Insulin Treatment
NCT02887677terminatedEffects of Dapagliflozin on Central Hemodynamics and Urine Albumin Excretion in Patients With Type 2 Diabetes.
NCT03419624terminatedThe Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients
NCT03344341terminatedA Phase IV Study in Drug-Naive Patients With T2DM in China
NCT02608905terminatedEffect of Dapagliflozin on Inflammation and Endothelial Function
NCT02811484withdrawnEfficacy of Exenatide-LAR and Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Type 2 Diabetes
NCT02719132withdrawnEffect of DapagliFLOzin on Quality of Life in Patients With Type 2 Diabetes in a Real Clinical PrActice
NCT02520518terminatedDoes Dapagliflozin Promote Favorable Health Benefits That Are Independent Of Weight Loss?
NCT01257412suspendedEvaluation of Efficacy and Safety of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise Alone
NCT01068756terminatedEffect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects
NCT00726505terminatedRenal Mechanism of Action/Splay vs. TmG

All Dapagliflozin trials (552)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT ID	Acronym	Title	Phase	Status	Enrollment	Sponsor	Started
NCT05521984		Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)	P1	recruiting	20	Washington University School of Medicine	Apr 2023
NCT06364930		SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes Mellitus	P4	recruiting	412	Chinese University of Hong Kong	Mar 2024
NCT06642623	ENVELOP	A Prospective Trial of Enavogliflozin to Evaluate Cardio-renal Outcome in Type 2 Diabetes Mellitus Patients	P4	recruiting	2,862	Yonsei University	Jan 2024
NCT07310433	NHA	Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prostate Cancer	P2	not yet recruiting	60	Yung NA	Jun 2026
NCT07108985		Effect of Add-on SGLT2i, TZD, or Combination Therapy in Type 2 Diabetes Patients on DPP4 Inhibitors	P4	not yet recruiting	100	Yonsei University	Sep 2025
NCT07280585	STOP-PKD	STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease	P3	recruiting	420	University of Cologne	Dec 2025
NCT07539259	RELIEF-AS	To Establish Whether Dapagliflozin and Spironolactone in Patients With Severe Aortic Stenosis Undergoing Aortic Valve Replacement, Result in Better Left Ventricular Mass Regression, Myocardial Health and Patient Reported Outcomes	P2	not yet recruiting	445	University College, London	Dec 2026
NCT07323524	Dapa-Active LN	Dapagliflozin in Active Lupus Nephritis	P4	recruiting	33	Brigham and Women's Hospital	May 2026
NCT06742723	BaxDuo-Pacific	A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure	P3	recruiting	5,000	AstraZeneca	Mar 2025
NCT06677060	Prevent-HF	Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin	P3	recruiting	11,300	AstraZeneca	Mar 2025
NCT07273838		Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome	P2	recruiting	130	Yale University	Mar 2026
NCT07516847	DAPA-MDS1	Dapagliflozin for Anemia in Lower-Risk Myelodysplastic Syndromes	P2	not yet recruiting	37	Seug yun Yoon, MD	Sep 2026
NCT07254572	CASCADES	Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes	P4	recruiting	300	National Institute of Cardiology, Warsaw, Poland	Jul 2025
NCT06907251	DALCO	Dapagliflozin for Long COVID Syndrome	P3	not yet recruiting	192	Ottawa Heart Institute Research Corporation	Apr 2026
NCT07235280		Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung Adenocarcinoma	Early P1	recruiting	48	Jonsson Comprehensive Cancer Center	Dec 2025
NCT07245069	Alpaca	Use of Dapagliflozin in Primary Prevention of Cardiotoxicity of Anthracycline Chemotherapy in Breast Cancer Patients	P2	recruiting	100	University Medical Centre Ljubljana	Feb 2025
NCT07025629	DAPA-ICU	Dapagliflozin for Cardio-renal Protection After ICU Discharge	P3	recruiting	600	Assistance Publique - Hôpitaux de Paris	Dec 2025
NCT07342764		Dapagliflozin Versus Metformin for the Management of Antipsychotic-Induced Weight Gain: A Pragmatic Pilot Randomized Controlled Trial	P4	not yet recruiting	110	Sultan Qaboos University	Sep 2026
NCT07403955		The Effect of Dapagliflozin on Myocardial Strain in Patients With Acute Heart Failure	N/A	not yet recruiting	188	Qilu Hospital of Shandong University	Feb 2026
NCT06072326	ASPIRE-1	dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation	P2	not yet recruiting	36	University Medical Center Groningen	Jan 2026
NCT06642272	APPLE TREE	A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health Record	P4	recruiting	17,200	Herlev and Gentofte Hospital	Oct 2024
NCT06140537		Efficacy and Mechanisms of Dapagliflozin in Promoting Kidney Function and Cardiovascular Health in Kidney Transplant Recipients	P4	recruiting	80	University of Colorado, Denver	Feb 2024
NCT06759909		Dapagliflozin on Outcomes of Rhythm Control Strategy (Pharmacological ± Interventional) in Patient with Atrial Fibrillation	P1	not yet recruiting	100	Assiut University	Jan 2025
NCT05852704	STENOTYPE	SGLT2 Inhibitor TrEatment iN Patients Awaiting cOronary arTery bYpass Surgery to Reduce Post-opErative AF	P3	recruiting	800	Region Örebro County	Apr 2024
NCT06785116	DAPA-HP	A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP)	P4	recruiting	200	University of Michigan	Mar 2025
NCT07491718	TAKO MEMRI	Manganese-enhanced Magnetic Resonance Imaging in Takotsubo Cardiomyopathy	N/A	recruiting	100	University of Edinburgh	Aug 2025
NCT04591639	DAPA-MEMRI	The DAPA-MEMRI Trial	N/A	recruiting	160	University of Edinburgh	Aug 2020
NCT05986136		Activation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel Disease	P2/P3	recruiting	50	Mostafa Bahaa	Aug 2023
NCT07469722	POINTER-HF	POcus INTERvention for Tailoring Diuretic Strategy in Acute Decompensated Heart Failure	P2/P3	not yet recruiting	128	Hospital de Clinicas de Porto Alegre	Mar 2026
NCT07174687		SGLT2 Inhibitors in Geographic Atrophy	P2	recruiting	70	Washington University School of Medicine	Dec 2025
NCT07239570	CKD-bioMatch	A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease	P4	recruiting	125	Peter Rossing	Jun 2025
NCT05788276	DEAKTransplant	Can Dapagliflozin Preserve Structure and Function in Transplanted Kidneys?	P4	recruiting	330	Oslo University Hospital	May 2023
NCT05321706	DAPARHT	DAPAgliflozin for Renal Protection in Heart Transplant Recipients	P3	recruiting	430	Oslo University Hospital	Jun 2022
NCT07482943		The Effect of Dapagliflozin on Exercise and Cardiac Functional Status of Patients After Fontan Procedure	P4	not yet recruiting	30	The University of Hong Kong	Apr 2026
NCT05938712	HALLMARK	The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients	P2	recruiting	20	University Health Network, Toronto	Oct 2023
NCT07392788	GlifloFastER	Early Gliflozin for Elderly Patients With Acute Decompensated Heart Failure in the Emergency Department	N/A	not yet recruiting	144	Centre Hospitalier Universitaire de Besancon	Apr 2026
NCT06268873		A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.	P3	active not recruiting	2,554	AstraZeneca	Mar 2024
NCT07187570	RECUR-AF	RECURrence of Atrial Fibrillation After Cardioversion of Patients Randomized to Dapagliflozin or Usual Care	P3	recruiting	1,600	Region Stockholm	Jun 2025
NCT06174753	DAPA STEMI	Dapagliflozin in STEMI	P3	recruiting	256	Ottawa Heart Institute Research Corporation	Jan 2025
NCT06562582	STAMI-BAS	STunning in Acute Myocardial Infarction - BAS	P4	recruiting	120	Vastra Gotaland Region	Jan 2025
NCT06528405	ESS-AKD	The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease	P2	recruiting	264	National Taiwan University Hospital	Nov 2024
NCT05989347		Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy	P1	recruiting	20	Yale University	Oct 2024
NCT06304857	PROTECTAA	CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL	P3	recruiting	188	4th Military Clinical Hospital with Polyclinic, Poland	Apr 2024
NCT06572215	DYNAMO	DYNAMic Renal Assessment: NOvel Methods to Assess KIDNEY Functional Reserve	—	recruiting	44	King's College Hospital NHS Trust	Dec 2023
NCT05174052	DAPA-AF	Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)	P3	recruiting	28	University of Oklahoma	Jun 2022
NCT07436663	SGLT2i/DPPi	Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC	P4	not yet recruiting	150	Tanta University	Feb 2026
NCT07405216	IECA-MEX	Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Early Stages of Chronic Kidney Disease	P4	recruiting	200	Centenario Hospital Miguel Hidalgo	Apr 2026
NCT06054035		SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes	P4	recruiting	170	University Hospital Tuebingen	Oct 2023
NCT05374291		The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD	P3	enrolling by invitation	1,750	University Medical Center Groningen	Nov 2022
NCT02969798	IFG	Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)	N/A	recruiting	700	The University of Texas Health Science Center at San Antonio	Jan 2014
NCT06668753		Effect of SGLT2 Inhibitors on NAFLD in Type 2 Diabetic Patients with Diabetic Nephropathy	—	not yet recruiting	114	Assiut University	Nov 2024
NCT06887062	DERAIL-LVV	Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV)	P2	recruiting	60	University of Edinburgh	Mar 2025
NCT07056699		SGLT2i, Pioglitazone, and Ketone Production in T1D	P3	not yet recruiting	24	The University of Texas Health Science Center at San Antonio	Jul 2026
NCT06307652	BalanceD-HF	Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function	P3	recruiting	4,800	AstraZeneca	Apr 2024
NCT06954090	SIGNAL	Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study	P4	enrolling by invitation	50	Steno Diabetes Center Copenhagen	Nov 2025
NCT06610526		A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease	P4	active not recruiting	731	AstraZeneca	Aug 2024
NCT07222917	BaxDuo-Baltic	A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.	P2	recruiting	218	AstraZeneca	Dec 2025
NCT07082114		A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus	P3	recruiting	800	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	Jul 2025
NCT06820567		Effects Dapagliflozin on Inflammatory Markers Erythropoiesis and Iron Metabolism in Patients With Type 2 Diabetes and CKD	P3	not yet recruiting	210	Assiut University	Mar 2025
NCT06420167	FLORAL	DapagliFLOzin in Renal AL Amyloidosis (FLORAL)	P2	recruiting	20	Barbara Ann Karmanos Cancer Institute	Jul 2024
NCT07297589	EPIC-CT	Epicardial Cardiac Fat-CT (EPIC-CT)	P3	recruiting	136	Instituto Mexicano del Seguro Social	Dec 2025
NCT06890143		The Efficacy and Safety of Dapagliflozin in the Treatment of Hereditary Kidney Disease With Proteinuria in Children	P3	recruiting	44	Children's Hospital of Fudan University	Mar 2025
NCT06762964		CAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation	P2	recruiting	27	Mayo Clinic	May 2025
NCT06087835		Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)	P3	active not recruiting	1,835	AstraZeneca	Nov 2023
NCT06772168		Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia	P3	recruiting	240	CMG Pharmaceutical Co. Ltd	Apr 2024
NCT07491042		Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients.	N/A	recruiting	38	Oman Ministry of Health	Apr 2026
NCT05886088	DÁLIA	Efficacy and Safety of LID104 in the Treatment of Type II Diabetes Mellitus	P3	not yet recruiting	597	EMS	Feb 2024
NCT06922656		Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration?	P4	not yet recruiting	60	Dasman Diabetes Institute	Sep 2025
NCT07331727	EAT-DARE-AF	Epicardial Adipose Tissue-Targeted DApagliflozin for Reducing Electrical Remodeling in Atrial Fibrillation	N/A	not yet recruiting	280	Shanghai Chest Hospital	Jan 2026
NCT07311551	BMI	A Comparison of Effectiveness, Safety, and Cost-effectiveness of Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes Mellitus and High Body Mass Index (BMI)	P4	not yet recruiting	112	Bhavya Bhavya, MD	Dec 2025
NCT06668389	STEPS	Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary Status Trial	P4	recruiting	106	The University of Hong Kong	May 2025
NCT06626737	DAPALAG-01	Dapagliflozin in Allo-HCT for aGVHD	P2	recruiting	72	The First Affiliated Hospital of Soochow University	Apr 2025
NCT06317051	OPTIMAR	Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART)	P3	active not recruiting	300	Kirby Institute	Dec 2024
NCT05944016	DOUBLE_PROTECT	Phase 3 Clinical Trial with Dapagliflozin in Chronic Kidney Disease in Adolescents and Young Adult Patients	P3	recruiting	102	University Hospital Goettingen	Mar 2024
NCT06398977		Dapagliflozin Delays the Loss of Renal Function in Peritoneal Dialysis Patients	N/A	recruiting	70	Sichuan Academy of Medical Sciences	Mar 2024
NCT06560801		Dapagliflozin on Renal Morphology and Renal Perfusion in Patients One Year After Kidney Transplantation	P4	recruiting	48	University of Erlangen-Nürnberg Medical School	Jul 2023
NCT06155604		SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease	P2	recruiting	150	The University of Hong Kong	Jan 2023
NCT04451837		Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology	P2	active not recruiting	200	Region Skane	Sep 2020
NCT07351643	DAPA-PCAT	CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes in Non-diabetic ACS Patients Without HF	P4	not yet recruiting	110	Shenyang Northern Hospital	Feb 2026
NCT07239011		Dapagliflozin in Depression	P1/P2	recruiting	60	Tanta University	Nov 2025
NCT06750458		Dapagliflozin Versus Dexamethasone Role in Pre-operative Management of Non- Diabetic Brain Tumor Patients	P3	not yet recruiting	75	Tanta University	Aug 2025
NCT06111443		Effect of Dapagliflozin on the Recurrence of Atrial Tachyarrhythmia in Patients Undergoing Catheter Ablation of Atrial Fibrillation	P2/P3	active not recruiting	196	Chang Gung Memorial Hospital	Dec 2023
NCT07033585	GD-T2D	Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers	P2/P3	active not recruiting	600	Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair	Jun 2025
NCT06434025	COMBINED-HF	IV Iron and SGLT2 Inhibitor on Ventricular Function and Myocardial Iron Content in Heart Failure With Iron Deficiency	P3	not yet recruiting	99	Hospital de Clinicas de Porto Alegre	May 2024
NCT07026968		A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes	P3	active not recruiting	815	CSPC Ouyi Pharmaceutical Co., Ltd.	Jun 2025
NCT06982079		Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Kidney Function in Advanced Chronic Kidney Disease	P3	recruiting	60	Ain Shams University	May 2025
NCT07303556	ICDDTKZ26	Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs	N/A	active not recruiting	120	Nazarbayev University	Dec 2024
NCT07018622	DAPA-ARMOR	Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity	P2	recruiting	46	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran	May 2025
NCT07515391		Dapagliflozin Effect on Glucose Variability in Patients Post Bariatric Surgery	P2	enrolling by invitation	30	Dasman Diabetes Institute	Oct 2019
NCT05764057	DAPAPROTECTOR	DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction	P3	recruiting	450	Assistance Publique - Hôpitaux de Paris	Jun 2023
NCT06612086		Dapagliflozin in Mangement of Pulmonary Hypertension Patients	P1	not yet recruiting	70	Assiut University	Oct 2024
NCT06972732	TELOS	A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes	P4	recruiting	204	Boryung Pharmaceutical Co., Ltd	Jun 2025
NCT06427226		Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity	P2	recruiting	46	Tanta University	Oct 2024
NCT06532682		Efficacy of Dapagliflozin in Early Diabetic Nephropathy in Type 1 Diabetes	P4	active not recruiting	54	The First Affiliated Hospital with Nanjing Medical University	Jul 2024
NCT02879409		HbA1c Variability in Type II Diabetes	N/A	active not recruiting	150	Weill Cornell Medical College in Qatar	Nov 2016
NCT07295223	GALACTUS	Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)	P3	recruiting	44	Instituto Mexicano del Seguro Social	Dec 2025
NCT07555106	DAPA-GRAFT	Dapagliflozin in Living-Donor Kidney Transplant Recipients	P2	active not recruiting	54	University of Guadalajara	Sep 2024
NCT05719714		Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease	P1/P2	recruiting	60	Northwestern University	Jan 2024
NCT06226896		Effects of Dapagliflozin on Progression of Alport Syndrome	—	active not recruiting	222	Nanjing University School of Medicine	Nov 2023
NCT07214818	SGLT2-NS	SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome	P2/P3	recruiting	75	Mansoura University	Nov 2025
NCT07204743		Efficacy and Safety of Dapagliflozin in Children With Proteinuria	N/A	active not recruiting	10	Al-Quds University	Aug 2025
NCT06845163	DAPA-DME	Randomized Clinical Trial to Evaluate the Effect of Dapagliflozin in Patients With Diabetic Macular Edema	P2	recruiting	56	Alexandria University	Feb 2025
NCT04887935		Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer	P1	recruiting	24	Washington University School of Medicine	Jun 2024
NCT06009874		Clinical Investigation of the Cardioprotective Effect of Early Administration of SGLT2 in Patients Presented With AMI	N/A	recruiting	80	Mohammad Hussien Tantawy Soliman	Oct 2023
NCT06711185	DAPA-MYOCANCER	Effect of DAPAglifozin on MYOcardial Remodeling of Breast CANCER Patients Treated with Anthracycline Based Chemotherapy	P3	recruiting	80	University of Campinas, Brazil	Jan 2024
NCT07198191	SGLT2i-AMI	SGLT2 Inhibitor Use After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Nationwide Cohort Study	—	active not recruiting	200,000	Yonsei University	Sep 2014
NCT07396844		The Food Effect on Pharmacokinetics of Fixed Dose Combination of Gemigliptin/Dapagliflozin/Metformin in Healthy Volunteers	P1	not yet recruiting	28	LG Chem	Jul 2026
NCT07351864	FIN-SGLT2-HF	Finerenone Plus SGLT2 Inhibitors in Heart Failure	P4	not yet recruiting	60	Mansoura University	Jan 2026
NCT06942910	ZODIAC	A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria	P2	recruiting	224	AstraZeneca	May 2025
NCT03762850	PROTECT	A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy	P3	active not recruiting	406	Travere Therapeutics, Inc.	Dec 2018
NCT06589765		A Study of HRS-7535 Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Metformin	P3	recruiting	800	Shandong Suncadia Medicine Co., Ltd.	Sep 2024
NCT07083401		A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fed)	P1	recruiting	40	Boryung Pharmaceutical Co., Ltd	Jul 2025
NCT07083388		A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fasting)	P1	recruiting	52	Boryung Pharmaceutical Co., Ltd	Jul 2025
NCT06851962	EPHIC-DIA2	Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.	P4	active not recruiting	504	Fundación para la Investigación del Hospital Clínico de Valencia	May 2025
NCT06491680		Cardiotoxicity in Breast Cancer Patients	P4	recruiting	40	Helwan University	Sep 2024
NCT05741658	FonDap	The Fontan Dapagliflozin Pilot Study	P4	enrolling by invitation	29	Johns Hopkins University	Nov 2023
NCT05345327	START	SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes	P3	recruiting	994	The George Institute	Jan 2023
NCT04764097	DECODED	Dapagliflozin Effect on Cardiovascular Outcomes in Haemodialysis for End Stage Renal Disease	P2/P3	withdrawn	0	Tan Tock Seng Hospital	Jun 2021
NCT03899402		Triple Therapy in T1DM	P2/P3	active not recruiting	78	State University of New York at Buffalo	May 2019
NCT07076615	Dapagliflozin	The Effect of Dapagliflozin on Patients With Cardiomyopathy	P4	recruiting	100	May Mohamed Abdalla	Aug 2025
NCT06111768	SGLT2i in CRS	Sodium-Glucose Cotransporter-2 Inhibitor for Acute Cardiorenal Syndrome: A Feasibility Study	P2	active not recruiting	30	Yale University	May 2024
NCT06740786		Efficacy and Safety of Dapagliflozin in Preventing Atrial Fibrillation Recurrence After Catheter Ablation	N/A	not yet recruiting	250	Xu Liu	Dec 2024
NCT06499948	COMBINE-ALPORT	Albuminuria Lowering Effect of Dapagliflozin, Spironolactone and Their Combination in Adult Patients With Alport Syndrome (COMBINE-ALPORT)	P4	completed	12	Stefan Lujinschi	Feb 2024
NCT07404137		A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food	P1	completed	26	AstraZeneca	Feb 2026
NCT06405178		Adjuvant Therapy With Letrozole in Induction of Ovulation With Polycystic Ovarian Syndrome	P3	completed	200	Beni-Suef University	Mar 2026
NCT05762952	SMILE	Effect of Dapagliflozin on Microvascular Function in Women With Symptoms of Coronary Artery Disease	P1	recruiting	40	University of Virginia	Jun 2023
NCT06442280	DAPA-TONIC	SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HF	P4	not yet recruiting	544	University of Palermo	Jun 2024
NCT07120828	CYP8B1-SGLT2-T	The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity	P4	completed	260	Erbil Polytechnic University	Jul 2025
NCT07399470		A Clinical Study in Healthy Adults to See How the Body Processes and How Safe a Tablet That Combines Gemigliptin, Dapagliflozin, and Metformin is, Compared With Taking Zemiglo and Xigduo XR Together While Fasting.	P1	active not recruiting	58	LG Chem	Jan 2026
NCT05179668	DAPA-HD	SGLT2 Inhibition in Hemodialysis	P2	completed	220	Medical University of Vienna	Oct 2022
NCT05042505	Dapa-LiT	Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver Transplantation	N/A	completed	100	Medanta, The Medicity, India	Jan 2022
NCT05965440	DAPA-GUT	Impact of Dapagliflozin on Intestinal Microbiota Composition and on the Metabolites Derived From the Intestinal Microbiota in Non-diabetic Chronic Renal Failure Patients	N/A	completed	50	Hospices Civils de Lyon	Nov 2023
NCT03982381	SMARTEST	SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes	P4	completed	2,067	Uppsala University	Sep 2019
NCT05884866	DapaBalci-Leap	A Study to Investigate the Mechanistic Effects of Dapagliflozin Alone or in Combination With Balcinrenone, Compared to Balcinrenone and Placebo on Body Fluid and Electrolyte Handling and Energy Metabolism in Participants Over 50 Years of Age With Chronic Kidney Disease.	P2	completed	103	Klinikum Nürnberg	Jul 2023
NCT05179356	DAPAH	Dapagliflozin in Pulmonary Arterial Hypertension	P2	completed	52	Mads Ersbøll	Jan 2023
NCT04707261	ADIDAS	Association Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients (ADIDAS)	P4	recruiting	1,990	Xiangtan Central Hospital	Aug 2021
NCT06578520		Effect of the Use of Dapagliflozin in Patients With Refractory Heart Failure	P4	recruiting	31	Fundación para la Investigación del Hospital Clínico de Valencia	Jul 2024
NCT06297681		Combination of Daratumumab and BD Regimen and Dapagliflozin in the Treatment of M-protein Related Cardiac Disease	—	unknown	40	Beijing Chao Yang Hospital	Mar 2024
NCT05443932		Dapagliflozin and Hydrochlorothiazide in Recurring Kidney Stone Patients	P4	unknown	32	Medical University of Vienna	Mar 2024
NCT06187493		Treatment of Patients With Diabetic Kidney Disease	N/A	unknown	70	Assiut University	Jan 2024
NCT05782972		Therapeutic Response of Sodium-glucose Co-transporter Type-2 Inhibitor in Non-diabetic MAFLD Patients: a Pilot Study	P4	active not recruiting	50	Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation	Mar 2023
NCT05776043	EMPATHY	Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart Failure	P3	unknown	1,364	Medical University of Warsaw	Mar 2022
NCT06000462	DAPA-ANDO	The Effect of Dapagliflozin on Weight Loss in Obese Adults Without Diabetes	P4	active not recruiting	150	Oman Ministry of Health	Apr 2024
NCT07020377	NAFLD	Dapagliflozin in Nonalcoholic Fatty Liver Disease (NAFLD) and Type 2 Diabetes Mellitus Patients (T2DM).	P1/P2	active not recruiting	60	Amira Bisher,PhD	Jan 2024
NCT06759077		Cardio Protective Effect of SGL2I in Hemodialysis Patients and Its Impact on Patient Quality of Life	P3	active not recruiting	126	Al-Azhar University	Dec 2024
NCT05468203	PREVENTS-AKI	PREVENTion With Sglt-2 Inhibition of Acute Kidney Injury in Intensive Care	P3	terminated	51	The George Institute	Nov 2023
NCT02616666	DECIDE	A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients	P4	completed	632	University of Liverpool	Aug 2016
NCT05759000		Dapa Acute Heart Failure Study	—	unknown	100	Chinese University of Hong Kong	Apr 2023
NCT06748105	DAPACOID	Dapagliflozin as Prophylaxis for Glucocorticoid-Induced Hyperglycemia	P2	active not recruiting	38	Lauro Fabián Amador Medina	Dec 2024
NCT05914857		Evaluation of the Safety and Efficacy of SGLT2 Inhibitors in Pre-diabetic Patients	P2	unknown	120	Yangjin	Dec 2023
NCT06344247		Comparison of the Efficacy and Safety of SGLT2i and GLP-1 Receptor Agonists in Obese Patients With Kidney Disease	N/A	unknown	48	RenJi Hospital	Sep 2023
NCT07333742		A Clinical Study to See How the Body Handles and How Safe a Combination Tablet of Gemigliptin, Dapagliflozin, and Metformin 50/10/1000mg is Compared to Taking Gemigliptin 50mg Separately With Dapagliflozin/Metformin 10/1000mg in Healthy Adults After a Meal	P1	completed	50	LG Chem	Sep 2025
NCT05058859	SGLT-2	Long Term Clinical Efficacy of Sodium-glucose Cotransporter-2 (SGLT-2) Inhibitor in Cystinurics	P2	withdrawn	0	University of California, San Francisco	Sep 2023
NCT06897605		Impact of Dapagliflozin in Anemic Chronic Kidney Disease Patients	P2	recruiting	80	Mansoura University	Apr 2025
NCT06510270		Dapagliflozin in Reducing Epicardial Adipose Tissue in Heart Failure with Preserved Ejection Fraction	N/A	not yet recruiting	70	Aswan University	Aug 2024
NCT05833958	PiVOT	Polypill Versus Metformin in New Onset Type 2 Diabetes	P2	withdrawn	0	George Medicines PTY Limited	Sep 2024
NCT05590143	MERCURI-2	proMoting Effective Renoprotection in Cardiac sURgery Patients by Inhibition of SGLT-2	P4	active not recruiting	784	Amsterdam UMC	Jun 2023
NCT05795400		Administration of the SGLT-2 Inhibitor Dapagliflozin in the Patients With Amyloid Cardiomyopathy	N/A	completed	50	National Medical Research Center for Cardiology, Ministry of Health of Russian Federation	Jun 2022
NCT06192108	ACHIEVE-2	A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin	P3	completed	962	Eli Lilly and Company	Jan 2024
NCT07338331	AS-NAFLD	Comparative Effects of Aspirin and SGLT2 Inhibitors on Liver Enzymes, Lipid Profile, and FibroScan Findings in Non-Alcoholic Fatty Liver Disease	N/A	completed	80	Galala University	Apr 2023
NCT06919523		Clinical Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patients With Refractory Cirrhotic Ascites	P2	not yet recruiting	70	Mansoura University	Apr 2025
NCT06888505	DAPA-AIC	Dapagliflozin to Prevent Anthracycline-Induced Cardiotoxicity	P2	completed	94	Hawler Medical University	Sep 2024
NCT06535529		Acetazolamide Versus Dapagliflozin in Acute Decompensated Heart Failure Patients	P3	recruiting	60	Helwan University	Aug 2024
NCT06012266		Repurposing Empagliflozin and Dapagliflozin for Paediatric Heart Failure: Translational Approach and Dose Rationale	P2	unknown	12	Centre Hospitalier Universitaire Vaudois	Aug 2024
NCT04640493		SGLT2-Inhibitors for Sleep Apnea in Heart Failure	P2	withdrawn	0	Columbia University	Dec 2023
NCT06778330		The Effect of Combination of Dapagliflozin and Sildenafil in Treatment of Heart Failure Patients With Secondary Pulmonary Hypertension	N/A	completed	100	Fayoum University	Jan 2025
NCT06783166		Assessing the Clinical Outcomes of Dapagliflozin Versus Acetazolamide in Patients With Acute Heart Failure	P2/P3	recruiting	100	Mansoura University	Aug 2024
NCT06421870		Renoprotective Effects of Dapagliflozin Versus Pentoxiphylline in Chronic Kidney Disease Patients	P3	unknown	210	Ain Shams University	Mar 2024
NCT06373523	SHIELD	MASLD in Primary Hypothyroidism and Efficacy of Dapaglifozin	Early P1	not yet recruiting	60	Post Graduate Institute of Medical Education and Research, Chandigarh	Sep 2024
NCT06286878		Pleiotropic Effects of Dapagliflozin in Patients With Acute Coronary Syndromes	P2/P3	recruiting	80	University of Sao Paulo	Dec 2021
NCT06415773	HARMONY	Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin	P3	completed	367	HighTide Biopharma Pty Ltd	Jun 2024
NCT05516498	ZEAL	Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)	P2	terminated	205	AstraZeneca	Oct 2022
NCT06979388		A Study to Investigate the Effect of Food on Balcinrenone/Dapagliflozin Pharmacokinetics in Fed and Fasted State and Pharmacokinetics of Balcinrenone When Dosed With a P-gp Inhibitor in Healthy Participants.	P1	completed	14	AstraZeneca	May 2025
NCT06433479	DARE-AF	Efficacy of Dapagliflozin on Recurrence After Catheter Ablation for Atrial Fibrillation	N/A	completed	200	Beijing Anzhen Hospital	Jul 2024
NCT06901609		Effect of Genetic Polymorphism on the Clinical Outcome to SGLT2 Inhibitors in Heart Failure Patients	—	active not recruiting	200	Ain Shams University	Nov 2023
NCT05565976	DECIST	Dapagliflozin Effect in Cognitive Impairment in Stroke Trial	P2/P3	unknown	270	Jaime Daniel Mondragon	Aug 2020
NCT05435235	DAPA-PCI-AKI	Dapagliflozin in the Prevention of Post-Coronary Angioplasty Acute Kidney Injury	P4	suspended	250	Albert Einstein Healthcare Network	Sep 2024
NCT06327815		Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM	P4	completed	633	AstraZeneca	Mar 2024
NCT05194592		Comparison of the Effects of Dapagliflozin and Gemigliptin on Ketone Metabolism and Cardiac Remodeling in Type 2 Diabetes	P4	unknown	122	Wonju Severance Christian Hospital	Jan 2022
NCT04363697		Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)	P4	completed	2,401	The TIMI Study Group	Sep 2020
NCT06719661		The Impact of Clinical Pharmacist Intervention and Dapagliflozin as Add-On Therapy in the Management of Type 2 Diabetes Mellitus.	N/A	completed	138	University of Sulaimani	Dec 2024
NCT05621551		Dapagliflozin Therapy In Cardiac Surgery	P4	completed	178	China National Center for Cardiovascular Diseases	Nov 2022
NCT06639087	AURORA	A Phase Ib Study of AZD5462 on Top of Dapagliflozin in Participants With Heart Failure and Moderate Renal Impairment	P1	terminated	8	AstraZeneca	Sep 2024
NCT06350123	MIRO-CKD	Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease	P2	completed	324	AstraZeneca	May 2024
NCT05848102	DEFORM	Dapagliflozin Effect on FunctiOnal Mitral Regurgitation and Myocardial Fibrosis (DEFORM)	P4	unknown	166	Sun Yat-sen University	Dec 2022
NCT06341842	PROTECT	Potential Protective Role of SGLT-2 Inhibitors for Chemotherapy-induced Cardiotoxicity	P2	unknown	316	Fondazione IRCCS Policlinico San Matteo di Pavia	Oct 2023
NCT05957887		Short and Intermediate Term Effect of Dapagliflozin on Left Ventricular Remodeling in Anterior STEMI Patients	P3	unknown	120	Mohamed Nabil Elkholy	Apr 2022
NCT06812429	EFSII	Effects of Sodium-Glucose Co-transporter 2 Inhibitors on Inflammation	Early P1	completed	6	Washington University School of Medicine	May 2024
NCT06281899	PRODAPA-CKD	Effect of Low Protein Diet on Top of Dapagliflozin on Chronic Kidney Disease in Patients With Type 2 Diabetes Mellitus	P4	unknown	200	Anemia Working Group Romania	Jan 2022
NCT06619600	DAPA-STEMI	Effect of Dapagliflozin in Myocardial Fibrosis and Ventricular Function in Patients With a ST-segment Elevation Myocardial Infarction	P3	active not recruiting	54	Hospital Clinic of Barcelona	May 2021
NCT05570305	ZODIAC	Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria	P2	completed	42	University Medical Center Groningen	Oct 2022
NCT05686616	Reduction-TR	SGLT2 Inhibitor for Severe Tricuspid Regurgitation	N/A	unknown	72	Samsung Medical Center	Apr 2022
NCT06813222		Anemia-Related Outcomes in Patients With CKD Treated With Dapagliflozin	—	active not recruiting	100	Damanhour University	Apr 2021
NCT05359263	DECODE-CKD	Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with CKD	P2	recruiting	222	Tor Biering-Sørensen	Jun 2022
NCT05139914	SFRNDM2	Assessment of Dapagliflozin on Vascular Health in Patients With Type 2 Diabetes	P4	terminated	4	Boston University	May 2022
NCT06576375		Efficacy of Dapagliflozin Versus Metformin in Polycystic Ovary Syndrome	P3	recruiting	70	Future University in Egypt	Sep 2024
NCT06113900		Assessment of Safety and Efficacy of SGLT2is Among LN Patients	P1/P2	unknown	50	Ain Shams University	Dec 2023
NCT06915870		Comparison of Empagliflozin and Dapagliflozin in Patients With Heart Failure Taking Standard Treatment	N/A	completed	108	Fatima Maqsood	Jul 2024
NCT06263673		Anti-Diabetic Medications to Fight PD and LBD	P4	completed	18	Mayo Clinic	May 2024
NCT05713851	DAKI-CKD	Dapaglifozin to Avoid Acute Kindey Injury (AKI) to Chronic Kidney Disease (CKD) Transition: DAKI-CKD Study	P2/P3	unknown	100	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran	Jan 2023
NCT06147518		To Compare the Safety and Efficacy of Dapagliflozin Plus Metformin Versus Sitagliptin Plus Metformin for Treatment of Diabetes in Patients With Compensated and Stable Decompensated Cirrhosis	N/A	unknown	240	Institute of Liver and Biliary Sciences, India	Dec 2023
NCT04783870		Effect of Dapagliflozin on LV Remodeling Post AMI	P4	unknown	60	Instituto Mexicano del Seguro Social	Mar 2021
NCT05050500		Effects of Dapagliflozin on Inflammatory Factorslevel and Prognosis in Type 2 Diabetes With Acute Myocardial Infarction	P4	completed	143	Qingdao Central Hospital	May 2023
NCT06127433		The Effect of Short-term Insulin Intensive Therapy Based on the Application of Insulin Pump and Real-time Dynamic Glucose Monitoring Technology on Reversing the Newly Diagnosed Type 2 Diabetes	P4	unknown	210	Sun Yat-sen University	Mar 2023
NCT06065280		Sodium-glucose Transport 2 Inhibitors (SGLT2i) in HFrEF Patients	N/A	completed	80	Damanhour University	Nov 2022
NCT04696185	DapaTAVI	Dapagliflozin After Transcatheter Aortic Valve Implantation	P4	completed	1,257	Spanish Society of Cardiology	Jan 2021
NCT05792540		Clinical Study to Evaluate the Possible Efficacy of Dapagliflozin and Atorvastatin in Patients With Major Depressive Disorders	P2	completed	75	Tanta University	Jun 2023
NCT06269484	ZEAL UNLOCK	A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK	P2	completed	73	AstraZeneca	Feb 2024
NCT05685394	Dare-Esrd	DApagliflozin Cardiovascular Effects on Patients at End-stage REnal Disease	P4	unknown	80	University of Campinas, Brazil	Jan 2023
NCT07083232		The Effect of Sitagliptin, Pioglitazone and Dapagliflozine on Myocardial Infarction in Diabetic Rats	P4	completed	50	Al-Azhar University	Oct 2024
NCT05676684	SOGALDI-PEF	Dapagliflozin With or Without Spironolactone for HFpEF	P2/P3	completed	108	Universidade do Porto	Sep 2022
NCT05550441		Effect of Dapagliflozin on VT in Patients With Heart Failure.	P4	unknown	120	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Nov 2022
NCT06651021		A Phase I PK Study of Balcinrenone/Dapagliflozin in Healthy Chinese Participants	P1	completed	10	AstraZeneca	Oct 2024
NCT04869124	DAPA-VOLVO	Dapagliflozin on Volume Vascular Outcomes.	P4	completed	80	Frank Ruschitzka	Feb 2021
NCT05505994		The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin	P3	unknown	340	Daewoong Pharmaceutical Co. LTD.	Sep 2022
NCT05998837	GLUTREPRO	GLUcose Transport and REnalPROtection in Chronic Kidney Disease	P2/P3	completed	34	IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy	Apr 2021
NCT04930549	DAPAVASC	Vascular Impact of Dapagliflozin in CKD Patients (DAPAVASC)	P2	completed	32	University Hospital, Rouen	Oct 2022
NCT06233045	DAP-030-23	Dapagliflozin Tablet 10 mg Relative to Forxiga® Tablets 10 mg	P1	unknown	30	Bio-innova Co., Ltd	Jul 2024
NCT06690723	D3DOSA	Vitamin D and SGLT-2 Inhibitor in CPAP-naive Obstructive Sleep Apnea	P3	completed	160	University Malaysia Sarawak	Jun 2022
NCT04743453		EFFECT OF ADDING DAPAGLIFLOZIN TO ALLOGRAFT DYSFUNCTION OF RENAL TRANSPLANTED PATIENTS.	P4	completed	211	University of Sao Paulo General Hospital	Aug 2021
NCT06201000		Effect of Genetic Polymorphisms on the Clinical Response to SGLT2 Inhibitors in Heart Failure Patients	—	unknown	282	October 6 University	Dec 2023
NCT05849766		Effect of Dapagliflozin on Cardiac Structure, Function and Secondary Mitral Regurgitation in Patients with Left Ventricle Dysfunction	P3	completed	150	October 6 University	Apr 2023
NCT06365541		The Efficacy and Safety of Dapagliflozin in Improving Heart Failure in Dialysis Patients	P4	unknown	40	The People's Hospital of Gaozhou	Mar 2024
NCT05710367		Effects Of Sodium Glucose Cotranspoter 2 Inhibitors On Heart And Kidneys In Fabry Disease Patients	P2	unknown	46	Albina Nowak, MD	Aug 2023
NCT07077525		Effect of Vildagliptin Versus Dapagliflozin as Add on Therapy to Metformin on Cardiovascular Risk Factors	P4	completed	196	Al-Azhar University	Jun 2023
NCT05717257	DAPA-SERVE	Dapagliflozin in Systemic Right Ventricle (DAPA-SERVE)	P4	unknown	50	Monaldi Hospital	Aug 2022
NCT05196347	DAPA-advKD	Dapagliflozin and Renal Surrogate Outcomes in Advanced Chronic Kidney Disease	P3	completed	180	Kaohsiung Medical University	May 2022
NCT04965935	INFINITI2019	Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients	P3	completed	52	University Health Network, Toronto	Jul 2021
NCT05816733	DETAIL-CMIV	Dapagliflozin Evaluation on Atrial Fibrillation Patients Followed Cox Maze IV Procedure	P4	unknown	348	Kun Hua	Sep 2023
NCT05459701	T2DM	Dapagliflozin in Type 2 Diabetes Mellitus Patients (T2DM) With Nonalcoholic Fatty Liver Disease (NAFLD)	P4	completed	50	Rehab Werida	May 2022
NCT03968224		Effectiveness of Dapagliflozin for Weight Loss	P2/P3	completed	160	Centro Medico Nacional Siglo XXI IMSS	Aug 2018
NCT05254626		Efficacy and Safety of Dapagliflozin in Patients with Non-alcoholic Steatohepatitis	P2	completed	100	Cairo University	Aug 2022
NCT06721442	DAPA-ECG	Effect of Dapagliflozin on Electrocardiographic Parameters in Type 2 Diabetes Patients: DAPA - ECG Study	P4	completed	174	Beneficência Portuguesa de São Paulo	Jan 2023
NCT05420285	ICARD	Cardiometabolic Effects of Dapagliflozin in Heart Failure With Reduced or Mildly Reduced Ejection Fraction	P2	unknown	40	Assistance Publique - Hôpitaux de Paris	Jun 2022
NCT04333823	ATTEMPT	Adolescent Type 1 Diabetes Treatment With SGLT2i for hyperglycEMia & hyPerfilTration Trial	P3	active not recruiting	100	The Hospital for Sick Children	Dec 2020
NCT03919656		SGLT-2 Inhibition, Metabolomics and Cardiovascular/Kidney Disease	P4	completed	60	Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud	May 2019
NCT04794517	ADAPT	Dapagliflozin in Non-diabetic Stage IV CKD	P2	completed	32	Mario Negri Institute for Pharmacological Research	Nov 2021
NCT04782245	ARCADIA-HF	Acute Reno-Cardiac Action of Dapagliflozin In Advanced Heart Failure Patients on Heart Transplant Waiting List	P2	withdrawn	0	Hospices Civils de Lyon	Sep 2022
NCT05308160		A Single Center, Randomized, Open Label, Parallel Group, Phase 3 Study to Evaluate the Efficacy of Dapagliflozin in Subjects With Nonalcoholic Fatty Liver Disease	P3	unknown	75	National Taiwan University Hospital	Jun 2021
NCT05250011	EVOLUTION-HF	Observation of Italian Patients With Heart Failure Being Treated With Dapagliflozin in Clinical Practice	—	completed	252	AstraZeneca	Apr 2022
NCT05849220		Dapagliflozin in Non Alcoholic Fatty Liver Disease Associated Cirrhosis and Its Role in Preventing Development of Chronic Kidney Disease.	N/A	unknown	144	Institute of Liver and Biliary Sciences, India	May 2023
NCT03723252	DEAN	Dapagliflozin Efficacy and Action in NASH	P3	completed	154	Nanfang Hospital, Southern Medical University	Mar 2019
NCT05966818		Effect of Dapagliflozin in Non-Diabetic Patients With Nephrotic Syndrome.	P4	unknown	90	Ain Shams University	Aug 2023
NCT07363707	(Dapa)& (Empa)	A Study Between Dapagliflozin and Empagliflozin Effect on NAFLD in Patients With Type 2 Diabetes.	P4	completed	108	Beni-Suef University	May 2023
NCT06012279		Clinical Outcomes of Dapagliflozin in Acute Heart Failure With Reduced Ejection Fraction (CODA-HFrEF)	P4	completed	117	Cairo University	Aug 2023
NCT03499704	EPIDOTE	A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy	P4	completed	133	Celltrion Pharm, Inc.	Feb 2020
NCT05704088		SGLT2 Inhibitors Between Reno Protective Effects and Impact on Bone and Mineral Disease Among Lupus Nephritis Patients	P4	completed	100	Mansoura University	Oct 2022
NCT03199053	T2DM	Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old	P3	completed	256	AstraZeneca	Oct 2017
NCT05390307	OTID	Obesity Treatment to Improve Diabetes	N/A	completed	60	Dasman Diabetes Institute	Apr 2023
NCT05748925		Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients	P4	completed	84	Mansoura University	Oct 2022
NCT05162690	DINE	Efficacy of Dapagliflozin in Diabetes Associated Peripheral Neuropathy	P2/P3	unknown	40	Post Graduate Institute of Medical Education and Research, Chandigarh	May 2022
NCT05347459		Cognitive Protective Effect of Newer Antidiabetic Drugs	—	unknown	100	Alexandria University	Mar 2022
NCT05225077		Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients	P4	unknown	600	Dong-A University	Jan 2022
NCT05915949	Location-F	Comparison of Dapagliflozin, Lobeglitazone, and Its Combination in Efficacy and Safety	P4	unknown	99	Seoul National University Bundang Hospital	Jan 2022
NCT03423355		Dapagliflozin Effect on Erythropoiesis and Physical Fitness	P4	withdrawn	0	University Hospital Tuebingen	Sep 2021
NCT04796428	GOLDEN-AGE	GliflOzin in eLderly Diabetic patiENts: A praGmatic Intraclass Evaluation Trial	P4	unknown	1,167	Center for Outcomes Research and Clinical Epidemiology, Italy	Jun 2021
NCT04258371	DAPA-SWEET	DAPAgliflozin Sodium Water glucosE EffecTs in Patients at High Cardiovascular Risk	P2	unknown	50	University Health Network, Toronto	Feb 2020
NCT05262257		Evaluation and Intervention of Cognitive Function in Patients With Diabetes Mellitus.	Early P1	unknown	120	The First Affiliated Hospital with Nanjing Medical University	Apr 2022
NCT03710460		Effect of Dapagliflozin/Metformin XR vs Monotherapies on Anthropometric Indicators in Obesity	P4	unknown	33	University of Guadalajara	Jul 2019
NCT06383832		Effect of Dapagliflozin on Body Weight in Overweight Women Consuming Different Proportions of Carbohydrate Diet.	P4	completed	36	Sun Jia	Oct 2021
NCT07344922		SGLT2 Inhibitors in Non-Diabetic CKD: Effects on Vascular Calcification and Anemia	P3	completed	100	Mansoura University	Sep 2022
NCT04780438		Dapagliflozin to Prevent Atrial Fibrillation Recurrence After Transcatheter Pulmonary Venous Isolation.	Early P1	unknown	350	G.Gennimatas General Hospital	Sep 2021
NCT04806633		Dapagliflozin to Prevent the Incidence of Contrast Induced Nephropathy After Heart Catheterization and Percutaneous Coronary Intervention	Early P1	unknown	1,722	G.Gennimatas General Hospital	Apr 2021
NCT05310916		Effect of SGLT2i on Diabetic Retinopathy in Type 2 Diabetes Mellitus Patients	P3	unknown	60	Nidae Alaa	Jun 2022
NCT04620590		Dapagliflozin Treatment in Type 2 Diabetes	P4	completed	17	Emerald Clinical Inc.	Apr 2021
NCT06063109		A Clinical Trial to Evaluate the Safety and the Pharmacokinetic Interaction of Telmisartan and Dapagliflozin.	P1	completed	51	THPharm Corp.	Oct 2023
NCT05735197		Effect of Dapagliflozin on Renal Outcomes and Bone Mineral Disease in Non-diabetic Chronic Kidney Disease Patients	P4	completed	100	Mansoura University	Sep 2022
NCT05558098	DEFENDER	Dapagliflozin in Patients With Critical Illness	P3	completed	507	Hospital Israelita Albert Einstein	Nov 2022
NCT05335629		Evaluation of the Effect of SGLT-2 Inhibitors on Cardiac Remodeling in Post Myocardial Infarction Patients	N/A	completed	54	Ain Shams University	Jun 2022
NCT04595370	MIRACLE	Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease	P2	completed	153	AstraZeneca	Jan 2021
NCT06026787		Clinical Value of Adding Dapagliflozin in Patients With Nephrotic Syndrome	P4	completed	60	Ain Shams University	Aug 2022
NCT05217654		Trial to Investigate the Effect of Dapagliflozin on Ischemia Reperfusion Induced Endothelial Dysfunction	P1	unknown	32	Medical University of Vienna	Feb 2022
NCT05606718	DEFORM	Dapagliflozin Effect on FunctiOnal Mitral Regurgitation and Myocardial Remodeling	P4	unknown	98	Sun Yat-sen University	Apr 2022
NCT05025735		Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer	P2	unknown	25	Saint Luke's Health System	Aug 2021
NCT05601336		of Sodium Glucose Cotransporter-2 Inhibitors on Metabolic, Hormonal and Clinical Parameters in PCO	P3	unknown	200	Beni-Suef University	Jan 2022
NCT05392959	DAPAMICRO	Effect of the Antidiabetic Drug Dapagliflozin on the Coronary Macrovascular and Microvascular Function in Type 2 Diabetic Patients	P4	terminated	4	Centre Hospitalier Universitaire Saint Pierre	Jun 2022
NCT02911792	Hyper	Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration	P4	completed	72	The University of Texas Health Science Center at San Antonio	Dec 2016
NCT04564742	DAPA-MI	Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack.	P3	completed	4,017	AstraZeneca	Dec 2020
NCT05406505	DAPA-RESPONSE-AHF	Effect of Dapagliflozin in Patients With Acute Heart Failure (DAPA-RESPONSE-AHF)	P2/P3	completed	87	Mansoura University	Apr 2022
NCT05618223	Dapa-Rhemis	Dapagliflozin Effect on Rheumatic Mitral Stenosis	P3	unknown	36	Universitas Sebelas Maret	Dec 2022
NCT06241638		Improving HbA1c Levels by Methylcobalamin Vitamin in Diabetic Volunteers	N/A	completed	80	Al-Balqa Applied University	Jul 2022
NCT04792190	DAPA-AF	Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation	P4	completed	25	University of Rochester	Jul 2021
NCT05226897		Clinical Trial to Assess the Efficacy and Safety of YYC405 in Type 2 Diabetes Patients	P3	unknown	256	Yooyoung Pharmaceutical Co., Ltd.	Jul 2021
NCT04717986	DAPA-AMI	Dapagliflozin Effects on Mayor Adverse Cardiovascular Events in Patients With Acute Myocardial Infarction (DAPA-AMI)	N/A	completed	188	Instituto Mexicano del Seguro Social	Jan 2021
NCT04956809		Effect of Dapagliflozin on Submaximal Exercise Tolerance in Heart Failure	P2	completed	3	University of Pennsylvania	Oct 2021
NCT05998525		Dapagliflozin Effects on Coronary Calcium and Epicardial Fat Assessed by Cardiotomography	P3	completed	54	Hilda Elizabeth Macías Cervantes	Jun 2021
NCT04724837	ZENITH-CKD	Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial)	P2	completed	542	AstraZeneca	Apr 2021
NCT04340908		Effects of SGLT2 Inhibitor on Type 2 Diabetic Patients Undergoing Cardiac Surgery	P4	unknown	500	Hongchang Guo	Jan 2021
NCT02981966		Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects	P4	completed	32	The University of Texas Health Science Center at San Antonio	May 2019
NCT04298229	DICTATE-AHF	Efficacy and Safety of Dapagliflozin in Acute Heart Failure	P3	completed	240	Vanderbilt University Medical Center	Apr 2020
NCT04170543		A Phase 2b Diabetic Kidney Disease Study	P2	completed	609	AstraZeneca	Nov 2019
NCT04899349	EPIK-B4	Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant	P2	terminated	2	Novartis Pharmaceuticals	Apr 2022
NCT05440591	DMVascular	Effects of Dapagliflozin and Metformin on Vascular Function in Newly-Diagnosed Treatment-Naive Type 2 Diabetes	P4	unknown	150	Tan Tock Seng Hospital	Apr 2019
NCT06127212		Bioequivalence Study of Dapagliflozin 10 mg Film-coated Tablets	N/A	completed	24	Dexa Medica Group	Mar 2023
NCT05429593		A Research Study Investigating How Semaglutide and Dapagliflozin Act in Your Body When Dosed in One Tablet	P1	completed	152	Novo Nordisk A/S	Jun 2022
NCT04860011	DAPARESIST	DAPAgliflozin Versus Thiazide Diuretic in Patients With Heart Failure and Diuretic RESISTance	P3	unknown	61	NHS Greater Glasgow and Clyde	Apr 2021
NCT04707352	MODA	Impact on Atrial Remodeling of Dapaglifozin in Patients With Heart Failure .	P3	completed	162	Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia	Feb 2021
NCT02981069		Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM	P4	completed	90	The University of Texas Health Science Center at San Antonio	Dec 2017
NCT04445714		To Assess Safety of Fixed Dose Combination of Dapagliflozin and Saxagliptin in Type 2 Diabetes Mellitus Patients	P4	completed	196	AstraZeneca	Apr 2021
NCT04885712		A Study to Evaluate the Efficacy and Safety of Pioglitazone 15mg or 30mg Add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin	P3	completed	378	Boryung Pharmaceutical Co., Ltd	May 2021
NCT05591235		Effect of Metformin, Dapagliflozin, Combination of Metformin and Pioglitazone in Patients With Type 2 Diabetes	P3	unknown	60	Nanjing First Hospital, Nanjing Medical University	Nov 2022
NCT05268926	TIMOTHY	TreatIng Microalbuminuria Over 24 Weeks in Subjects With or Without Type 2 Diabetes or HYpertension	P2	terminated	9	University Medical Center Groningen	Feb 2022
NCT04706637	EVOMETA	A Clinical Trial to Evaluate the Bone Metabolism and the Blood Sugar of Evogliptin and Dapagliflozin	P4	unknown	120	Kyung Hee University Hospital at Gangdong	Feb 2021
NCT04004793	READ	Remission of Type 2 Diabetes With Dapagliflozin (READ Trial)	P4	completed	328	Shanghai Zhongshan Hospital	Jun 2020
NCT05457933		Efficacy and Safety of Dapagliflozin for the Hospital Management of Patients With Type 2 Diabetes	P4	completed	250	Medanta, The Medicity, India	Jul 2022
NCT06326034		Impact of Dapagliflozin as Add-on Therapy on Glycemic Status and Quality of Life in Type 2 Diabetic Patients	P4	completed	40	Mohammed Mahmood Mohammed	May 2022
NCT05418946	PRECARE	The Effects of Dapagliflozin in Normal Clinical Practice in T2D	—	unknown	1,400	University of Milan	Jun 2022
NCT05418465		Huangqi Guizhi Wuwu Decoction in CKD Stage 2-4 Diabetic Nephropathy	N/A	unknown	100	The First Affiliated Hospital of Dalian Medical University	Jan 2022
NCT05250752	PRESERVE	Reduction of Peritoneal Glucose Uptake With Use of SGLT2 in Humans Undergoing Peritoneal Dialysis Treatment	P2	unknown	10	Holbaek Sygehus	Nov 2021
NCT05797935		Evaluation of Changes in Pancreatic Fat Content Using Advanced MR Sequences in Diabetics on Dapagliflozin Therapy	P4	completed	50	Post Graduate Institute of Medical Education and Research, Chandigarh	Aug 2021
NCT04531397		Efficacy and Safety of Dapagliflozin in Children With Proteinuric Chronic Kidney Disease	P4	withdrawn	0	Children's Hospital of Fudan University	Jan 2021
NCT04739215	CARDIA-STIFF	Effects of SGLT2 Inhibition on the Mechanisms of Cardiac Damage in the Diabetic Patient With HFpEF	P4	unknown	62	Hospital General Universitario Gregorio Marañon	Jan 2021
NCT04255238		A Study to Evaluate the Efficacy and Safety of Dual add-on Therapy With Gemigliptin 50 mg and Dapagliflozin 10 mg Added to Metformin Who Have Inadequate Glycemic Control on Metformin Alone	P3	unknown	468	LG Chem	Jun 2020
NCT04730947	DAPA	Dapagliflozin (DAPA) Effects in HFpEF	P2	completed	38	Mayo Clinic	Feb 2021
NCT03782259		Effects of SGLT-2 Inhibition on Myocardial Fibrosis and Inflammation as Assessed by Cardiac MRI in Patients With DM2	P4	completed	62	University of Washington	Feb 2019
NCT03331289		Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria	P4	completed	107	The University of Texas Health Science Center at San Antonio	Feb 2018
NCT04213677	DEAP	Dapagliflozin Efficacy and Action in PCOS	P3	completed	165	Nanfang Hospital, Southern Medical University	Mar 2020
NCT04545411		Combination GRA and SGLT-2i Treatment in Type 1 Diabetes	P1/P2	completed	12	University of California, San Diego	Feb 2021
NCT03313752	DapaHeart	Effects of SGLT2 Inhibition on Myocardial Insulin Sensitivity	P3	completed	25	Giaccari Andrea	Dec 2017
NCT05343078	DARE-ESKD 1	Pharmacokinetics and Dialyzability of Dapagliflozin in Dialysis Patients	P4	completed	5	University of Campinas, Brazil	Apr 2022
NCT05105698		Food-effect Bioavailability of Gemigliptin and Dapagliflozin 50/10 mg	P1	unknown	28	LG Chem	Jan 2022
NCT05045274		The Effect of Early Administration of Dapagliflozin in STEMI Patients With LV Systolic Dysfunction	N/A	unknown	300	Assiut University	Dec 2021
NCT05159882		Safety and Efficacy of THR-1442 Compared to Dapagliflozin as Add-on Therapy to Metformin in T2DM	P3	unknown	390	Newsoara Biopharma Co., Ltd.	Apr 2021
NCT04401904	SGLT2i	SGLT2 Inhibition in Older Obese Adults With Pre-diabetes	P1/P2	completed	20	The University of Texas Health Science Center at San Antonio	Jun 2020
NCT06374043	@HOME	Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin.	P4	completed	20	University Medical Center Groningen	May 2021
NCT04492722		A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease	P2	terminated	613	AstraZeneca	Oct 2020
NCT03871621	ELUCIDATE	Left Ventricular Functional Changes of Uncontrolled Diabetes by Dapagliflozin Treatment Trial	P4	completed	76	Mackay Memorial Hospital	Apr 2019
NCT03714594		Effects of Dapagliflozin+Saxagliptin in Addition to Metformin v/s Saxagliptin or Dapagliflozin in Patients With DM2.	P2	completed	48	University of Pisa	Jul 2018
NCT04234867	Dapa-Stress	Study to Explore the Effect of Dapagliflozin and Stress in Adolescent and Adult Subjects With Type 1 Diabetes (T1D)	P1	terminated	2	Kinderkrankenhaus auf der Bult	May 2022
NCT04778787		Sodium-glucose Cotransporter Type 2 Inhibitors for Acute Cardiorenal Syndrome Prevention	P4	completed	370	I.M. Sechenov First Moscow State Medical University	Jan 2021
NCT05109949		Acute Effect of Empagliflozin vs Dapagliflozin Over Pulse Wave Velocity in Type Two Diabetes	P3	unknown	72	Centro Universitario de Ciencias de la Salud, Mexico	Mar 2020
NCT05141552	SDHF	The Safety of Dapagliflozin in Hemodialysis Patients With Heart Failure	N/A	unknown	20	RenJi Hospital	Jan 2022
NCT04956263		A Comparison of Postprandial Glucose After a MMTT, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study in Subjects With Type 1 Diabetes	P2	completed	19	Youngene Therapeutics Inc., Ltd.	Jun 2021
NCT03801642		Dapagliflozin In Alzheimer's Disease	P1/P2	completed	46	Jeff Burns, MD	Jan 2019
NCT03748810		Head-to-head Comparison of Empagliflozin and Dapagliflozin	—	completed	600	Chungbuk National University Hospital	Jan 2016
NCT05330013		The Effect of Inflammation in Heart Failure	P2	withdrawn	0	National Heart, Lung, and Blood Institute (NHLBI)	Jun 2022
NCT04393246		mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms	P2/P3	completed	454	Cambridge University Hospitals NHS Foundation Trust	Jul 2020
NCT05266404		Phase 1 Bioequivalence Study of Dapagliflozin/Sitagliptin FDC vs Loose Combination of Single Components	P1	completed	46	AstraZeneca	Mar 2022
NCT04475042	STADIA-HFpEF	Stratified Treatment to Ameliorate Diastolic Left Ventricular Stiffness in Heart Failure With Preserved Ejection Fraction	P2	unknown	26	Mariëlle Scheffer	Jul 2020
NCT05014594	SGLT-2	Sodium-glucose Linked Transporter 2 (SGLT-2) Inhibitors in Recurrent Ascites: a Pilot RCT	P2	unknown	44	Post Graduate Institute of Medical Education and Research, Chandigarh	Sep 2021
NCT05424315	DACAMI	Impact of DApagliflozin on Cardiac Function Following Anterior Myocardial Infarction in Non-Diabetic Patients	P2/P3	completed	100	Omar Younis	Oct 2021
NCT04818034	SGLT	The Effect of Sodium-glucose Cotransporter (SGLT) 2 Inhibitors on Cystine Stone Formation: A Preliminary Study	P2	completed	10	University of California, San Francisco	Aug 2021
NCT04735042	UTI-flog	SGLT-2 and DPP-4 Inhibition, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections.	—	completed	60	University of Pisa	Oct 2020
NCT04534270		Efficacy and Safety of Dapagliflozin in Children With Proteinuria	P4	completed	23	Children's Hospital of Fudan University	Jul 2020
NCT03619213	DELIVER	Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.	P3	completed	6,263	AstraZeneca	Aug 2018
NCT04249778		Dapagliflozin at Discharge on Hospital Heart Failure Readmission	P4	completed	105	Emory University	Jul 2020
NCT04356742		Efficacy and Safety of Dapagliflozin When Added to Ongoing Metformin and Evogliptin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control	P3	completed	198	Dong-A ST Co., Ltd.	May 2020
NCT04570865	DAPA-MEMS	Dapagliflozin And Pulmonary Artery Hemodynamics in Heart Failure With Reduced Ejection Fraction Patients With CardioMEMS®	P4	unknown	100	Scripps Health	Dec 2020
NCT04240171		Dapagliflozin Versus Glimepiride Effect in Patient With Type 2 Diabetes Mellitus	—	completed	60	Damanhour University	Dec 2020
NCT04542291	SGLT2	Targeting Pancreatic Cancer With Sodium Glucose Transporter 2 (SGLT2) Inhibition	P1	completed	15	Washington University School of Medicine	Feb 2021
NCT05236998		A Pharmacokinetic Study of SID1903 (FDC of Dapagliflozin and Sitagliptin) in Healthy Adult Volunteers	P1	completed	45	SK Chemicals Co., Ltd.	Nov 2021
NCT02338921		Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy	P4	completed	78	Seoul National University Bundang Hospital	Jan 2015
NCT03660683		Effect of Saxagliptin and Dapagliflozin on Endothelial Progenitor Cell in Patients With Type 2 Diabetes Mellitus	P4	terminated	15	Sabyasachi Sen	Oct 2018
NCT04170998		Efficacy and Safety of Evogliptin When Added to Ongoing Metformin and Dapagliflozin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control	P3	completed	283	Dong-A ST Co., Ltd.	Jan 2020
NCT03704818		Dapagliflozin Effects on Hypoglycemia	P1	completed	22	University of California, San Diego	Oct 2018
NCT04080518	DAPA-Shuttle1	Hepato-renal Regulation of Water Conservation in Heart Failure Patients With SGLT-2 Inhibitor Treatment	P4	completed	40	National Heart Centre Singapore	Nov 2019
NCT04634500	ENHANCE-M	The Efficacy and Safety of DWP16001 in Combination With Metformin in Patients With Type 2 Diabetes.	P3	completed	200	Daewoong Pharmaceutical Co. LTD.	Nov 2020
NCT02962492		An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes	N/A	completed	70	University at Buffalo	Nov 2016
NCT04991571		Study to Collect Samples for MIST Analysis of Zibotentan and Bioavailability of Zibotentan and Dapagliflozin in Heatlhy Participants	P1	completed	27	AstraZeneca	Jul 2021
NCT04200586	SGLTi	The Effects of SGLTi on Diabetic Cardiomyopathy	P4	unknown	30	The University of Hong Kong	Apr 2020
NCT03030235	PRESERVED-HF	Dapagliflozin in PRESERVED Ejection Fraction Heart Failure	P4	completed	324	Saint Luke's Health System	Mar 2017
NCT04544319		Clinical Trial to Compare the PK of the Fixed-dose Combinations and Each Component of Gemigliptin/Dapagliflozin 50/10 mg	P1	unknown	44	LG Chem	Oct 2020
NCT03592667		Dapagliflozin on Blood Pressure Variability and Ambulatory Arterial Stiffness Index in Hypertension	P4	unknown	20	University of Guadalajara	Feb 2019
NCT04923295		The Effect of Dapagliflozin on Ultrafiltration Among Peritoneal Dialysis Patients	N/A	completed	20	An-Najah National University	Jun 2021
NCT03537131	DEPTH	Dapagliflozin During Exercise for the PrevenTion of Hypoglycaemia	P2	terminated	9	University of Oxford	Jun 2018
NCT03721874	MaasFlex	Effects of 2 Weeks Treatment With Dapagliflozin in Subjects With an Impaired Glucose Homeostasis on Nocturnal Substrate Oxidation	P4	completed	16	Maastricht University	Apr 2019
NCT04856007		A Study to Assess the Bioequivalence of Fixed Dose Combination of Dapagliflozin/Metformin XR Relative to Co-administration of the Individual Components in Healthy Chinese Subjects.	P1	completed	80	AstraZeneca	Apr 2021
NCT04882813		Replication of the DAPA-CKD (Chronic Kidney Disease) Trial in Healthcare Claims Data	—	completed	87,727	Brigham and Women's Hospital	Dec 2020
NCT04350593	DARE-19	Dapagliflozin in Respiratory Failure in Patients With COVID-19	P3	completed	1,250	Saint Luke's Health System	Apr 2020
NCT03970044		Effectiveness of Exenatide Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept.	P4	completed	67	Consano Clinical Research, LLC	Jul 2019
NCT03269058	Cinétique DAPA	Evaluate the Effects of Dapagliflozin in Patients With Type 2 Diabetes	P4	completed	28	Centre Hospitalier Universitaire Dijon	Dec 2017
NCT04856969		Clinical Trial to Evaluate Pharmacokinetic Interaction of ATB-1011 and ATB-1012 in Healthy Adult Volunteers	P1	completed	38	Autotelicbio	Mar 2021
NCT04304560		Value of SGLT2 Inhibitor (Dapagliflozin) as an Added Therapy in Diabetic Patients With Heart Failure With Reduced Ejection Fraction; Randomized Controlled Clinical Trial	P2	unknown	60	Damanhour University	Mar 2020
NCT04330079		Effects of dapaglifloziN Therapy on Myocardial Perfusion Reserve in Prediabetic Patients With Stable coronarY Artery Disease	P4	terminated	2	CHEOL WHAN LEE, M.D., Ph.D	May 2020
NCT04287387		Response of Gut Microbiota in Type 2 Diabetes to Hypoglycemic Agents	P4	unknown	180	Peking Union Medical College Hospital	Mar 2020
NCT03961659		Effects of Liraglutid, Dapagliflozin and Acarbose on the Cognitive Function, Olfactory Function, and Odor-induced Brain Activation in Overweight/Obese T2DM Patients Controlled Inadequately With Metformin Monotherapy.	N/A	unknown	87	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	May 2019
NCT04215523		Replication of the DECLARE Diabetes Trial in Healthcare Claims	—	completed	49,790	Brigham and Women's Hospital	Jul 2019
NCT04880993		Bioequivalence of Dapagliflozin 10 mg Tablets Under Fasting Conditions	P1	completed	30	Jiangsu Hansoh Pharmaceutical Co., Ltd.	Dec 2020
NCT03658031		Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction	P3	unknown	576	Hamad Medical Corporation	Mar 2019
NCT04881006		Bioequivalence of Dapagliflozin 10 mg Tablets Under Fed Conditions	P1	completed	30	Jiangsu Hansoh Pharmaceutical Co., Ltd.	Dec 2020
NCT04575675		Dapagliflozin on Hypotensive Heart Failure Patients After Sacubitril/Valsartan Therapy	P4	completed	78	Cheng-Hsin General Hospital	May 2020
NCT04195243		Dapagliflozin vs Empagliflozin on Flow Mediated Dilation in Type 2 Diabetes Mellitus	P3	unknown	24	Centro Universitario de Ciencias de la Salud, Mexico	Dec 2019
NCT04385589		Dapagliflozin in Diabetic Patients (Type 2) With Decompensated Heart Failure	P4	completed	100	Assiut University	May 2020
NCT05066516		The Pharmacokinetics, Safety and Tolerability of IN-C009 in Healthy Subjects	P1	completed	48	Korea University Anam Hospital	Jun 2020
NCT03959501		Metabolic Responses of Dapagliflozin vs Sitagliptin in T2DM Patients Inadequately Controlled With Insulin Therapy	P4	completed	60	The University of Hong Kong	Aug 2017
NCT02635386	PCOS	EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)	P3	completed	119	Woman's	Mar 2016
NCT02235298		Dapagliflozin Effects on Epicardial Fat	P4	completed	100	University of Miami	Sep 2015
NCT02796170		Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 Diabetes	P4	completed	11	Tulane University School of Medicine	Mar 2016
NCT03608358		Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin	P3	terminated	41	AstraZeneca	Feb 2019
NCT04014192		Effects of SGLT2 Inhibitors on Islet Cell Function and Insulin Sensitivity in Patients of Type 2 Diabetes Mellitus	P4	unknown	40	Peking Union Medical College Hospital	Sep 2019
NCT03877224		DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction	P3	completed	504	AstraZeneca	Apr 2019
NCT02751398		Impact of Dapagliflozin on DIAstolic Dysfunction in Type 2 Diabetic Patients	P4	completed	60	Yonsei University	Aug 2016
NCT03036150	Dapa-CKD	A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease	P3	completed	4,304	AstraZeneca	Feb 2017
NCT02725593		Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years	P3	completed	72	AstraZeneca	Jun 2016
NCT04242758	PURITY	Phthalates Exposure in Type 2 Diabetic Patients and Diuretic Therapy	P4	unknown	30	University of Pisa	Jun 2019
NCT03361098	DECREASE	DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2	P4	completed	65	Amsterdam UMC, location VUmc	Sep 2017
NCT03152084	DAPASALT	The Study Will Evaluate Average 24-hr Sodium Excretion During Dapagliflozin Treatment in Patients With Type 2 Diabetes Mellitus With Preserved or Impaired Renal Function or Non-diabetics With Impaired Renal Function.	P4	terminated	24	AstraZeneca	Jul 2017
NCT03877237		DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction	P3	completed	313	AstraZeneca	Apr 2019
NCT03887416		Effect of Dapagliflozin on Nighttime Blood Pressure in Type 2 Diabetes	P4	unknown	225	LM Diagnósticos S.L.	Apr 2019
NCT04304430	DARWIN-FUP	Comparative Effectiveness of Dapagliflozin Versus DPP-4 Inhibitors	—	completed	11,206	University of Padova	Oct 2018
NCT04120623		Therapeutic Effect of Dapagliflozin Combined With CSII on Newly Diagnosed Type 2 Diabetes Mellitus	P4	unknown	100	Nanjing First Hospital, Nanjing Medical University	Oct 2019
NCT02965443	DapaSaxaBBIT	Dapagliflozin + Saxagliptin in a Basal-bolus Insulin Treatment	P4	terminated	4	University Hospital Tuebingen	Feb 2018
NCT03007329	EXENDA	Effects of Combined Dapagliflozin and Exenatide Versus Dapagliflozin and Placebo on Ectopic Lipids in Patients With Uncontrolled Type 2 Diabetes Mellitus.	P4	completed	34	Medical University of Vienna	Mar 2017
NCT03982238		Effects of Hypoglycemic Drugs on Testosterone Levels in Type 2 Diabetes Patients	P4	completed	74	Majianhua	Jun 2019
NCT03556033		Effect of Dapagliflozin on IAH in T1DM	P2	completed	15	Radboud University Medical Center	Nov 2018
NCT03190694	DIAMOND	Effects of Dapagliflozin in Non-diabetic Patients With Proteinuria	P2	completed	53	Hiddo Lambers Heerspink	Nov 2017
NCT02984644	AZ11040	Paradoxical Stimulation of Hepatic Glucose Production With Dapagliflozin	P3	completed	30	The University of Texas Health Science Center at San Antonio	Sep 2017
NCT03338855	DAPAMAAST	Effects of 5 Weeks Treatment With Dapagliflozin in Type 2 Diabetes Patients on How the Hormone Insulin Acts on Sugar Uptake in Muscles.	P4	completed	26	AstraZeneca	Mar 2018
NCT02887677		Effects of Dapagliflozin on Central Hemodynamics and Urine Albumin Excretion in Patients With Type 2 Diabetes.	P4	terminated	85	Hellenic Society for Medical Education	Oct 2016
NCT02592421		SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2	P3	completed	30	The University of Texas Health Science Center at San Antonio	Oct 2015
NCT02419612		A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone	P3	completed	444	AstraZeneca	Aug 2015
NCT02919059		Study to Asses the Effect of Dapagliflozin on Central Blood Pressure Reduction.	P4	unknown	159	IInstituto Gallego de Medicina Vascular	Dec 2016
NCT02973477	T2D	Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)	P4	completed	45	University of Michigan	Jan 2017
NCT03419624		The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients	P3	terminated	13	Universitätsklinikum Hamburg-Eppendorf	Feb 2018
NCT03364985		Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP16001 After Oral Administration in Healthy Male Volunteers	P1	completed	123	Daewoong Pharmaceutical Co. LTD.	Dec 2017
NCT03036124	DAPA-HF	Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure	P3	completed	4,744	AstraZeneca	Feb 2017
NCT02653482	DEFINE-HF	Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure	P4	completed	263	Saint Luke's Health System	Mar 2016
NCT03344341		A Phase IV Study in Drug-Naive Patients With T2DM in China	P4	terminated	304	AstraZeneca	Dec 2017
NCT03168295	PROTOCOL 3	PROTOCOL 3: Role of the Renal Nerves in the Increase in EGP in Response to Glucosuria	P4	completed	34	The University of Texas Health Science Center at San Antonio	Oct 2016
NCT02956811	DAPA-LVH	Does Dapagliflozin Regress Left Ventricular Hypertrophy In Patients With Type 2 Diabetes?	P4	completed	66	University of Dundee	Feb 2017
NCT02919345	ADDENDA	Assessment of Dapagliflozin Effect on Diabetic Endothelial Dysfunction of Brachial Artery	P4	completed	98	University of Campinas, Brazil	Jan 2017
NCT02608905		Effect of Dapagliflozin on Inflammation and Endothelial Function	P4	terminated	17	Baylor College of Medicine	Nov 2015
NCT03387683	DAPACARD	A Clinical Study to Investigate the Effects of Dapagliflozin on Heart Work, Heart Nutrient Uptake, and Heart Muscle Efficiency in Type 2 Diabetes Patients	P4	completed	53	AstraZeneca	Feb 2018
NCT04149067		Study of Real-world Evidence With SGLT2i (Dapagliflozin) and DPP4i (Sitagliptin) in Type 2 Diabetes Patients in Spain	—	completed	1,080	Fundación Pública Andaluza para la gestión de la Investigación en Sevilla	Jun 2017
NCT03377335		Dapagliflozin, Cardio-Metabolic Risk Factors and Type-2 Diabetes	P4	unknown	186	University of Palermo	Dec 2017
NCT02925559	EFFORT	Effect of Anti-diabetic Drugs on Glycemic Variability	P4	completed	135	Centro de Diabetes Curitiba Ltda	Oct 2016
NCT03766724		Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Evogliptin and Empagliflozin or Dapagliflozin in Healthy Male Adults	P1	completed	42	Dong-A ST Co., Ltd.	Nov 2018
NCT02695810		The PRE-D Trial: Effect of Dapagliflozin, Metformin and Physical Activity in Pre-diabetes	P2	completed	120	Steno Diabetes Center Copenhagen	Feb 2016
NCT03398577		Effects of SGLT2 Inhibitor in Diabetic Patients With Coronary Artery Disease	P4	unknown	61	Sheba Medical Center	Feb 2018
NCT02811484	Dexlar	Efficacy of Exenatide-LAR and Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Type 2 Diabetes	P4	withdrawn	0	Weill Medical College of Cornell University	Jun 2016
NCT03565458		Gemigliptin, Dapagliflozin, Empagliflozin DDI Study	P1	unknown	48	LG Chem	Apr 2018
NCT03180489		Does Dapagliflozin Provide Additional Health Benefits To Dietary Counseling For Weight Loss?	P2	completed	62	Christopher Bell	May 2017
NCT03202563		Trial to Evaluate the Efficacy on Glycemic Variability and Safety of Gemigliptin Compared With Dapagliflozin Added on Metformin Alone or Diabetes Medication Naïve Patient in Type 2 Diabetes Mellitus (Stable II Study)	P4	completed	71	LG Chem	Aug 2017
NCT02433678		An Investigation Into The Anti-hypertensive And Potential Anti-inflammatory Actions Of Dapagliflozin	P4	completed	52	University at Buffalo	Nov 2015
NCT02682563	RED	Renoprotective Effects of Dapagliflozin in Type 2 Diabetes	P4	completed	44	M.H.H. Kramer	Feb 2016
NCT02610088		Effect of Dapagliflozin on Vascular Functions in Patients With Type 2 Diabetes Compared to Gliclazide	P4	completed	32	Seoul National University Bundang Hospital	Nov 2015
NCT01730534	DECLARE-TIMI58	Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events	P3	completed	17,190	AstraZeneca	Apr 2013
NCT02798757		Evaluation of the Tubular Effects of Dapagliflozin Using 1HNMR Spectroscopy	P4	completed	50	University of Ioannina	Jun 2016
NCT02577159	DAPHNIS	Dapagliflozin on Hyperlipidemia and Insulin Resistance in Type 2 Diabetic Patients (DAPHNIS Study)	P4	unknown	50	Osaka University	Jul 2015
NCT03178591		Effects of DPP4 Inhibitor Versus SGLT2 Inhibitor	P4	completed	43	Chiang Mai University	Oct 2014
NCT03316131	UA	A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA	P2	completed	36	AstraZeneca	Oct 2017
NCT02558270		Effects of SGLT-2 Inhibition on Hepatic Glucose and Energy Metabolism	P2	unknown	20	Medical University of Vienna	Jun 2016
NCT02613897		ESR-15-11293 - Saxa/Dapa, Safety and Efficacy Study	N/A	completed	56	The University of Texas Health Science Center at San Antonio	Jan 2016
NCT01439854	DAPA MITO	Study of Dapagliflozin on Mitochondrial Dysfunction and Impaired Insulin Signaling/Action	N/A	completed	18	The University of Texas Health Science Center at San Antonio	Mar 2011
NCT03006471		Effect of Dapagliflozin on Blood Pressure Variability in Prediabetes and Prehypertension	P4	completed	30	University of Guadalajara	Mar 2016
NCT03492580		A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease	—	completed	714,582	Janssen Research & Development, LLC	Feb 2018
NCT03216278		The Purpose of the Study is to Compare Two Fixed Dose Combination Tablets of Dapagliflozin/Metformin XR in Healthy Subjects Under Fasting and Fed Conditions	P1	completed	284	AstraZeneca	Sep 2017
NCT02547935		A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD	P2/P3	completed	459	AstraZeneca	Sep 2015
NCT03074630	DICE	Dapagliflozin and Cholesterol Metabolism in Type 2 Diabetes (DM2)	P4	completed	12	Amsterdam UMC, location VUmc	May 2016
NCT02460978	DEPICT 2	Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes	P3	completed	815	AstraZeneca	Jul 2015
NCT02371187		Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?	P2	completed	37	Christopher Bell	Jun 2015
NCT02564926	BEYOND	Foxiga Korea Local Phase 4 Study	P4	completed	125	AstraZeneca	Jan 2016
NCT03089333		Effects of SGLT2 Inhibitor on Hemodynamic Parameters in Resistant Hypertensive Subjects	P4	completed	16	University of Campinas, Brazil	Jul 2016
NCT02229396		Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo	P3	completed	695	AstraZeneca	Sep 2014
NCT02987738	DapaDream	Pilot Study to Explore the Efficacy of DAPAglifozin as add-on to Closed-loop Control in Patients With Type 1 Diabetes	P1	completed	30	Kinderkrankenhaus auf der Bult	Feb 2017
NCT02719132	FLORA	Effect of DapagliFLOzin on Quality of Life in Patients With Type 2 Diabetes in a Real Clinical PrActice	P4	withdrawn	0	AstraZeneca	Jul 2016
NCT03138356		Bioequivalence Study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy Subjects	P1	completed	126	AstraZeneca	May 2017
NCT02551874		A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin	P3	completed	650	AstraZeneca	Oct 2015
NCT02413398	DERIVE	A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes	P3	completed	321	AstraZeneca	Jun 2015
NCT03249506	T2DM	Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)	—	completed	25,358	Janssen Research & Development, LLC	May 2016
NCT02532855	T2DM	A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)	P3	completed	614	Merck Sharp & Dohme LLC	Oct 2015
NCT02397421	REFORM	Safety and Effectiveness of SGLT-2 Inhibitors in Patients With Heart Failure and Diabetes	P4	completed	56	University of Dundee	Mar 2015
NCT02268214	DEPICT 1	Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes	P3	completed	833	AstraZeneca	Nov 2014
NCT03169959	PK	A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.	P1	completed	85	AstraZeneca	May 2017
NCT02681094		A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes	P3	completed	905	AstraZeneca	Feb 2016
NCT02914691	DapKid	Effects of Dapagliflozin Treatment on Urinary Proteomic Patterns in Patients With Type 2 Diabetes	P4	completed	40	Peter Rossing	Aug 2015
NCT02475070		Vildagliptin Versus Dapagliflozin on Glucagon	P4	completed	28	Lund University	Jan 2016
NCT02582814		The Safety and Efficacy of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM	P3	completed	151	AstraZeneca	Oct 2015
NCT02520518		Does Dapagliflozin Promote Favorable Health Benefits That Are Independent Of Weight Loss?	P2	terminated	9	Christopher Bell	Aug 2015
NCT02459353	DIVE	Effect of Dapagliflozin on Glycemic Variability	P4	completed	86	The Catholic University of Korea	Aug 2015
NCT02253121	GluCon-COPD	Glucose Control During Glucocorticoid Therapy in Acute Exacerbation of Chronic Obstructive Pulmonary Disease	P4	completed	46	Slotervaart Hospital	Feb 2015
NCT02585804	TRANSLATE	Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects	P4	completed	10	University Health Network, Toronto	Sep 2015
NCT02471404		Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea	P4	completed	939	AstraZeneca	Sep 2015
NCT02700334		Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes	P4	completed	24	University of Guadalajara	Oct 2016
NCT02211742	DapaT1DM	Dapagliflozin in Type 1 Diabetes	P4	completed	12	Medical University Innsbruck	Aug 2014
NCT02719756		Effect of SGLT-2 Inhibitor Dapagliflozin on Glycemic Variability in Patients With Diabetes Mellitus Type 2	P4	unknown	100	Research Clinical Centre of the Russian Railways, JSC	Apr 2016
NCT02765204		A Single-dose Cross-over Study to Assess Direct and Indirect Effects of Dapagliflozin on Pancreatic Alpha and Beta Cells in Patients With Type 2 Diabetes	P4	completed	15	Uppsala University	Mar 2016
NCT02777073	1974	Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes	N/A	completed	43	University at Buffalo	Mar 2016
NCT02372955		Mechanistic Study of the Systolic Blood Pressure Lowering Effect of Dapagliflozin in Type 2 Diabetes	P4	unknown	21	Gulf Regional Research & Educational Services, LLC	Feb 2015
NCT02327039	DAPA-HDL	The Effects of Dapagliflozin on HDL Particles Subtypes and Reverse Cholesterol Transport in Type 2 Diabetic Patients	P4	completed	33	University of Padova	Mar 2015
NCT02284893		Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone	P3	completed	461	AstraZeneca	Sep 2014
NCT02582840		The PK and PD of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM	P1	completed	42	AstraZeneca	Oct 2015
NCT02722239		An Open-label, Randomized, Crossover Study of Comparative Pharmacokinetics and Bioequivalence of Dapagliflozin + Metformin, 10 mg + 1000 mg Versus the Combined Use of Forxiga™, 10 mg and Two Glucophage® Long, ER Tablets, 500 mg Co-administered to Healthy Volunteers Under Standard Fed Conditions	P1	completed	40	AstraZeneca	Mar 2016
NCT02518945		Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes	P3	completed	26	University at Buffalo	Aug 2015
NCT02420392		Effects of Dapagliflozin on the Incretin Sensitivity of the Pancreatic Beta Cell	N/A	completed	30	Seoul National University Hospital	Feb 2015
NCT02426541	DERISC	Effects of Dapagliflozin 10 mg on Insulin Resistance in Patients With Type 2 Diabetes Mellitus	P4	completed	55	AstraZeneca	Mar 2015
NCT02637037		A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects	P1	completed	80	AstraZeneca	Dec 2015
NCT02313220	Dapalost	Exploratory Study to Investigate the Effect of Dapagliflozin and Exenatide Combined on Body Weight	P2	completed	50	Uppsala University	Dec 2014
NCT02096705		Phase III Insulin Add-On Asia Regional Program - ST	P3	completed	477	AstraZeneca	Mar 2014
NCT02279407	EFFECTII	A Study to Investigate Effects of Omega-3 Carboxylic Acids and Dapagliflozin on Liver Fat Content in Diabetic Patients	P2	completed	223	AstraZeneca	Jan 2015
NCT02325206	DAPA-IIT1	Phase 1 Study to Explore the Safety and Pharmacokinetics of DAPAglifozin in Adolescents and Adults With Type 1 Diabetes	P1	completed	36	Kinderkrankenhaus auf der Bult	Dec 2014
NCT02157298		Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin.	P4	completed	266	AstraZeneca	Jun 2014
NCT02383238	Dapa	Effect of Dapagliflozin on Microvascular and Macrovascular Circulation and Total Body Sodium Content	P3	completed	59	University of Erlangen-Nürnberg Medical School	Mar 2014
NCT02113241		Effect of Dapagliflozin Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion	P2/P3	completed	24	University of Guadalajara	Apr 2014
NCT01646320		Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes	P3	completed	320	AstraZeneca	Sep 2012
NCT01619059		Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes	P3	completed	315	AstraZeneca	Jun 2012
NCT02501616		Effect of Dapagliflozine on Systemic and Renal Endothelial Function	P4	unknown	22	Seoul National University Hospital	Dec 2014
NCT02223065		Bioequivalence Study Coadministered to Healthy Subjects in the Fasted State	P1	completed	36	AstraZeneca	Sep 2014
NCT01525238		PK Study of Dapagliflozin in Pediatric Subjects With T2DM	P1	completed	53	AstraZeneca	Jul 2012
NCT02060201	FDC	Bioequivalence/Food Effect - Saxa/Dapa Dual Fixed Dose Combination (FDC)	P1	completed	72	AstraZeneca	Feb 2014
NCT01877889		A Study to Compare the Pharmacodynamics of Canagliflozin and Dapagliflozin in Healthy Volunteers	P1	completed	60	Janssen-Cilag International NV	Jul 2013
NCT01606007		Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes	P3	completed	1,282	AstraZeneca	Jul 2012
NCT01392677		Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea	P3	completed	311	AstraZeneca	Oct 2011
NCT01535677		To Compare the Similarity of a Combination Dapagliflozin/Metformin Tablet With the Two Drugs Administered Separately	P1	completed	71	AstraZeneca	Apr 2013
NCT01257412		Evaluation of Efficacy and Safety of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise Alone	P3	suspended	375	AstraZeneca	Jan 2012
NCT01095666		A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone	P3	completed	1,484	AstraZeneca	Jun 2010
NCT01195662		A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication	P3	completed	2,245	AstraZeneca	Oct 2010
NCT01137474		A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker	P3	completed	2,996	AstraZeneca	Jul 2010
NCT00660907		Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients	P3	completed	1,217	AstraZeneca	Mar 2008
NCT01042977		Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease	P3	completed	964	AstraZeneca	Mar 2010
NCT01031680		Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension	P3	completed	922	AstraZeneca	Feb 2010
NCT01662999		Drug Interaction Study of Saxagliptin in Combination With Dapagliflozin in Healthy Participants	P1	completed	42	AstraZeneca	Aug 2012
NCT01498185	PK	BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes	P2	completed	171	AstraZeneca	Feb 2012
NCT01294436		Evaluate Safety as Mono or Combination Therapies With Anti-diabetes Mellitus Drugs in Japanese Subjects With Type 2 Diabetes Mellitus	P3	completed	728	AstraZeneca	Feb 2011
NCT01294423		Evaluate Efficacy and Safety in Japanese Subjects With Type 2 Diabetes Mellitus	P3	completed	261	AstraZeneca	Feb 2011
NCT01095653		A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise	P3	completed	1,179	AstraZeneca	Jun 2010
NCT00855166		Evaluation of the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type 2 Diabetes	P3	completed	182	AstraZeneca	Feb 2009
NCT00984867		Dapagliflozin DPPIV Inhibitor add-on Study	P3	completed	833	AstraZeneca	Oct 2009
NCT01217892		Evaluation of Dapagliflozin Taken Twice-daily	P3	completed	400	AstraZeneca	Nov 2010
NCT00663260		Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment	P2/P3	completed	631	AstraZeneca	Jun 2008
NCT00673231		Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin	P3	completed	1,240	AstraZeneca	Apr 2008
NCT01165268	T2DM	Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus (T2DM)	P1	completed	24	AstraZeneca	Aug 2010
NCT00976495		Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes	P2	completed	154	AstraZeneca	Oct 2009
NCT01156246		Study to Assess the Effect of Food on Combination Dapagliflozin/Metformin Tablet in Healthy Volunteers	P1	completed	18	AstraZeneca	Jun 2010
NCT00831779		Effects of Dapagliflozin on Insulin Resistance and Insulin Secretion in Subjects With Type 2 Diabetes	P2	completed	116	AstraZeneca	Apr 2009
NCT00528372		A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise	P3	completed	1,067	AstraZeneca	Sep 2007
NCT01135446	ULDS	Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Ultra Low Doses of Dapagliflozin in Healthy Subjects	P1	completed	35	AstraZeneca	May 2010
NCT00683878	TZD	Add-on to Thiazolidinedione (TZD) Failures	P3	completed	972	AstraZeneca	Jul 2008
NCT00972244		Trial to Evaluate the Efficacy and Safety of Dapagliflozin in Japanese Type 2 Diabetes Mellitus Patients	P2	completed	417	AstraZeneca	Aug 2009
NCT00859898		Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes	P3	completed	1,093	AstraZeneca	Apr 2009
NCT00680745		Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients	P3	completed	597	AstraZeneca	Apr 2008
NCT00528879		A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone	P3	completed	915	AstraZeneca	Sep 2007
NCT01068756		Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects	P1	terminated	14	AstraZeneca	Mar 2010
NCT01072578		A Study to to Assess the Effect of Dapagliflozin When Administered Once a Day Versus Twice a Day on Blood Glucose	P1	completed	16	AstraZeneca	Feb 2010
NCT01055691		A Study Comparing the Amount of Metformin and After Taking a Combination Tablet vs. Separate Tablets	P1	completed	120	AstraZeneca	Jan 2010
NCT01055652		Drug-drug Interaction Study of Dapagliflozin With Voglibose in Japanese Type 2 Diabetes Mellitus Patients	P1	completed	28	AstraZeneca	Jan 2010
NCT01002807	FDC	Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State	P1	completed	15	AstraZeneca	Nov 2009
NCT00736879		Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes	P3	completed	497	AstraZeneca	Sep 2008
NCT00930865		Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects	P1	completed	42	AstraZeneca	Jul 2009
NCT00908271		Study of the Absolute Oral Bioavailability of Dapagliflozin in Healthy Subjects	P1	completed	7	AstraZeneca	Jul 2009
NCT00726505	MOA	Renal Mechanism of Action/Splay vs. TmG	P1	terminated	1	AstraZeneca	Jun 2009
NCT00904176		Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy Subjects	P1	completed	30	AstraZeneca	Jun 2009
NCT00643851		An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets	P3	completed	994	AstraZeneca	Jun 2008
NCT00842556		Pharmacokinetic Drug Interaction Study of Dapagliflozin and Glimepiride or Sitagliptin in Healthy Subjects	P1	completed	18	AstraZeneca	Mar 2009
NCT00839683		Pharmacokinetic Drug Interaction Study of Dapagliflozin and Valsartan or Simvastatin in Healthy Subjects	P1	completed	24	AstraZeneca	Feb 2009
NCT00554450		Renal Impairment in Type 2 Diabetic Subjects	P1	completed	40	AstraZeneca	Mar 2006
NCT00562250		Pharmacokinetic Drug Interaction Study With Dapagliflozin and Glimepiride in Healthy Subjects	P1	completed	11	AstraZeneca	May 2008
NCT00538174	MAD	Phase I Multiple-Ascending Dose (Japan)	P1	completed	36	AstraZeneca	Nov 2007
NCT00688493		Effects of Single Oral Dose Dapagliflozin QT Study	P1	completed	36	AstraZeneca	Jul 2007
NCT00357370		A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes	P2/P3	completed	163	AstraZeneca	Oct 2006
NCT00546741		Drug Interaction With Metformin	P1	completed	18	AstraZeneca	Nov 2007
NCT00263276		A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus	P2	completed	389	AstraZeneca	Dec 2005

Dapagliflozin clinical trials: frequently asked questions

How many Dapagliflozin clinical trials are there?: 552 Dapagliflozin clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 84 are actively recruiting participants. 283 are marked completed.
Are Dapagliflozin clinical trials recruiting in 2026?: Yes — 84 Dapagliflozin trials are actively recruiting in 2026, with 409 U.S. sites across 44 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Dapagliflozin being studied for?: Dapagliflozin is being studied for Type 2 Diabetes, Diabetes Mellitus, Type 2, Type 2 Diabetes Mellitus, Heart Failure, Chronic Kidney Diseases and 409 more. The trials are grouped by indication on this page.
What phase is Dapagliflozin in?: Dapagliflozin clinical trials span 175 Phase 4, 128 Phase 3, 82 Phase 2, 68 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Dapagliflozin clinical trials?: The lead sponsor across the most Dapagliflozin trials is AstraZeneca, with 268 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Dapagliflozinas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed June 26, 2026.

Related pages on Hipa.ai:

Dapagliflozin overview Dapagliflozin evidence & publications